Transcriptional co-regulators TBL1X and TBL1XR1 control tumor growth and tumor cell metabolism in pancreatic cancer by Stoy, Christian
INAUGURALDISSERTATION
zur Erlangung der Doktorwürde der
Naturwissenschaftlich-Mathematischen Gesamtfakultät
d"
Ruprecht-Kar15-Universität
Heidelberg
vorgelegt von
Diplom-Biologe Christian Stoy
geboren in Marktheidenfeld
Tag der mündlichen Prüfung:
----

Transcriptional co-regulators TBllX and TBllXRl control
tumor growth and tumor cell metabolism in pancreatic cancer
Gutachter:
PD Dr. Karin Müller-Decker
Prof. Dr. Stephan Herzig

Statement of authorship (Selbstständigkeitserklärung)
I hereby declare that this thesis has been wrien only by the undersigned, without any unauthorized use of services
of a third party. No sources or aids have been used in the preparation of this thesis other than those indicated in the
thesis itself. Where the work of others has been quoted or reproduced, the source is always given. is thesis, in same
or similar form, has not been available to any audit authority yet.
I erkläre hiermit, dass i die vorliegende Arbeit selbstständig und ohne unzulässige Hilfe Drier verfasst habe. I habe keine anderen
als die angegebenen Hilfsmiel und ellen verwendet. Insbesondere habe i wörtli oder sinngemäß aus anderen Werken übernommene
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Summary
Pancreatic ductal adenocarcinoma (PDAC) is among the ten most frequent cancers in the western world, and also one
of the most lethal. e mortality rate approximately equals the incidence rate and the ﬁve-year survival rate is only
around 5%, mainly due to advanced stage at diagnosis, non-resectability, and frequent chemotherapy resistance. Epi-
demiological studies show that obesity and/or type 2 diabetes increase the risk of PDAC. Both conditions have been
increasing world wide during the last 20–30 years, and have become a global health hazard.
e transcriptional co-regulators TBL1X (transducin-beta-like 1, X-linked) and TBL1XR1 (transducin-beta-like 1X-
related protein 1) mediate the exchange of co-repressors to co-activators on target gene promoters. ey have been
shown by previous work in our lab to regulate lipid metabolism in liver and white adipose tissue. Furthermore, they
interact with Wnt/β-catenin signaling, a pathway frequently altered in cancers. Recent studies have shown a growth-
regulating role of TBL1XR1 in various cancer entities, but not in pancreatic cancer.
e aim of the present study was therefore to investigate whether TBL1X and/or TBL1XR1 play a role in pancreatic
cancer and might link tumor initiation or progression with obesity or type 2 diabetes.
While the laer could not be conﬁrmed, the present study was able to show that TBL1X and TBL1XR1 were highly
expressed in human and murine pancreatic cancer. e expression was speciﬁc for PanIN precursor lesions and carci-
noma cells, while healthy tissue showed lile to no expression. In human patients, multiple genes involved in metabolic
processes showed a high correlationwith TBL1X and TBL1XR1 expression. In vitro studies revealed a growth-promoting
eﬀect of TBL1X and TBL1XR1 in pancreatic cancer cells and gene expression microarrays indicated cell cycle and p53
signaling as the most prominently regulated pathways. Furthermore, both proteins, especially TBL1X, aﬀected tumor
cell glucose metabolism and cellular response to glucose withdrawal.
Application of a syngeneic subcutaneous allogra mouse model conﬁrmed the growth-regulating eﬀect of Tbl1x in
vivo. Ablation of Tbl1x additionally sensitized murine Panc02 tumor cells to gemcitabine, the most commonly used
chemotherapeutic agent for pancreatic cancer. Tbl1x-deﬁcient cells had markedly reduced levels of PI3 kinase, a major
regulator of cell growth and metabolism, as well as downstream mediators. TBL1X was conﬁrmed to bind to PI3 kinase
promoter region and its expression correlated with PI3 kinase in human patients.
Taken together, this study is the ﬁrst to show a role of TBL1X in cancer, and of TBL1XR1 in pancreatic cancer, both
in humans and in mice. e control of PI3 kinase by TBL1X on the transcriptional level is a plausible explanation for
the observed sensitization to gemcitabine, making TBL1X an aractive target for future cancer therapies to enhance
treatment response and patient survival.
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Summary
Zusammenfassung
Das duktale Adenokarzinom des Pankreas gehört zu den zehn häuﬁgsten Tumorarten in der westlichen Welt und ist
zugleich eine der tödlichsten. Die Mortalität entspricht in etwa der Inzidenz, die Fünahresüberlebensrate beträgt nur
rund 5%. Dies rührt hauptsächlich daher, dass die Tumoren zum Zeitpunkt der Diagnose meist in einem fortgeschrie-
nen Stadium und o nicht resektierbar sind. Zudem sprechen sie häuﬁg nicht auf Chemotherapie an. Epidemiologische
Studien zeigen, dass Feleibigkeit und/oder Typ-2-Diabetes mit einem erhöhten Risiko ür Pankreaskrebs einhergehen.
Beide Stoﬀwechselstörungen haben in den letzten 20–30 Jahren weltweit zugenommen und entwickeln sich mehr und
mehr zu einer Bedrohung ür die globale Gesundheit.
Die transkriptionellen Koregulatoren TBL1X (transducin-beta-like 1, X-linked) und TBL1XR1 (transducin-beta-like
1X-related protein 1) vermieln den Austausch von Korepressoren gegen Koaktivatoren auf den Promotoren von Zielge-
nen. Frühere Untersuchungen in unserer Arbeitsgruppe konnten zeigen, dass sie den Festoﬀwechsel in der Leber und
in weißem Fegewebe regulieren. Des weiteren interagieren sie mit dem Wnt/β-catenin-Signalweg, der in Krebszellen
häuﬁg fehlreguliert ist. Neuere Studien haben ür TBL1XR1 eine wachstumsregulierende Funktion in verschiedenen
Tumorarten nachgewiesen, jedoch nicht ür Pankreaskrebs.
In der vorliegenden Studie sollte deshalb untersucht werden, ob TBL1X und/oder TBL1XR1 im Pankreaskrebs eine
Funktion haben und ob sie eine Verbindung herstellen können zwischen Tumorentstehung oder Tumorprogression und
Feleibigkeit oder Typ-2-Diabetes.
Während letzteres nicht bestätigt werden konnte, zeigte die vorliegende Studie, dass TBL1X und TBL1XR1 in Pankre-
astumoren desMenschen und derMaus stark exprimiert waren. Die Expressionwar hierbei speziﬁsch ür die PanIN-Vor-
läuferläsionen und Krebszellen, während gesundes Gewebe keine oder nur eine geringe Expression aufwies. In humanen
Patienten besaß eine Vielzahl an stoﬀwechselrelevanten Genen eine starke Korrelation ihrer Expression mit derjenigen
von TBL1X und TBL1XR1. In-vitro-Studien konnten nachweisen, dass TBL1X und TBL1XR1 einen wachstumsördern-
den Eﬀekt auf Krebszellen haben und Genexpressions-Microarrays brachten Zellzyklus und den p53-Signalweg als stark
regulierte zelluläre Signalwege zu Tage. Des weiteren beeinﬂussten beide Proteine, und speziell TBL1X, den Glucose-
stoﬀwechsel von Pankreaskrebszellen sowie ihr Wachstumsverhalten in Abwesenheit von Glucose.
Miels eines syngenen subkutanen Allotransplantat-Modells in der Maus konnte die wachstumsregulierende Funk-
tion von Tbl1x in vivo bestätigt werden. Darüber hinaus waren Tbl1x-deﬁziente murine Panc02-Pankreaskrebszellen
sensitiver gegenüber dem bei Pankreaskrebs meist verwendeten ChemotherapeutikumGemcitabin. Diese Zellen wiesen
zudem geringere Mengen des Proteins PI3-Kinase auf, eines wichtigen Regulators ür Zellwachstum und Stoﬀwechsel,
und auch in der PI3-Kinase-Signalkee nachgeschaltete Proteine waren in ihrer Menge reduziert. Nachfolgend konnte
gezeigt werden, dass TBL1X an die Promotorregion des PI3-Kinase-Gens bindet und dass in humanen Tumoren die Ex-
pression von TBL1X mit derjenigen von PI3-Kinase korreliert.
Die vorliegende Studie ist die erste, die eine Funktion von TBL1X in Krebs und von TBL1XR1 im Pankreaskrebs
aufzeigt, sowohl im Menschen als auch in der Maus. Die Kontrolle von PI3-Kinase durch TBL1X auf transkriptioneller
Ebene ist eine plausible Erklärung ür die beobachtete Sensitivierung gegenüber Gemcitabin. TBL1X ist somit ein at-
traktives Ziel ür zukünige Krebstherapien zur Verbesserung des Ansprechens auf Chemotherapie und des Überlebens
der Patienten.
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1 Introduction
1.1 The pancreas
e pancreas is located in the upper abdomen. It has a length of 16–20 cm, a width of 3–4 cm, a thickness of 1–2 cm and
a weight of 70–100 g. e head lies in the bend of the duodenum with the main body reaching behind the stomach and
the tail touching the spleen (see ﬁgure 1.1 on the following page).
It is both an exocrine and endocrine organ. e exocrine part constitutes the majority of the pancreatic tissue and
consists of acinar tissue producing pancreatic ﬂuid rich in digestive enzymes (lipases, proteases, amylases) that is re-
leased to the duodenum via the main and accessory pancreatic duct. e acini are clustered in a grape-like manner and
are located at the ends of the highly branched ductal system. e ductal cells enrich the pancreatic ﬂuid with mucous
and bicarbonate. Embedded into the exocrine tissue are the islets of Langerhans that constitute the endocrine part of the
organ. ey contain several cell types secreting various hormones, namely α-cells (15–20% of total islet cells, producing
glucagon), β-cells (65–80%, producing insulin and amylin), δ-cells (3–10%, producing somatostatin), PP-cells (3–5%,
producing pancreatic polypeptide) and ε-cells (<1%, producing ghrelin) [1]. ese hormones are distributed throughout
the body via the bloodstream (see ﬁgure 1.2C). Insulin and glucagon are the major regulators of glucose homeostasis
in the body. During fasting, when blood glucose levels are low, glucagon is secreted promoting glycogenolysis in the
liver and glucose release into the blood. Aer a meal, blood glucose rises which in turn stimulates insulin secretion
promoting energy storage by means of glucose uptake and glycogen synthesis in liver and muscle, as well as fat uptake
and lipid synthesis in adipose tissue.
1.2 Pancreatic cancer
Tumors arising from the exocrine tissue of the pancreas comprise about 95% of all pancreatic cancers [4]. Of these, the
vast majority (85–90%) are pancreatic ductal adenocarcinoma (PDAC), whereas islet tumors and other non-adenocar-
cinoma tumors only account for less than 15% of pancreatic cancers [3]. e tumor commonly arises in the head of
the pancreas, is characterized by a dense stroma, and is prone to inﬁltrate surrounding tissues, including lymph nodes,
lymphatic vessels, spleen, peritoneal cavity, liver, and lung. In the early stages it oen is asymptomatic or accompanied
by unspeciﬁc symptoms such as diﬀuse pain in the upper abdomen, anorexia, nausea and vomiting, weight loss (can
be associated with anorexia, early satiety, diarrhea, steatorrhea, or in later stages also chachexia), painless jaundice,
or diabetes mellitus. Furthermore, the early precursor lesions are too small to be detected with imaging technologies
and can only be discerned under the microscope, thus requiring a biopsy. erefore, PDAC is in most cases diagnosed
late and in an advanced stage, resulting in a dismal prognosis (see section 1.2.1). e time range between the original
gene mutation (see section 1.2.2) until the establishment of a primary tumor is estimated at 11.7±3.1 years. It then takes
another 6.8±3.4 years to develop metastases and patients die 2.7±1.2 years later [5].
1.2.1 Epidemiology
In Germany, as of 2009/10, 3.2% of all newly diagnosed cancers in men and 3.6% in women were pancreatic, placing
PDAC as the 10ᵗʰ or 6ᵗʰmost frequent cancer entity, respectively. Among cancer mortality, pancreatic cancer was the 4ᵗʰ
most common in both sexes with 6.4% of all cancer deaths in men and 7.9% in women. e age-standardized incidence
rate was 13.8 per 100,000 in men and 10.0 per 100,000 in women, resulting in an estimate of 8,020 men and 8,060 women
in total. Mortality was equally high with 12.8 per 100,000 in men and 9.5 per 100,000 in women or 7,537 and 7,950 total
cases, respectively. e relative 5-year survival rate was 8% in both sexes. Both incidence and mortality have been
relatively constant since the late 1990s and equally high due to the poor prognosis of the disease [6].
For other industrialized countries the picture looks similar. In the U. S. in 2009, 2.62% of the total cancer incidence
in women and 2.54% in men was aributed to pancreatic cancer, which ranked it the 12ᵗʰ or 10ᵗʰ most common cancer,
respectively. In total, 18,421 women and 18,979 men were diagnosed with pancreatic cancer in that year. Concerning
cancer mortality, pancreatic cancer ranked 5ᵗʰ in both sexes, comprising 6.56% of all cancer deaths in women and 6.02%
in men. Absolute mortality was 17,758 cases among women and 17,870 among men. [7]. When diagnosed with PDAC,
52% of patients already have distant metastases and 26% have regional spread [8].
1.2.2 Histopathology and etiology
Pancreatic ductal adenocarcinoma is characterized by cells that re-gained a duct-like phenotype. e disease progresses
via precursor lesions called pancreatic intraductal neoplasia (PanIN) that are categorized in stages 1–3 of increasing
cellular and nuclear atypia (see table 1.1 on page 3 and ﬁgure 1.3 on page 4).
Mutations of the small GTPase Kras are found in about 95% of human PDAC. ey aﬀect the glycine at codon 12
(usually G12D or G12V mutations), thus compromising the GTPase function. e mutant protein is therefore highly
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Figure 1.1: Location of the pancreas in the abdominal cavity
e pancreas is located behind the stomach with the tail touching the spleen and the head lying in the bend of the duodenum. e
highly branched pancreatic duct system collects the digestive ﬂuid produced in the exocrine tissue and releases it into the duodenum
via the duodenal and the accessory pancreatic duct papilla. e terminal part of the main pancreatic duct merges with the terminal
part of the common bile duct so that bile and digestive ﬂuid are released together via the duodenal papilla; adapted from [2]
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Figure 1.2: Anatomy of the pancreas
A Pancreatic ducts with acini; B Detailed structure of acini and eﬀerent pancreatic duct; C islet of Langerhans surrounded by
acinar tissue;D H&E staining of human pancreas; Ac: acinar tissue – Is: islet of Langerhans; D: pancreatic duct; scale bar 100 μm;
panelsA–C adapted from [3]
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Table 1.1: Characterization of PanIN lesions according to Hruban et al. [11]
Normal duct Morphology: cuboidal to low-columnar epithelium; amphophilic¹ cytoplasm; no mucinous cyto-
plasm;
Nuclei: regularly shaped; no nuclear crowding or atypia
PanIN-1A Morphology: ﬂat, epithelial lesions; tall cells of columnar shape; high in supranuclear mucin
Nuclei: small, round to oval, located at basal membrane
Mutations: Kras mutations in 35–36% of lesions [12, 13];
p16/Ink4a inactivation in 31% of lesions [14]
PanIN-1B Morphology: epithelial lesions; (micro)papillary or basally pseudostratiﬁed² architecture; other-
wise identical to PanIN-1A
Mutations: Kras mutations in 43–44% of lesions [12, 13]
p16/Ink4a inactivation in 44% of lesions [14]
PanIN-2 Morphology: Flat or mostly papillary mucinous epithelial lesions
Nuclei: some nuclear abnormalities (some loss of polarity, nuclear crowding, enlarged nuclei,
pseudo-stratiﬁcation² and hyperchromasia³); mitoses are rare and non-apical (non-
luminal) and not atypical
Mutations: Kras mutations in 87% of PanIN-2–3 lesions [13]
p16/Ink4a inactivation in 50% of lesions [14]
PanIN-3 Morphology: papillary or micropapillary, rarely ﬂat; cribriforming⁴; small clusters of epithelial
cells budding oﬀ into the lumen; potentially luminal necroses
Nuclei: loss of polarity; goblet cells with nuclei oriented towards the lumen and mucin-rich
cytoplasm towards the basal membrane; mitoses potentially abnormal; nuclear ir-
regularities; prominent (macro)nucleoli
Mutations: Kras mutations in 87% of PanIN-2–3 [13] or in 86% of PanIN-3 lesions [12]
p16/Ink4a inactivation in 85% of lesions [14]
p53 mutations in 57% of lesions [14]
loss of Smad4 in 28% of lesions [14]
impeded in its ability to hydrolyze bound GTP. Once activated by upstream signaling events, it remains in its active
state for much longer periods of time than wild type Kras [9] and can initiate a feed-forward loop of inﬂammation [10].
e capability of mutant Kras to reprogram pancreatic cells to a ductal phenotype giving rise to PanIN lesions pro-
gressingwith age has been shown and elaborated in variousmousemodels, the ﬁrst ones being the p48 +/Cre; Kras +/LSL-G12D
and Pdx1-Cre; Kras +/LSL-G12D models by Hingorani et al. [15] in 2003. Despite the universal occurrence of mutant Kras
in human PDAC and its capability of reprogramming pancreatic cells in mouse models, Kras signaling alone is not suf-
ﬁcient for a progression to fully developed PDAC. It rather relies on sequential tuning of other signaling pathways and
loss of function of tumor suppressors such as p53, p16/Ink4a (Ink4a/Arf) or Smad4 which are also observed in higher-
grade PanIN lesions with increasing frequency (see table 1.1). In the original model of Hingorani et al. [15] only 2 out of
29 mice (one p48 +/Cre; Kras +/LSL-G12D and one Pdx1-Cre; Kras +/LSL-G12D) at the age of 8.25 and 6.25 months, respectively,
spontaneously developed and succumbed to invasive PDAC. erefore, in a second model, the authors crossed Pdx1-
Cre; Kras +/LSL-G12D mice with Pdx1-Cre; Trp53 +/LSL-R172H mice to create Pdx1-Cre; Kras +/LSL-G12D; Trp53 +/LSL-R172H mice
expressing both G12D-mutant Kras and R172H-mutant p53 speciﬁcally in the pancreas [16]. ese animals showed a
much more rapid disease progression with a high frequency of metastases resulting in a median survival of 5 months
and 100% mortality aer 12 months whereas p48 +/Cre; Kras +/LSL-G12D animals had a median survival rate of 15 months.
During progression from pre-invasive to invasive disease the cells lost the wild type p53 allele thus becoming hemizy-
gous for the mutant R172H allele, a feature also observed in humans. is loss of heterozygosity might be triggered by
the mutant allele via chromosomal instability that is then further aggravated once the wild type allele is lost [16]. In
another model, Aguirre et al. [17] created triple-transgenic Pdx1-Cre; Kras +/LSL-G12D; Ink4a/Arf ﬂ/ﬂ mice with pancreas-
speciﬁc expression of mutant KrasG12D and homozygous deletion of Ink4a/Arf. ese animals were clinically normal
¹staining with either acid or basic dyes
²describing a type of layered epithelium in which the nuclei of adjacent cells are at diﬀerent levels
³increased staining capacity of nuclei for hematoxylin due to an increase in chromatin
⁴perforated like a sieve
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Figure 1.3: Progression from PanINs to PDAC
A PanIN-1 lesion.B PanIN-2 lesion.C PanIN-3 lesion.D invasive carcinoma embedded in extensive ﬁbrotic stromal tissue. Scale
bars 100 μm.
until 7 weeks of age but falling moribund between weeks 7–11 with symptoms of weight loss, ascites and jaundice.
Necropsy revealed tumors between 4–20mm in size that were highly invasive, frequently aﬀecting the duodenum and
spleen and occasionally obstructing the common bile duct. On the other hand, Pdx1-Cre; Ink4a/Arf ﬂ/ﬂ mice did not de-
velop pancreatic tumors. At the age of 5 weeks all examined Pdx1-Cre; Ink4a/Arf ﬂ/ﬂ mice had developed small PDACs
while still clinically asymptomatic. In contrast, Pdx1-Cre; Ink4a/Arf ﬂ/+ mice hemizygous for Ink4a/Arf only showed
low-grade PanIN lesions. Taken together, these two mouse models as well as others (see [18, Tab. 1]) support the idea
of a two-hit model of human PDAC with initiating Kras mutations and progression to PDAC aer subsequent loss of
function of tumor suppressors p16/Ink4a (Ink4a/Arf) and p53.
e cell type of origin for pancreatic cancer is still under debate, however, epithelial, acinar and islet cells are the like-
liest candidates as they have been implicated in several mousemodels. Carriere et al. [19] usedNestin-Cre; Kras +/LSL-G12D
mice where Cre-recombinase triggers recombination and expression of mutant Kras in pancreatic exocrine progenitors
and descending acinar and some rare ductal cells, but also in the central nervous system. is model was suﬃcient to
invoke PanIN lesions. In Ela-tTA; tetO-Cre; Kras +/LSL-G12V mice, Cre is both under the control of the elastase promoter
and the tet-OFF system. In the absence of doxycycline, recombination of mutant Kras takes place resulting in its expres-
sion in acinar and centroacinar cells. ese animals also were capable of developing PanIN lesions [20]. Habbe et al.
[21] used three diﬀerent mouse models where Cre was induced by tamoxifen injection allowing to trigger mutant Kras
expression in adult mice. In the Ela-CreERT2; Kras +/LSL-G12D andMist1-CreERT2; Kras +/LSL-G12D animals the recombination
took place in mature acinar cells whereas in Pdx1-CreERT2; Kras +/LSL-G12D mice Cre was activated in mature β-cells. Both
acinar models showed the full spectrum of PanIN lesions while the Pdx1-CreERT2; Kras +/LSL-G12D β-cell model did not
present any neoplasms during a follow-up of 12 months. Insulin-expressing cells can however give rise to PanIN lesions
when stressed with cerulein-induced pancreatitis as was shown by Gidekel Friedlander et al. [22] using Rip-CreERT;
Kras +/LSL-G12D; LSL-LacZ mice. Because there are no conditionally inducible Kras models available that are speciﬁc for
ductal and centroacinar cells, these are still under debate regarding their capability to undergo transformation. Since
in the p48 +/Cre; Kras +/LSL-G12D and Pdx1-Cre; Kras +/LSL-G12D mouse models Kras recombination is triggered in pancre-
atic progenitors resulting in mutant Kras expression throughout the entire organ, these two remaining cell types can
however not be entirely excluded to potentially give rise to PanIN lesions.
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1.2.3 Risk factors
1.2.3.1 Smoking, alcohol and pancreatitis
emost prominent risk factor for PDAC is cigaree smoking. Meta-analysis showed that current smokers are at a 2.2-
fold (95%CI: 1.71–2.83) higher risk for pancreatic cancer [23, 24]. Roughly 25% of pancreatic tumors can be aributed
to cigaree smoking [25]. Other frequent risk factors are alcohol abuse and pancreatitis. Individuals who consumed
more than 6 drinks per day had an OR of 1.46 (95%CI: 1.16–1.83) compared to those who took less than one drink per
day [26]. Having a history of chronic pancreatitis resulted in a 2.71-fold (95%CI: 1.96–3.74) increased OR for pancreatic
cancer when the interval between the two diagnoses was more than two years [27].
1.2.3.2 Genetic predisposition
A familial history of pancreatic cancer with two or more ﬁrst degree relatives being diagnosed with PDAC is a strong
indicator of a genetic predisposition. is may be the case in up to 10% of patients [28] and oen involves the BRCA2
gene that is well known for its role in hereditary breast cancer [29]. In cases with familial background, genetic testing
should be considered to allow preventive measures. In such high-risk individuals, screening measures that would other-
wise be too expensive or burdensome, such as endoscopic ultrasound and nuclear magnetic resonance (NMR) imaging,
are advisable to detect tumors in an early stage.
1.2.3.3 Metabolic syndrome
In recent years it has become evident that constituents of the metabolic syndrome, namely obesity and type 2 diabetes,
are risk factors for various cancer entities, including PDAC.
Several prospective cohort studies showed an increased risk for obese individuals (BMI ≥30) compared to normal-
weight individuals (BMI <25) with RR from 1.2–3.0 (summarized by Giovannucci and Michaud [30, p. 2215f and ﬁg.
4]). Four case-control studies from the U. S. and Canada using direct interviews reported elevated risks for pancreatic
cancer in obese individuals with OR from 1.3–2.0 [31–34]. Calle et al. [35] also observed an elevated risk of mortality
from pancreatic and other cancers with increasing BMI in a large prospective cohort study.
For diabetic patients, it is important to clearly distinguish between long-lasting and recent-onset cases of type 2 dia-
betes. PDAC patients are oen diagnosed with type 2 diabetes several months to several years before cancer diagnosis.
In these cases it is likely that the previously undetected pancreatic cancer caused the recent onset of diabetes. A meta-
analysis by Everhart [36] concluded that diabetes of 5 years or more increases the RR for PDAC by a factor of 2 (95%CI:
1.2–3.2). In a further meta-study, Huxley et al. reported an OR of 1.5 (95%CI: 1.3–1.8) for individuals with a diabetes
history of >5 years compared to an OR of 2.1 (95%CI: 1.9–2.3) for those with <4 years of diabetes [37, p. 2079]. ese and
other ﬁndings [38] support both the role of diabetes as a risk factor for PDAC as well as the eﬀect of reverse causality
in patients with recent-onset diabetes. Further evidence is provided by the Whitehall study [39] and the Chicago Heart
Association Detection Project [40] where individuals with blood glucose levels of ≥11.1mm/≥200mg/dl 1 h [40] or 2 h [39]
aer a 50 g oral glucose load had a 2- to 4-fold increased risk of pancreatic cancer death during a follow-up period of 25
years. Even when omiing deaths within the ﬁrst 10 years of follow up, the 4-fold risk increase in the Whitehall study
was only slightly reduced [39].
1.2.4 Pancreatic cancer and metabolic syndrome
Possible mechanisms to explain the higher risks of pancreatic cancer in obesity and type 2 diabetes have been widely
discussed [30, 41, 42] and are the subject of ongoing research. In particular, the insulin/IGF-Ⅰ axis as well as oxidative
stress and inﬂammation are considered key pathways.
e activation of IGF-Ⅰ (insulin-like growth factor Ⅰ) receptor (IGF-ⅠR) leads to enhanced proliferation, invasive growth,
expression of angiogenic mediators, and reduced apoptosis in pancreatic cancer cells in vitro [43]. When the IGF-
Ⅰ receptor was being blocked, growth of human pancreatic cancer cells in nude mice was reduced and radiation- or
chemotherapy-induced apoptosis of tumor cells was upregulated [44]. Further evidence for the role of insulin signaling
was provided by a case-control study from Li et al. [45]. ey could show that diabetic patients treated with metformin,
a drug that lowers hepatic gluconeogenesis and enhances insulin sensitivity, had a lower risk for pancreatic cancer with
an RR of 0.38 (95%CI: 0.22–0.69). On the other hand, an increased risk for pancreatic cancer was observed in patients
that had been treated with insulin or insulin secretagogues compared to those who had never taken one of these drugs.
Diabetic patients treated with insulin had an overall RR for PDAC of 4.99 (95%CI: 2.59–9.61) and an RR of 5.04 (95%CI:
2.38–10.7) when only considering those with >2 years of diabetes. Patients treated with insulin secretagogues had an
overall RR of 2.52 (95%CI: 1.32–4.84) while those that had not been previously treated with insulin had an RR of 3.82
(95%CI: 1.78–8.20) and those with >2 years of diabetes history had an RR of 1.74 (95%CI: 0.80–3.77).
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is is interesting considering the nature of insulin and IGF-Ⅰ signaling. e insulin receptor is highly expressed
in adipose tissue, muscle and kidney whereas the IGF-Ⅰ receptor is found in all tissue types. e insulin receptor is a
heterotetrameric aggregate of two extracellular α-subunits that are responsible for ligand binding and two intracellular
β-subunits responsible for signal transduction. e two receptors have a sequence homology of >50% and also the two
ligands, insulin and IGF-Ⅰ, are 40–50% homologous. erefore, both ligands can interact with either receptor, albeit
the aﬃnity of insulin to the insulin receptor is 1000 times higher than to the IGF-Ⅰ receptor and vice versa IGF-Ⅰ binds
to its cognate receptor with 100–500 higher aﬃnity than to the insulin receptor [46]. In seings of hyperinsulinemia,
as observed in metabolic syndrome, high insulin levels could thus also activate IGF-ⅠR signaling and promote tumor
growth. Furthermore, high concentrations of insulin decrease the levels of IGF-Ⅰ binding proteins IGFBP1 and IGFBP2
resulting in increased amounts of unbound and thus bioactive IGF-Ⅰ [41].
Hyperglycemia in diabetic patients has been found to raise levels of superoxide by the mitochondrial electron trans-
port chain in susceptible cells [47]. is process is considered a key mechanism to downstream damaging events in
diabetes. Particularly the formation of advanced glycation end products (AGE) and their binding to the receptor of AGE
(RAGE) are a focus of ongoing research. AGE form under conditions of high blood glucose by spontaneous chemical
reaction of protein amino acids with the oxo group of glucose or other carbohydrates. Binding of AGE to RAGE can
lead to increased inﬂammation via the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway
leading to formation of intracellular ROS (reactive oxygen species). Interestingly, RAGE were found to be expressed in
several pancreatic cancer cell lines [48, 49]. is upregulation of RAGE could also be shown in Pdx1-Cre; Kras +/LSL-G12D
mice [50]. Crossing these animals with RAGE–/–mice resulted in delayed carcinogenesis. Furthermore, shRNA-mediated
RAGE knockdown in vitro resulted in decreased IL-6 (interleukin 6) secretion, reduced IL-6-induced proliferation and
STAT3 (signal transducer and activator of transcription 3) phosphorylation as well as decreased autophagy.
e above mentioned protective eﬀect of metformin on tumor growth observed by Li et al. [45] could also be demon-
strated in a mouse model of obesity and hyperinsulinemia by Algire et al. [51] using subcutaneous allogras. Later
studies by the same group [52] could show that metformin action on tumors was not only indirect by its eﬀects on low-
ering blood glucose and insulin levels. In fact, the drug was capable of reducing endogenous Ras-induced ROS levels,
DNA damage, and mutations in cells in vitro and ameliorating ROS-induced toxicity in mice.
e eﬀect of obesity on pancreatic cancer was also studied in a transgenic mousemodel (p48 +/Cre; Kras +/LSL-G12D) under
high fat diet (HFD) conditions [53]. e authors observed an accelerated progression of PanIN lesions. Since obesity is
known to cause low-grade inﬂammation [54, 55], the levels of circulating TNFα (tumor necrosis factor alpha) and IL-6
were measured and indeed found to be elevated in p48 +/Cre; Kras +/LSL-G12Dmice on HFD. Crossing p48 +/Cre; Kras +/LSL-G12D
mice with TNF-receptor 1 deﬁcient (TNFR–/–) mice led to aenuated PanIN progression under the obesogenic regimen
and reversed pancreatic insuﬃciency observed in p48 +/Cre; Kras +/LSL-G12D animals on a HFD.
Another study examining the eﬀects of HFD on tumor growth in the pancreas was done by Philip et al. [56] using Ela-
Cre ERT; Kras +/LSL-G12D mice expressing mutant Kras in acinar cells aer tamoxifen-induced activation of Cre. Here, the
HFD exacerbated Kras activity and downstream signaling and resulted in enhanced PanIN lesions, pancreatic inﬂamma-
tion, and ﬁbrosis. Moreover, these mice showed elevated levels of COX-2 (cyclooxygenase 2) and increased recruitment
of F4/80+ macrophages under HFD conditions. Crossing Ela-Cre ERT; Kras +/LSL-G12D mice with COX-2 ﬂ/ﬂ mice resulted
in mice with acinar cell speciﬁc expression of mutant Kras and concomitant deletion of COX-2. With this model it was
possible to reverse the HFD-induced eﬀects observed previously in Ela-Cre ERT; Kras +/LSL-G12D mice, namely enhanced
PanIN progression, ﬁbrosis, inﬂammation, Kras activity, and macrophage inﬁltration. e COX-2 inhibitor celecoxib
was also able to lower the levels of inﬂammation, ﬁbrosis, and PanIN formation in Ela-Cre ERT; Kras +/LSL-G12D animals.
Moreover, the HFD could provoke the progression of PanINs to cancer in both Ela-Cre ERT; Kras +/LSL-G12D and Pdx1-Cre;
Kras +/LSL-G12D mice resulting in decreased median survival rates compared to animals on a normal diet.
1.2.4.1 Global perspective
Obesity and diabetes have been constantly rising worldwide during the last 3–4 decades [57–59]. ey are now not
only a problem in developed countries (ﬁgure 1.4 on the facing page) but are also on the rise in middle- and low-income
countries [60]. According to the World Health Organization (WHO), the global obesity prevalence has almost doubled
from 1980–2008 [61]. Approximately 1.4 billion or 35% of adults over 20 years of age were overweight (BMI ≥25)
and around 500 million or 12% were obese (BMI ≥30) in 2008 [62] (see also appendix A on page 79). Concomitantly,
347 million people worldwide had diabetes in 2013 (see also appendix A on page 79) of which 80% lived in low- and
middle-income countries [63].
Regarding this worldwide dramatic trend and the fatal nature of pancreatic cancer it is of great scientiﬁc and public
interest to learn more about the underlying mechanisms and identify distinct molecular pathways linking metabolic
perturbations to initiation and promotion of tumors.
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Figure 1.4: Trends of obesity and diabetes in the U. S.
Overview of obesity (BMI ≥30) and diabetes prevalence in the U. S. from 1994–2010. Data obtained from CDC [64].
1.2.5 Therapy
According to the recent S3 guideline [65], surgery is the only potentially curative measure of therapy. Only localized
cancers, which occur in approximately 20% of PDAC patients [66], are considered suitable for surgery with curative
intent. Non-resectable tumors are treated with neoadjuvant chemotherapy to reduce tumor size in aempts to reach
resectability. Aer surgery, adjuvant chemotherapy with gemcitabine or a combination of 5-ﬂuorouracil and folinic acid
has been shown to increase the 5-year survival rate from approximately 10 to 20% [65, 67–72]. Many tumors, however,
are resistant to gemcitabine in the ﬁrst place or become resistant during therapy. On the other hand, a survival of 5
years aer diagnosis does not guarantee a cure, as death of recurrent disease is still possible. Most patients eventually
succumb to the consequences of local invasion or metastases. Long term cures of the disease are very rare.
1.2.6 Gemcitabine resistance
Gemcitabine (2’,2’-diﬂuoro-2’-deoxycytidine) is a DNA base analog. It is transported into the cell via the transmembrane
transporter hENT1 (human equilibrative nucleoside transporter-1) and intracellularly converted to either the inactive
compound 2’,2’-diﬂuoro-2’-deoxyuridine by cytidine deaminase (CDA) or to its corresponding triphosphate by deoxy-
cytidine kinase (DCK). e triphosphate is then incorporated into newly synthesized DNA instead of cytidine. is
causes an arrest of strand elongation during DNA replication leading to apoptosis. It can also bind to the active site of
ribonucleotide reductase (RNR) thus irreversibly deactivating the enzyme [73]. When RNR is inhibited, the cell can no
longer produce deoxyribonucleotides required for DNA replication and repair resulting in apoptosis.
Poor response of a tumor to gemcitabine can be aributed to multiple factors including accessibility of tumor cells
to the drug, uptake into cells, intracellular metabolism or shuling the drug out of the cell. Changes in the expression
of hENT1 as well as downstream gemcitabine metabolizing enzymes, including DCK and ribonucleoside reductases M1
(RRM1) and M2 (RRM2), have been shown to play a role in gemcitabine resistance [74, 75]. Gemcitabine incorporation
into cells was diminished with low expression levels of the transporter hENT1 or with dense stroma, indicating an
involvement of the extracellular matrix [75].
Other studies suggest that the picture is more complex and the cell’s capability to take up gemcitabine can not be
aributed to the up- or downregulation of a single gene but rather the ratios of several genes have to be considered
[76]. Wang et al. [77] have shown an association of gemcitabine resistance with an epithelial-mesenchymal transition
(EMT) phenotype and with induction of HIF-1α (hypoxia-inducible factor 1-alpha). e PI3 kinase/Akt pathway that is
oen dysregulated in pancreatic cancer has also been connected to gemcitabine resistance [78–80]. Overall, gemcitabine
resistance of PDAC remains a complex issue and a focus of ongoing research.
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1.3 Transcriptional co-regulators TBL1X and TBL1XR1
1.3.1 Nuclear receptors
e eﬃcient and ﬁne tuned regulation of gene transcription is of fundamental importance in complex multicellular
organisms. One class of such regulators are nuclear receptors which intracellularly bind to lipophilic signalingmolecules
capable of passing the cellular membrane and then exert their function.
Type Ⅰ nuclear receptors bind their ligands in the cytosol, form homodimers, translocate to the nucleus and bind to
speciﬁc DNA sequences (hormone-response elements, HRE) on target gene promoters. ey then recruit co-activator
complexes and RNApolymerase to exert target gene transcription. Members of type Ⅰ nuclear receptors include androgen
receptor (AR), estrogen receptors (ER), glucocorticoid receptor (GR), and progesteron receptor (PR).
Type Ⅱ nuclear receptors always reside in the nucleus and bind as heterodimers (usually with retinoid X receptor
RXR) to their HREs. In the unliganded state they are oen associated with co-repressor complexes, such as NCoR (nu-
clear receptor co-repressor) and SMRT (silencing mediator of retinoid and thyroid hormone receptors) [81] or CtBP1/2
(C-terminal-binding protein 1/2) [82, 83]. ese co-repressors recruit HDAC3 (histone deacetylase 3) [84], a chromatin-
remodeling enzyme, that leads to hypoacetylation of histones resulting in densely packed chromatin that is inaccessible
to the transcription machinery. Aer ligand binding, the co-repressor complexes dissociate from the nuclear receptors
and co-activators and subsequently RNA polymerase are recruited to initiate target gene transcription. Type Ⅱ nuclear
receptors include retinoic acid receptor (RAR), retinoid X receptor (RXR) and thyroid hormone receptor (TR).
1.3.2 TBL1X and TBL1XR1 as nuclear receptor co-regulators
e two proteins TBL1X (Transducin β-like protein 1X) and TBL1XR1 (Transducin β-like 1X-related protein 1) are part
of the transcriptional co-repressor complexes associated with nuclear receptors of the steroid, thyroid hormone, and
retinoic acid receptor family. eir sequences are highly homologous. ey consist of an N-terminal LisH and F-box-
like domain followed by eight WD40 repeat domains (see ﬁgure B.1 on page 81).
1.3.2.1 Genomic location and first description
e TBL1X gene is located on the X-chromosome in human and mouse, and was ﬁrst described by Bassi et al. [85] as
being associated with X-linked ocular albinism with late-onset sensorineural deafness. Later studies identiﬁed it as part
of the large co-repressor complex containing NCoR, SMRT and HDAC3 [86, 87].
TBL1XR1 is genetically encoded on chromosome 3 in human and mouse and was ﬁrst identiﬁed by Zhang et al. [88]
as part of that complex. TBL1X and TBL1XR1 directly interact with SMRT and NCoR whereas their interaction with
HDAC3 is bridged by SMRT [87–89]. ey are functionally redundant but necessary for SMRT/NCoR/HDAC3-mediated
repression by unliganded TR, possibly by their ability to bind to histones H2B and H4 via their N-terminal domain [89].
1.3.2.2 TBL1X and TBL1XR1 as exchange factors
Perissi et al. [90] further delineated the function of TBL1X and TBL1XR1 showing that they act as exchange factors
for nuclear receptor-associated co-repressor complexes. Aer ligand binding, TBL1XR1 mediated the recruitment of
the E2-ubiquitin ligase UbcH5 and the 19S-proteasome resulting in degradation of the repressing SMRT/NCoR/HDAC3
complex followed by recruitment of co-activator complexes and target gene transcription. TBL1XR1 was required for
the ligand-induced transcriptional activation of RAR, TR, PPARγ (peroxisome proliferator-activated receptor gamma),
and ER as well as AP-1 (activator protein 1) and NF-κB, whereas TBL1X was only required for transcriptional activation
of TR, PPARγ, ER, and NF-κB.e N-terminal F-box domain of TBL1X and TBL1XR1 was required for binding of UbcH5.
Interestingly, even in the absence of NCoR and SMRT, TBL1X was required for signal-dependent transcriptional
activation but not in the absence of CtBP1/2 [91]. ese diﬀerent roles of TBL1X and TBL1XR1 on signal-induced
transcriptional activation are at ﬁrst sight surprising regarding their high sequence similarity (ﬁgure B.1 on page 81).
eir speciﬁcity lies within distinct phosphorylation sites. e two proteins are phosphorylated aer recruitment to
promoter sites and then either lead to TBL1XR1-dependent degradation of NCoR/SMRT or TBL1X-dependent degra-
dation of CtBP1/2 on target-gene promoters [91]. Since many promoters are simultaneously occupied by NCoR/SMRT
and CtBP1/2, this provides a dual checkpoint for transcriptional activation (ﬁgure 1.5 on the next page).
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Figure 1.5: Model of TBL1X and TBL1XR1 action in transcriptional regulation
TBL1XR1 is associated with NCoR/SMRT/HDAC3 and TBL1X with CtBP co-repressor complexes on unliganded nuclear receptors.
Upon ligand binding, they get phosphorylated by PKC, CK1 or GSK3. is leads to engagement of ubiquitin E2 ligases UbcH5 or
UbcH7 and the 19S-proteasomal subunit resulting in degradation of the NCoR/SMRT/HDAC3 or CtBP co-repressor complexes by the
26S-proteasome and subsequent recruitment of co-activator complexes triggering target gene expression.
Grey box: TBL1X and TBL1XR1 are associated with diﬀerent nuclear receptors as well as some non-nuclear receptor signaling
pathways. Images are a combined adaptation of ﬁgures 4H and 7 from Perissi et al. (2004) [90] and ﬁgure 5E from Perissi et al. (2008)
[91]. Proteasome 3D models were taken from PDB website (http://www.pdb.org/pdb/101/motm.do?momID=166).
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1.3.3 TBL1X and TBL1XR1 as regulators of Wnt/β-catenin signaling
Li andWang [92] identiﬁed the TBL1X/TBL1XR1 complex as critical players inWnt/β-catenin-mediated signal transduc-
tion. Activation ofWnt signaling led to an interaction of the arm repeats 1–8 of β-catenin with the N-terminal domain of
TBL1X and TBL1XR1 and recruitment toWnt target gene promoters. Depletion of either TBL1X or TBL1XR1 abrogated
expression of Wnt target genes. Interestingly, β-catenin still shuled to the nucleus in the absence of TBL1X/ TBL1XR1
but was unable to bind to target gene promoters. A later study [93] could demonstrate that TBL1X/TBL1XR1 only bound
to β-catenin when they were SUMOylated whereas binding to the NCoR/SMRT complex only occurred when they were
not SUMOylated.
e interplay of TBL1X/TBL1XR1 with β-catenin is particularly interesting, as the Wnt/β-catenin pathway plays
a critical role in development in general and also in pancreatic development [94]. It is oen aberrantly regulated in
cancers [95, 96], including pancreatic tumors [18, 97–99]. Concordantly, HT29 cells expressing shRNA against TBL1X
or TBL1XR1 were unable to form colonies in a so agar assay. Similarly manipulated UMSCC1 cells showed impeded
invasiveness in a Matrigel migration assay and reduced growth rates in nude mice [92]. Ampliﬁcation, upregulation,
deletion, or mutation of TBL1XR1 has also been detected in various tumors [100–104].
1.3.4 TBL1X and TBL1XR1 in metabolism
Two recent studies in our own group highlighted a previously unobserved role of TBL1X [105] and TBL1XR1 [106] in
metabolism. Ablation of TBL1X in the liver of mice led to hypertriglyceridemia, hepatic steatosis and inhibition of fay
acid oxidation. Conversely, overexpression resulted in decreased liver triglycerides and enhanced fay acid oxidation.
Moreover, TBL1X mRNA levels were found to negatively correlate with liver triglyceride content in humans. ese
eﬀects of TBL1X on hepatic lipid metabolism were mediated via PPARα (peroxisome proliferator-activated receptor al-
pha) [105]. Lack of TBL1XR1 in white adipose tissue resulted in decreased lipolysis via perturbation of cAMP-dependent
signal transduction. Adipocyte-speciﬁc knockout of TBL1XR1 in mice led to impaired lipid mobilization during fasting
and aggravated adiposity on HFD due to increased adipocyte cell size. Human patients that underwent a weight-loss
program showed increased TBL1XR1mRNA expression in their visceral white adipose tissue which positively correlated
with serum levels of adiponectin and free fay acids [106].
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Due to the reported epidemiological correlation of pancreatic cancer with obesity and type 2 diabetes, it was of interest
to identify transcriptional co-regulators that may explain these observations on the basis of distinct cellular mechanisms.
e two proteins TBL1X and TBL1XR1 were chosen as promising candidates as they were known regulators of
lipid metabolism in the liver [105] and adipose tissue [106] as well as in Wnt/β-catenin signaling [92], a known pro-
proliferative pathway in cancer.
e aim of the present study was to investigate whether TBL1X and/or TBL1XR1 play a role in pancreatic cancer and
might link tumor initiation or progression with obesity or type 2 diabetes.
To do so, human patient samples from tumor and adjacent non-tumor tissue of lean and obese patients were screened
for expression of transcriptional co-regulators, including TBL1X and TBL1XR1, to identify diﬀerences between tumor
vs. non-tumor tissue and lean vs. obese patients. e transgenic p48 +/Cre; Kras +/LSL-G12Dmouse model [15] was subjected
to a high fat diet regime to test tumor-promoting eﬀects of obesity and metabolic syndrome on pancreatic cancer, and
to validate observations made in human samples regarding TBL1X and TBL1XR1 expression.
For detailed mechanistic studies in vitro, the human pancreatic cancer cell lines Capan-1, BxPC-3, AsPC-1 and Capan-
2 were used. e role of TBL1X and TBL1XR1 in cancer cell growth and metabolism was examined by siRNA-mediated
knockdown, primarily in Capan-1 cells. Aﬀymetrix gene expression microarrays were employed for high-throughput
analysis of genes and cellular pathways regulated by TBL1X or TBL1XR1. Cell growth and proliferation was monitored
by cell counting and BrdU or EdU incorporation. Metabolic changes were assessed by glucose consumption, radioactive
2-deoxyglucose uptake, and extracellular ﬂux measurement.
To examine Tbl1x function in vivo, the mouse pancreatic cancer cell line Panc02 was subcutaneously injected into
the syngeneic C57BL/6 mouse strain. ese allogra tumors were then injected with shRNA-carrying adenovirus to
monitor eﬀects of Tbl1x on growth of established tumors. For a preventive approach, Panc02 cells were stably trans-
duced with shRNA using lentiviral gene transfer, followed by subcutaneous implantation into C57BL/6 mice. To test a
potential role of Tbl1x in chemotherapy resistance, these mice were treated with gemcitabine, the most commonly used
chemotherapeutic agent for human pancreatic cancer. Chromatin immunoprecipitation was employed to investigate
TBL1X binding to potential target gene promoters.
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3.1 Human patient screening
3.1.1 TBL1X and TBL1XR1 are upregulated in human pancreatic cancer
In order to identify the role of TBL1X and TBL1XR1 in human pancreatic ductal adenocarcinoma, their expression
levels were measured together with that of other transcriptional co-regulators in tumor resection samples. To inves-
tigate a potential role in obesity, cancer patients were grouped to lean (BMI ≤25) and obese (BMI ≥30) subgroups. All
cancer patients had a tumor staging between T3N0M0 and T3N1M1 (see appendix C on page 83 for explanation of
the TNM grading system). Tissue from organ donors served as a control. Detailed information on patients and organ
donors is given in appendix D on page 85. e transcriptional co-regulators TBL1X and TBL1XR1 were signiﬁcantly
upregulated in tumor tissue compared to adjacent non-tumor tissue from the same patient and to controls. Increased
expression in tumors was also observed for TSC22D4, which was previously identiﬁed in our lab as a binding partner
of TBL1X/TBL1XR1, as well as the histone-arginine transferase CARM1 and the transcriptional co-regulators NRIP1
and CRTC2 (ﬁgure 3.1 on the following page) but not for PGC1α. CARM1 methylates histones and is thus involved in
regulation of gene expression. It was shown to be dysregulated in lung cancer [107] and to play a role in breast cancer
[108]. NRIP1 is a regulator of hepatic triglyceride metabolism [109] and a co-regulator of cytokine promoter activity via
the NF-κB pathway [110]. It was furthermore shown to be involved in colorectal cancer [111]. CRTC2 (also known as
TORC2) is a transcriptional co-activator for the transcription factor CREB and a central regulator of gluconeogenic gene
expression in response to cAMP [112]. PGC1α is a transcriptional co-activator for steroid receptors [113] and nuclear
receptors [114, 115]. It is a major regulator of fay acid oxidation and the brown adipocyte speciﬁc uncoupling protein
UCP1 and was also shown to have tumor-promoting eﬀects [116, 117].
ere was, however, no statistically signiﬁcant diﬀerence between lean and obese patients for any of the genes ana-
lyzed.
To check if the upregulation in tumor samples might be due to inﬂammatory processes, samples from chronic pancre-
atitis patients were analyzed for TBL1X, TBL1XR1 and TSC22D4. Here, expression levels were quite variable compared
to healthy tissue samples. H&E stainings of the pancreas of these patients were examined to assess the degree of
pancreatitis (table D.1 on page 86) but there was no correlation between disease severity and expression levels. As an
additional control, cDNA from cultured primary pancreatic stellate cells was provided by Dr. Oliver Strobel from the
European Pancreas Center at Heidelberg University Clinic. Also in these samples there was no diﬀerence in TBL1X or
TBL1XR1 expression between cells from normal, pancreatitis or tumor tissue (ﬁgure 3.2 on the following page).
e upregulation of TBL1X and TBL1XR1 in tumor tissue was also conﬁrmed by immunobloing protein extracts
from the same patient material that was used for mRNA expression analysis (ﬁgure 3.3 on page 15). Immunoblot bands
from tumor samples were more prominent than bands from adjacent non-tumor tissue of the same patient. Similar to
the ﬁndings on mRNA level, there was no obvious diﬀerence between lean and obese individuals.
3.1.2 TBL1X and TBL1XR1 are highly expressed in human PanINs and carcinoma cells
To gain further knowledge about the cell types responsible for the upregulation of TBL1X and TBL1XR1, paraﬃn sec-
tions of patient tissue were stained for both proteins using immunohistochemistry as described in section 5.13.3.1 on
page 62 and section 5.13.3.3 on page 63. Healthy pancreatic tissue showed lile to no expression of TBL1X and TBL1XR1
whereas levels weremarkedly increased in PanIN lesions of all stages as well as carcinoma cells (ﬁgure 3.4 on page 15 and
ﬁgure 3.5 on page 16). Early PanIN lesions showed exclusively nuclear staining for TBL1X and TBL1XR1 whereas higher
grade PanINs also had low expression of TBL1XR1 in the cytoplasm. Carcinoma cells showed nuclear and cytoplasmic
staining for both TBL1X and TBL1XR1.
3.1.3 Expression of metabolic genes correlates with TBL1X and TBL1XR1
It is a well-established fact that tumors have an altered metabolism characterized by increased glycolysis, which was
already described more than 85 years ago by Warburg et al. [118]. e Warburg eﬀect has come back to the focus of
research in recent years [119–121]. Previous work in our own group has shown a crucial role for TBL1X and TBL1XR1
in metabolism [105, 106]. erefore, it was of interest to measure the expression levels of several candidate genes
for metabolic reprogramming (table 3.1 on page 17) in patient samples and to investigate if they would correlate with
TBL1X and TBL1XR1. According to literature, mRNA levels of ACLY (ATP citrate lyase), FASN (fay acid synthase),
G6PD (glucose-6-phosphate dehydrogenase), GLUT1 (glucose transporter 1), LDHa (l-lactate dehydrogenase A chain),
PDK1 (pyruvate dehydrogenase kinase 1) and SCD1 (stearyl-CoA desaturase) were higher in tumors while expression
of GLS2 (glutaminase 2) was lower. CPT1A (carnitine palmitoyl transferase 1, liver isoform) was upregulated in tumor
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Figure 3.1: Regulation of transcriptional co-regulators in human PDAC
Plots show mRNA expression of individual patients normalized to 18S-rRNA and relative to a pooled organ donor sample. Lines
between dots connect samples from the same patient. CP: chronic pancreatitis; BMI: body mass index; PDAC: pancreatic ductal
adenocarcinoma; TBL1X: transducin β-like protein 1X; TBL1XR1: transducin β-like 1X-related protein 1; TSC22D4: TSC22 domain
family protein 4; CARM1: co-activator-associated arginine methyltransferase 1; CRTC2: CREB-regulated transcription co-activator
2; NRIP1: nuclear receptor-interacting protein 1; PGC1α: peroxisome proliferator-activated receptor gamma co-activator 1-alpha;
* p ஸ 0.05, ** p ஸ 0.01, *** p ஸ 0.001 as determined by two-tailed paired Student’s t-test.
Figure 3.2: mRNA expression of TBL1X and TBL1XR1 in primary human pancreatic stellate cells
Primary stellate cells were isolated from patient material and cultured before extracting RNA and reverse transcribing to cDNA. Ex-
pression is displayed relative to the pooled organ donor sample that was also used as a reference in ﬁgure 3.1. CP: chronic pancreatitis.
Data are ploed as mean ± SEM. No statistical signiﬁcance was detected by one-way ANOVA.
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Figure 3.3: Protein expression of TBL1X and TBL1XR1 in pancreas of human patients
Protein extracts of human patients were immunobloed for TBL1X and TBL1XR1. Expression was higher in tumor samples than in
adjacent non-tumor tissue when comparing corresponding bands for each patient. NT: non-tumor; T: tumor; VCP: valosin-containing
protein (loading control)
Figure 3.4: Immunohistochemistry staining for TBL1X in human samples
Paraﬃn-embedded tissue sections from human patients were stained for TBL1X.A healthy tissue with acini, duct (arrow) and islet
of Langerhans (doed line) showing no or only very weak nuclear staining in acinar and ductal tissue and cytoplasmic staining in islet
cells;B–C PanIN-1 lesion with nuclear staining;D–E PanIN-2 lesion with nuclear staining;F–G PanIN-3 lesion with nuclear
and faint cytoplasmic staining;H–I tumor cells with nuclear and cytoplasmic staining; scale bar 100 μm unless stated otherwise.
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Figure 3.5: Immunohistochemistry staining for TBL1XR1 in human samples
Paraﬃn-embedded tissue sections from human patients were stained for TBL1XR1. A healthy tissue with acini, duct (arrow) and
islet of Langerhans (doed line) showing no or only very weak nuclear staining ; B–C PanIN-1 lesion with nuclear staining;
D–E PanIN-2 lesion with nuclear staining;F–G PanIN-3 lesion with nuclear staining;H–I tumor cells with nuclear and weak
cytoplasmic (I) staining; scale bar 100 μm unless stated otherwise.
16
3.1 Human patient screening
Table 3.1: Candidate genes for cancer-specific metabolic reprogramming
gene name process metabolic function regulation references
ACLY ATP citrate lyase lipid synthesis; cy-
tosolic acetyl-CoA
conversion of citrate
and CoA to acetyl-
CoA
↑ [122]
CPT1A/B carnitine palmitoyl
transferase
β-oxidation transport of fay
acids into mitochon-
dria
↓ [119]
FASN fay acid synthase lipid synthesis multi-enzyme com-
plex catalyzing
multiple reactions
in fay acid chain
elongation
↑ [119, 123]
G6PD glucose-6-phosphate
dehydrogenase
pentose phosphate
pathway; nucleotide
synthesis
conversion of
glucose-6-phosphate
to 6-phosphogluco-
nolactone
↑ [124]
GLS2 glutaminase 2 citric acid cycle; ROS
defense
conversion of
l-glutamine to
l-glutamate for
citric acid cycle
↓ [125]
GLUT1/2
(SLC2A1/2)
glucose transporter
1/2
glucose metabolism facilitated glucose
transport across
plasma membrane
↑ [119, 126]
LDHa l-lactate dehydroge-
nase A chain
lactate production /
proton extrusion
conversion of pyru-
vate to lactate
↑ [119, 127]
PDK1/4 pyruvate dehydroge-
nase kinase
fuel selection,
reduced oxidative
phosphorylation
inactivation of PDH
by phosphorylation;
reduced ﬂux through
citric acid cycle
↑ [119, 128]
SCD1 stearyl-CoA desatu-
rase
lipid metabolism desaturation of fay
acids
↑ [129]
tissue contrary to reports in literature [119]. CPT1B (carnitine palmitoyl transferase 1, muscle isoform), GLUT2 (glu-
cose transporter 2) and PDK4 (pyruvate dehydrogenase kinase 4) did not show a signiﬁcant regulation (ﬁgure 3.6 on the
following page). In the next step the log2 expression levels of these metabolic genes were ploed versus the log2 ex-pression levels of TBL1X or TBL1XR1 (appendix D, ﬁgure D.2 on page 88 and ﬁgure D.3 on page 89). Linear correlation
coeﬃcients and p values are summarized in table 3.2 on page 19. ACLY, CPT1A, CPT1B, FASN, G6PD, GLUT1, LDHa,
PDK1 and SCD1 had a strong and signiﬁcant positive correlation in gene expression with TBL1X and TBL1XR1. GLS2
had a weak negative correlation that was almost signiﬁcant for TBL1X and signiﬁcant for TBL1XR1. GLUT2 and PDK4
were not diﬀerentially upregulated in tumors and did thus not correlate with either TBL1X or TBL1XR1.
Taken together, these results showed that TBL1X and TBL1XR1 were highly expressed in human PDAC but not in
healthy or chronic pancreatitis tissue. e expression in tumors was speciﬁc for PanIN precursor lesions and cancer
cells implying a role in tumor initiation or progression. Furthermore, the expression levels of TBL1X and TBL1XR1
correlated with expression levels of genes important for tumor cell metabolism. Even though these correlations do not
prove a causal role for TBL1X or TBL1XR1 in the regulation of metabolic genes or vice versa, they are nevertheless an
interesting, and so far unobserved, feature of pancreatic ductal adenocarcinoma.
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Figure 3.6: mRNA expression of metabolic genes in human PDAC patients
Plots show expression of individual patients normalized to 18S-rRNA and relative to a pooled organ donor sample. Lines between dots
connect samples from the same patient. ACLY: ATP citrate lyase; CPT1A: carnitine palmitoyl transferase 1, liver isoform; CPT1B:
carnitine palmitoyl transferase 1, muscle isoform; FASN: fay acid synthase; G6PD: glucose-6-phosphate dehydrogenase; GLS2:
glutaminase 2; GLUT1: glucose transporter 1 (SLC2A1); GLUT2: glucose transporter 2 (SLC2A2); LDHa: l-lactate dehydrogenase A
chain; PDK1: pyruvate dehydrogenase kinase 1; PDK4: pyruvate dehydrogenase kinase 4; SCD1: stearyl-CoA desaturase. * p ஸ 0.05,
** p ஸ 0.01, *** p ஸ 0.001 as determined by two-tailed paired Student’s t-test.
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Table 3.2: Correlation of metabolic genes with TBL1X and TBL1XR1 expression in human patients
R2: correlation coeﬃcient of linear regression; p: signiﬁcance level for slope of regression line diﬀerent from zero, indicated in green
when signiﬁcant (p ஸ 0.05).
TBL1X TBL1XR1
gene R2 p R2 p
ACLY 0.6463 < 0.0001 0.7408 < 0.0001
CPT1A 0.7408 < 0.0001 0.6523 < 0.0001
CPT1B 0.2783 0.0003 0.3765 < 0.0001
FASN 0.4796 < 0.0001 0.5707 < 0.0001
G6PD 0.8074 < 0.0001 0.9083 < 0.0001
GLS2 0.0871 0.0597 0.1122 0.0262
GLUT1 (SLC2A1) 0.6731 < 0.0001 0.7756 < 0.0001
GLUT2 (SLC2A2) 0.0922 0.0568 0.0978 0.0438
LDHa 0.7535 < 0.0001 0.8835 < 0.0001
PDK1 0.7865 < 0.0001 0.8491 < 0.0001
PDK4 0.0499 0.1658 0.0154 0.433
SCD1 0.5723 < 0.0001 0.6598 < 0.0001
3.2 Mouse study on tumor-promoting eﬀects of high fat diet
3.2.1 Body weight and body fat increase during high fat diet feeding
Even though transcriptional co-regulator gene expression levels were equal for lean and obese patients, it may be pos-
sible that diﬀerences can only be observed at earlier stages of disease development and not in advanced cancer. To this
end, wild type and p48 +/Cre; Kras +/LSL-G12D mice were fed with a high fat diet (HFD) or low fat diet (LFD) for 12 weeks as
described in section 5.12.4 on page 61 with n = 5–13 per group. is regime leads to diet-induced obesity and metabolic
disorders and closely mirrors the human situation [130].
During the course of the experiment, animals on HFD became obese as expected. Interestingly, male p48 +/Cre;
Kras +/LSL-G12D animals but not females showed decreased weight gain, both on LFD and on HFD. Wild type males gained
49% of weight compared to the start of the experiment on LFD and 97% on HFD whereas p48 +/Cre; Kras +/LSL-G12D males
only gained 36% on LFD and 58% on HFD. Female wild type animals had a weight gain of 18% on LFD and 77%
on HFD and female p48 +/Cre; Kras +/LSL-G12D mice had similar results with 24% weight gain on LFD and 74% on HFD
(ﬁgure 3.7A on page 21). When calculating the area under curve for weight gain and performing a three-way ANOVA
(with factors sex, genotype and diet), a signiﬁcant main eﬀect for sex and diet alone, and the interaction of genotype
and diet was observed. Furthermore, there were almost signiﬁcant main eﬀects for genotype alone (p = 0.057), and for
the interaction of sex and genotype (p = 0.051, table E.2 on page 93).
ree-way ANOVA in males (with factors time, genotype and diet) showed signiﬁcant main eﬀects for genotype
and diet alone, as well as for the interaction of genotype and diet (table E.3 on page 94). In females there was a signiﬁ-
cant main eﬀect of diet alone, and the interaction of genotype and diet, but not for genotype alone (table E.4 on page 95).
e increase in body fat was in line with the weight gain. At the beginning of the study, all animals had an average
body fat content of 10.6 ± 2.7%. At the end of the 12-week period, wild type males had 29% body fat on LFD and 45%
on HFD while p48 +/Cre; Kras +/LSL-G12D males had 19% on LFD and 33% on HFD. Female wild type mice had 19% body
fat on LFD and 46% on HFD whereas p48 +/Cre; Kras +/LSL-G12D females had 13% on LFD and 34% on HFD (ﬁgure 3.7B).
ree-way ANOVA (with factors sex, genotype and diet) for the area under curve of body fat gave a signiﬁcant main
eﬀect for genotype and diet alone, as well as their interaction, whereas there was no signiﬁcant main eﬀect for sex
(p = 0.096, table E.5 on page 96).
When performing a three-way ANOVA in males only (with factors time, genotype and diet), there was a signiﬁcant
main eﬀect for genotype and diet alone, but not for the interaction of both (table E.6 on page 97). In females there was
a signiﬁcant main eﬀect for genotype and diet alone, as well as their interaction (table E.7 on page 98).
Perigonadal white adipose tissue (WAT) at necropsy was heavier in HFD animals compared to LFD animals except
for wild type males (ﬁgure 3.7C). ree-way ANOVA (with factors sex, genotype and diet) detected a signiﬁcant main
eﬀect for genotype and diet alone, and the interaction of sex and diet, both for absolute fat pad weight (table E.8 on
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page 99) and for fat pad weight relative to body weight (table E.9 on page 100). On the other hand, wild type males
showed a slight diﬀerence in liver weight whereas wild type females and p48 +/Cre; Kras +/LSL-G12D males and females had
no changes (ﬁgure 3.7D). ree-way ANOVA showed signiﬁcant main eﬀects for sex, genotype, and diet alone, and the
interaction of sex and genotype regarding absolute liver weight (table E.10 on page 101). For liver weight relative to
body weight there were signiﬁcant main eﬀects for sex and diet alone, as well as for the interaction of sex and genotype,
and the interaction of sex and diet (table E.11 on page 102). Also, contrary to predictions, male wild type animals on LFD
had high liver weights and histology revealed fay livers for all of them. Female wild type mice on LFD, on the other
hand, rarely developed fay livers and if so only to a very mild extend. Possible reasons for this have to be discussed
together with the observed diﬀerences in body weight and body fat development in male animals (see section 4.1 on
page 41).
3.2.2 High fat diet leads to increased fasting blood glucose levels
During the course of the 12-week feeding, animals on HFD showed signs of a pre-diabetic phenotype as expected.
Four weeks aer diet administration, HFD animals showed slightly increased blood glucose aer over night fasting and
diﬀerences where more pronounced in wild type animals, as was also reﬂected in three-way ANOVA with signiﬁcant
main eﬀects for genotype and diet (table E.12 on page 103). Eight weeks aer diet administration, wild type animals on
HFD showed greater diﬀerences than at four weeks, especially in males. In p48 +/Cre; Kras +/LSL-G12D mice the diﬀerences
between HFD and LFD animals were smaller than in wild type but slightly bigger than at four weeks. ree-way
ANOVA gave signiﬁcant main eﬀects for sex, genotype, and diet alone, as well as all possible interactions (table E.13 on
page 104). Twelve weeks aer start of the diet, animals were killed and blood glucose was determined again. is
was done in random fed state to not stress the animals by fasting and thus aﬀect the sampled organs. Blood glucose
levels under these circumstances were still higher in wild type animals on HFD compared to wild types on LFD even
though with a greater variance. No diﬀerence was observed in p48 +/Cre; Kras +/LSL-G12D animals (ﬁgure 3.8A on page 22).
ree-way ANOVA did not detect any signiﬁcant main eﬀects here (table E.14 on page 105).
Parallel to blood glucose measurement, blood was also sampled to determine insulin levels. At four and eight weeks,
no clear diﬀerenceswere discernible in the fasted state although somemales in bothwild type and p48 +/Cre; Kras +/LSL-G12D
showed relatively high values. In many samples, however, insulin levels were below the detection limit of the ELISA as
would be expected during fasting. In the random fed state aer 12 weeks of diet, insulin levels were increased in HFD
animals compared to LFD with diﬀerences being more pronounced in wild types. Especially some of the wild type males
on HFD had dramatically high insulin levels (ﬁgure 3.8B). ree-way ANOVA, however, did not detect signiﬁcant main
eﬀects, possibly due to the big variance introduced by the wild type males on HFD (tables E.15–E.17 on page 105–106).
3.2.3 High fat diet leads to decreased survival in p48 +/Cre; Kras +/LSL-G12D mice
Several p48 +/Cre; Kras +/LSL-G12D animals, predominantly males, became moribund during the course of the study. First
signs were diﬃculties in correctly moving the hind legs progressing to overt limping and in some cases complete paral-
ysis of the leg(s) within 2–3 days. is was oen accompanied by crouching and apathy, both signs of severe distress,
as well as weight loss. e laer might be due to either anorexia or decreased nutrient uptake as a consequence of
pancreatic exocrine insuﬃciency reﬂected in increased fecal triglycerides and free fay acids (table 3.3 on page 22).
When such behavior was observed, animals were killed for ethical reasons and blood and organs were sampled as de-
scribed in section 5.12.4 on page 61. Kaplan-Meier survival curves are shown in ﬁgure 3.9 on page 23. Somemice showed
structures resembling invasive carcinoma. A thorough analysis by an experienced mouse pathologist will, however, be
needed to conﬁrm and quantify these ﬁndings to judge if HFD promotes tumorigenesis in p48 +/Cre; Kras +/LSL-G12D mice.
Details on age and survival time of individual mice are given in appendix E on page 91, table E.1. ese results suggested
that obesity and diabetes aggravate disease development in pancreatic cancer leading to reduced survival.
3.2.4 Tbl1x and Tbl1xr1 are highly expressed in murine PanIN lesions
In protein extracts from pancreas, Tbl1x and Tbl1xr1 were highly expressed in p48 +/Cre; Kras +/LSL-G12D animals compared
to wild type mice (ﬁgure 3.10 on page 23). is nicely reﬂects the paern seen in human samples where expression in
tumor tissue was higher. Concomitantly, no diﬀerences could be detected between lean (LFD) and obese (HFD) mice for
expression of Tbl1x and Tbl1xr1.
Besides, also components of the insulin signaling cascade were examined, namely Irs1 (insulin receptor substrate 1),
Akt (protein kinase B) and Ampk (5’-AMP-activated protein kinase catalytic subunit alpha-2) as markers for diabetes
and obesity. Irs1 was found to be more expressed in HFD mice. Phosphorylation of Irs1 at tyrosine 895¹ was only
¹Phosphorylation of tyrosine 895 in IRS-1 generates a binding site for Grb2, which mediates the downstream signaling leading to MAP kinase
activation and mitogenesis [131]
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Figure 3.7: Weight and body fat development of p48 +/Cre; Kras +/LSL-G12D and wild type mice on HFD/LFD
5–12 week old wild type and p48 +/Cre; Kras +/LSL-G12Dmice were fed a HFD or LFD for 12 weeks.A: change in body weight compared
to day zero for males (le panel) and females (right panel); B: percent body fat in males (le panel) and females (right panel) as
determined by in vivo EchoMRI™ measurement;C: perigonadal white adipose tissue (WAT) at necropsy in wet weight (le panel)
and relative to total body weight (right panel, mg tissue per g body weight);D: liver weight at necropsy in wet weight (le panel)
and relative to total body weight (right panel, mg tissue per g body weight). Values inA andB ploed as mean ± SEM. Lines and
error bars inC andD: median with interquartile range.
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Figure 3.8: Metabolic parameters of p48 +/Cre; Kras +/LSL-G12D and wild type mice on HFD/LFD
5–12 week old wild type and p48 +/Cre; Kras +/LSL-G12D mice were fed a HFD or LFD for 12 weeks. A: blood glucose aer over night
fasting (16–18 h) at weeks 4 and 8 of HFD/LFD feeding and blood glucose at time of sacriﬁce (12 weeks of HFD/LFD feeding) in
random fed state;B: plasma insulin aer over night fasting (16–18 h) at weeks 4 and 8 of HFD/LFD feeding and serum insulin at
time of sacriﬁce (12 weeks of HFD/LFD feeding) in random fed state. Lines and error bars: median with interquartile range.
Table 3.3: Fecal triglycerides and free fay acids in p48 +/Cre; Kras +/LSL-G12D mice
Mice were put to fresh cages and feces were collected 24 h later from one cage with a male p48 +/Cre; Kras +/LSL-G12D mouse that had
been on HFD for 11 weeks, one cage with two male wild type mice on HFD for 11 weeks and one cage with four female mice on LFD
for 11 weeks, of which one was wild type and the others were p48 +/Cre; Kras +/LSL-G12D. Feces were weighed and lipids were extracted
and measured as described in section 5.19 on page 75.
total feces feces per triglycerides free fatty acids
group [mg] mouse [mg] morphology [nmol/mg] [nmol/mg]
male p48+/Cre;
Kras+/LSL-G12D HFD
112.1 112.1 big pieces, so, dark in
color
382.8 56.2
male wild type
HFD
112.5 56.25 small pieces, hard,
bright in color
n. d. 28.8
female mixed LFD 102.8 25.7 small pieces, hard,
bright in color
n. d 8.8
22
3.2 Mouse study on tumor-promoting effects of high fat diet
Figure 3.9: Survival curves of p48 +/Cre; Kras +/LSL-G12D and wild type mice on HFD/LFD
Mice were killed when becoming moribund and classiﬁed as dead for Kaplan-Meier analysis. p-values determined by pairwise com-
parison.
Figure 3.10: Protein expression of pancreas from p48 +/Cre; Kras +/LSL-G12D and wild type mice on HFD/LFD
Irs1: insulin receptor substrate 1; Akt: protein kinase B; Ampk: 5’-AMP-activated protein kinase catalytic subunit alpha-2; Vcp:
valosin-containing protein (loading control).
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Figure 3.11: Immunohistochemistry staining for Tbl1x in mouse pancreas
Paraﬃn-embedded tissue sections from wild type (A) or p48 +/Cre; Kras +/LSL-G12D mice (B–I) were stained for Tbl1x. A healthy
tissue with acini and islet of Langerhans (doed line) showing weak nuclear staining;B–C PanIN-1 lesion with nuclear staining;
D–E PanIN-2 lesion with nuclear staining;F–G PanIN-3 lesion with nuclear staining;H–I tumor cells with nuclear staining;
scale bar 100 μm.
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Figure 3.12: Immunohistochemistry staining for Tbl1xr1 in mouse pancreas
Paraﬃn-embedded tissue sections from wild type (A) or p48 +/Cre; Kras +/LSL-G12Dmice (B–I) were stained for Tbl1xr1.A healthy
tissue with acini, duct (arrow) and islet of Langerhans (doed line) showing weak nuclear and partial cytoplasmic staining;B–C
PanIN-1 lesion with nuclear staining;D–E PanIN-2 lesion with nuclear and sporadic faint cytoplasmic staining;F–G PanIN-3
lesion with nuclear and faint cytoplasmic staining;H–I tumor cells with nuclear and cytoplasmic staining; scale bar 100 μm.
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found in p48 +/Cre; Kras +/LSL-G12D animals with reduced levels in HFD animals. Phosphorylation at serine 1101² was
not markedly changed since the paern of band intensities mostly resembled that of total Irs1. Akt was slightly more
expressed in p48 +/Cre; Kras +/LSL-G12D mice compared to wild types and also in HFD animals compared to LFD. Phospho-
Akt levels were higher in HFD wild types compared to LFD wild types. Expression of Ampk was also higher in p48 +/Cre;
Kras +/LSL-G12D compared to wild types, and in HFD animals compared to LFD. Phospho-Ampk band intensities followed
the paern seen for total Ampk (ﬁgure 3.10 on page 23) indicating no change in phosphorylation. ese data suggested
that metabolic signaling was altered in pancreatic tumors, as reﬂected in elevated levels of phospho-Tyr895-Irs1, Akt
and Ampk in p48 +/Cre; Kras +/LSL-G12D animals.
Finally, it was of interest which cell types were responsible for increased expression of Tbl1x and Tbl1xr1 in p48 +/Cre;
Kras +/LSL-G12D mice. To that end paraﬃn sections were stained for both proteins using immunohistochemistry as de-
scribed in section 5.13.3.2 on page 63 and section 5.13.3.4 on page 63. In accordance with the observation made in
human samples, there was lile to no expression in healthy wild type tissue but pronounced staining in PanINs and
carcinoma cells of p48 +/Cre; Kras +/LSL-G12D animals. Tbl1x showed exclusively nuclear staining while Tbl1xr1 presented
nuclear staining in low grade PanINs and slight cytoplasmic staining in high grade PanINs and carcinoma cells (ﬁg-
ure 3.11 on page 24 and ﬁgure 3.12 on the previous page). erefore, TBL1X and TBL1XR1 expression in PanIN lesions
and carcinoma cells seems to be a conserved feature of PDAC, both in humans and mice.
3.3 In vitro studies on proliferation and metabolism
3.3.1 TBL1X and TBL1XR1 regulate proliferation in cell culture
Figure 3.13: Validation of siRNA-mediated knockdown in Capan-1 cells
Capan-1 cells were plated and on the following day transfected with siRNA as described in section 5.14.7 on page 65. 24 h later, cells
were either lyzed for RNA or protein extraction or mediumwas changed and cells were grown further before lysis and RNA or protein
extraction. A: mRNA expression levels for TBL1X relative to TBP. B: mRNA expression levels for TBL1XR1 relative to TBP. C:
protein expression of TBL1X. D: protein expression of TBL1XR1. VCP: valosin-containing protein (loading control). Data ploed
as mean ± SEM. * p ஸ 0.05 / ** p ஸ 0.01 / *** p ஸ 0.001 vs. no siRNA; # p ஸ 0.05 / ## p ஸ 0.01 / ### p ஸ 0.001 vs. siNC; determined by
two-tailed Welch’s t-test.
e strong upregulation of TBL1X and TBL1XR1 in human and mouse tumors and their known interaction with the
Wnt/β-catenin pathway [92, 93] led to the assumption that they might play a role in tumor cell growth. To investigate
this question, the human PDAC cell line Capan-1 was transfected with unspeciﬁc or TBL1X-speciﬁc siRNA (ﬁgure 3.13)
to study cell proliferation. Knockdown of TBL1X and TBL1XR1 led to a signiﬁcant reduction in BrdU incorporation 72 h
²Phosphorylation of IRS-1 at serine 1101 is mediated by PKCθ and results in an inhibition of insulin signaling in the cell, suggesting a potential
mechanism for insulin resistance in some models of obesity [132]
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Figure 3.14: TBL1X and TBL1XR1 regulate proliferation in Capan-1 cells
Capan-1 cells were plated and on the following day transfected with siRNA.A: 24 h aer transfection, mediumwas renewed and cells
were grown for another 48 h before labeling with BrdU for 45 min followed by ﬁxation and detection as described in section 5.15.1 on
page 65. Graph shows a representative experiment with duplicate wells per condition. ree random ﬁelds per well were imaged
and ≥ 1000 cells counted per condition.B: 24 h aer transfection, medium was renewed and cells were grown for another 24 or 48 h
before trypsinizing and counting in a Neubauer counting chamber. Graph shows a representative experiment with duplicate wells
per condition on 12-well plates.C: 24 h aer transfection, medium was renewed and cells were grown for another 24 or 48 h before
assessing cell viability with PrestoBlue® Cell Viability Reagent (Life Technologies™) as described in section 5.15.3 on page 66. Graph
shows a representative experiment with 8 wells per condition on a 96-well plate. Data ploed as mean ± SEM. * p ஸ 0.05 / ** p ஸ 0.01
/ *** p ஸ 0.001 vs. no siRNA; # p ஸ 0.05 / ## p ஸ 0.01 / ### p ஸ 0.001 vs. siNC; determined by two-way ANOVA.
aer transfection both in presence or absence of FBS. Accordingly, cell numbers were lower at 48 and 72 h aer transfec-
tion when counting cells or measuring cell viability via mitochondrial reduction of the resazurin-based dye PrestoBlue®
(ﬁgure 3.14). is clearly demonstrated that TBL1X and TBL1XR1 play a role in cell growth and proliferation.
To gain further insight, RNA samples from siRNA-mediated knockdown in Capan-1 cells aer 24 hwere analyzedwith
Aﬀymetrix gene expression arrays. At a signiﬁcance level of p <10−6.04, 885 genes were regulated by TBL1X and 864 by
TBL1XR1 with an overlap of 183 genes. Overrepresentation analysis and Gene Set Enrichment Analysis of annotated
gene sets revealed a signiﬁcant regulation of cell cycle-associated pathways and p53 signaling. A detailed listing is given
in appendix F. Figure 3.15 on the next page shows a heatmap of regulated cell cycle and p53 signaling genes.
3.3.2 TBL1X and TBL1XR1 are regulated by metabolic stimuli
Aer observing the eﬀect of TBL1X and TBL1XR1 on Capan-1 cell proliferation (ﬁgure 3.14) and their correlation with
metabolic genes in human samples (table 3.2 on page 19), it was tested whether these genes were regulated aer siRNA-
mediated knockdown. erefore, those four metabolic genes were chosen that had the strongest correlation in human
samples for both TBL1X and TBL1XR1, namely G6PD, GLUT1, LDHa and PDK1. No relevant change was, however,
seen for any of these genes aer knockdown of either TBL1X or TBL1XR1 (ﬁgure 3.16 on page 29).
Nevertheless, possible links between TBL1X/TBL1XR1 and cell metabolism were further examined, partially based
on the observations in p48 +/Cre; Kras +/LSL-G12D mice where HFD feeding led to decreased survival. erefore, it was
assessed whether metabolic stimuli were capable of regulating TBL1X or TBL1XR1 expression levels. When culturing
Capan-1 and BxPC-3 cells under low-glucose conditions, a signiﬁcant upregulation of TBL1X but not TBL1XR1 mRNA
expression could be observed (ﬁgure 3.17 on page 29). Furthermore, TBL1X mRNA levels increased over time, possibly
due to cell growth-dependent glucose depletion of the media. e upregulation was most striking in BxPC-3 cells that
also had a 30–50 fold lower basal expression of TBL1X (relative to TBP which had similar CT values in both cell lines).
To investigate TBL1X and TBL1XR1 expression in response to stimulation of metabolic pathways, cells were treated
either with insulin or forskolin, the laer raising intracellular cAMP levels thus mimicking glucagon signaling during
fasting. In accordance to the ﬁndings from the low-glucose experiment, a robust induction of TBL1X but not TBL1XR1
could be seen in three diﬀerent human pancreatic cancer cell lines aer forskolin stimulation. e opposite regulation
was observed in response to insulin (ﬁgure 3.18 on page 30). is suggested that TBL1X expression was regulated in
response to cellular energy status.
3.3.3 TBL1X and TBL1XR1 regulate tumor cell metabolism
Aer observing the eﬀect of metabolic stimulation on TBL1X expression, it was examined if the eﬀect of TBL1X and
TBL1XR1 knockdown on proliferation is also reﬂected in tumor cell metabolism. To do so, Capan-1 cells were cultured
and glucose consumption was measured. Knockdown of TBL1X and TBL1XR1 did indeed result in decreased glucose
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Figure 3.15: Heatmap of cell cycle and p53 signaling
Genes annotated to KEGG pathways “hsa04115 cell cycle” and “hsa04110 p53 signaling” and signiﬁcantly regulated by either TBL1X
or TBL1XR1 at p ழ 0.05 are ploed.
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Figure 3.16: Expression levels of metabolic genes aer knockdown of TBL1X or TBL1XR1
Metabolic genes that showed the strongest correlation with TBL1X and TBL1XR1 in human PDAC samples were analyzed in Capan-1
cells aer siRNA-mediated knockdown. Cells were plated and on the following day transfectedwith siRNA. 24 h later, cells were either
lyzed for RNA extraction or medium was changed and cells were grown further before lysis and RNA extraction. G6PD: glucose-
6-phosphate dehydrogenase; GLUT1: glucose transporter 1 (SLC2A1); LDHa: l-lactate dehydrogenase A chain; PDK1: pyruvate
dehydrogenase kinase 1. Data ploed as mean ± SEM. * p ஸ 0.05 / ** p ஸ 0.01 / *** p ஸ 0.001 vs. no siRNA; # p ஸ 0.05 / ## p ஸ 0.01 /
### p ஸ 0.001 vs. siNC; determined by two-tailed Welch’s t-test.
Figure 3.17: Regulation of TBL1X and TBL1XR1 expression by extracellular glucose levels
Capan-1 and BxPC-3 cells were seeded at 1×105 cells per well in 12-well plates in 1mlDMEMHigh Glucose Pyruvate (25mm glucose).
e following day, medium was changed to either fresh DMEM High Glucose Pyruvate (25mm glucose) or DMEM Low Glucose
Pyruvate (5.55mm glucose) and cells were grown for another 24, 48 or 72 h before lyzing and extracting RNA. Data ploed as mean
± SEM. * p ஸ 0.05 / ** p ஸ 0.01 / *** p ஸ 0.001 vs. 25mm glucose determined by two-way ANOVA.
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Figure 3.18: Regulation of TBL1X and TBL1XR1mRNA expression by stimulation with insulin and forskolin
mRNA expression levels of TBL1X and TBL1XR1 in Capan-1, Capan-2 and AsPC-1 human pancreatic cancer cell lines. 24–30 h aer
seeding, cells were serum-starved over night in DMEM High Glucose Pyruvate (25mm glucose) with 0.5% BSA and stimulated with
100 nm insulin or 10 μm forskolin for 6 h in serum-free media (DMEM High Glucose Pyruvate with 0.5% BSA). Graphs show pooled
data from 1–4 experiments per cell line with technical triplicates in each experiment ploed as mean ± SEM. *** p ஸ 0.001 determined
by Welch’s t-test.
consumption (ﬁgure 3.19A and ﬁgure 3.19B on the next page). A tracer study with radioactive 3H-2-deoxyglucose
further revealed that 48 h aer siRNA-transfection, glucose uptake rates were diminished by 25–35% (ﬁgure 3.19D). As
these data indicated a reduction in glycolytic activity, extracellular ﬂux measurement was performed using Seahorse
technology. is technique measures cellular oxygen consumption (indirect measure of mitochondrial function) and
culturemedia acidiﬁcation (indirect measure of glycolytic activity) in live cells in a 96-well format. Injection of chemicals
allows to assess diﬀerent functional parameters (see appendix G on page 117). In accordance with the previous ﬁndings,
a decrease in glycolytic activity could be detected 48 h aer siRNA-mediated knockdown of TBL1X. Mitochondrial
function, however, was not changed under the same conditions (ﬁgure 3.20 on the next page).
Next, the growth behavior of Capan-1 cells was examined under glucose-free conditions following siRNA-mediated
knockdown of TBL1X and TBL1XR1 by means of EdU incorporation³. Interestingly, Capan-1 cells with TBL1X-knock-
down had equal proliferation rates with and without glucose whereas in control-transfected and TBL1XR1-knockdown
cells proliferation was markedly reduced in the glucose-free condition (ﬁgure 3.21 on page 32). is suggested that
TBL1X-deﬁciency made cells less dependent on glucose.
3.3.4 The Urocortin 3 pathway is not involved in the regulation of TBL1X
A potential way by which insulin and forskolin might regulate the expression of TBL1X is the corticotropin-releasing
factor family member urocortin 3 (UCN3). It is expressed in pancreatic β-cells and stimulates insulin and glucagon secre-
tion [133] while being itself secreted aer stimulation with high glucose or the insulin secretagogue GLP1 (glucagon-like
peptide 1) in vitro. Expression is also high in pancreases from HFD or ob/ob mice [134]. Ucn3 exerts its intracellular
eﬀects by binding extracellularly to the G protein-coupled 7-transmembrane corticotropin-releasing hormone receptor
2 (CRHR2) while having a very low aﬃnity for CRHR1 [135]. When administered to the central nervous system, it
activates the hypothalamic-pituitary-adrenal axis resulting in decreased food intake and elevated blood glucose [136]
(ﬁgure 3.22 on page 32).
It was hypothesized that metabolic stimuli would induce UCN3 secretion which then activates intracellular signaling
regulating TBL1X expression. When checking mRNA levels of GLP1 receptor (GLP1R) as well as CRHR1 and CRHR2
in human samples, no signiﬁcant regulation was visible except for a slight upregulation of CRHR1 in tumors of lean
patients (ﬁgure 3.23 on page 33). Moreover, Capan-1 cells did not express neither the Ucn3-speciﬁc receptor CRHR2
nor its homolog CRHR1. erefore, the conclusion was made that this pathway does not play a role in the observed
metabolic regulation of TBL1X.
³Since the experiments shown in ﬁgure 3.14 on page 27 the Click-iT® EdU Imaging Kit (Invitrogen™) had been introduced to the market. Due to
its easier and less time consuming handling as well as longer shelf life and beer performance, this kit was then applied instead of the previously
used BrdU kit.
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Figure 3.19: TBL1X and TBL1XR1 regulate glucose uptake in Capan-1 cells
Capan-1 cells were treated as described in section 5.15.6 on page 68. A: absolute glucose consumption (mean of 3 independent
experiments with technical triplicates for each group). B: glucose consumption was normalized to account for siRNA-aﬀected cell
growth by dividing absolute values by area under curve. C: Cell growth model for normalization. Cells were seeded at 1×105 cells
per well on 12-well plates and counted at end of assay. Cell growth was modeled postulating exponential growth. siRNA was applied
24 h aer seeding and assumed to take eﬀect 6 h later, therefore growth rates were considered equal for all groups until this time
point and diverging aerwards to reach cell numbers measured at end of assay. Area under curve was calculated for each group and
used for normalization. D: radioactive 2-deoxyglucose uptake assay was performed as described in section 5.15.7 on page 68. Data
ploed as mean ± SEM. * p ஸ 0.05 / ** p ஸ 0.01 / *** p ஸ 0.001 vs. no siRNA; # p ஸ 0.05 / ## p ஸ 0.01 / ### p ஸ 0.001 vs. siNC, determined
by one-way ANOVA.
Figure 3.20: TBL1X alters glycolytic function in Capan-1 cells
Capan-1 cells were treated as described in section 5.15.4 on page 66.A: Mitochondrial functionmeasured by oxygen consumption rate
(OCR) under basal conditions (time points 1–4) or aer injection of indicated chemicals.B: Glycolytic activity function measured by
extracellular acidiﬁcation rate (ECAR) under basal conditions (time points 1–4) or aer injection of indicated chemicals. Data ploed
as mean ± SEM. n = 9 wells per condition; * p ஸ 0.05 / ** p ஸ 0.01 / *** p ஸ 0.001 vs. no siRNA; # p ஸ 0.05 / ## p ஸ 0.01 / ### p ஸ 0.001
vs. siNC, determined by one-way ANOVA.
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Figure 3.21: TBL1X deficiency enhances growth of Capan-1 cells in the absence of glucose
Cells were seeded on chamber slides and on the following day transfected with siRNA. 24 h aer transfection, medium was changed
to DMEM with 10% dialyzed FBS with or without 25mm glucose. Cells were grown for another 48 h before labeling with EdU for
45 min followed by ﬁxation and staining as described in section 5.15.2 on page 66. Graph shows representative experiment with
duplicate wells per condition. 5 random ﬁelds per well were imaged and ≥ 870 cells counted per well. Data ploed as mean ± SEM.
* p ஸ 0.05 / ** p ஸ 0.01 / *** p ஸ 0.001 vs. no siRNA; # p ஸ 0.05 / ## p ஸ 0.01 / ### p ஸ 0.001 vs. siNC; $ p ஸ 0.05 / $$ p ஸ 0.01 /
$$$ p ஸ 0.001 vs. +glucose, determined by two-way ANOVA.
Figure 3.22: Schematic overview of Ucn3 action
Ucn3 is expressed in pancreatic β-cells. Its secretion can be stimulated by high glucose, GLP1 or forskolin. It then stimulates glucagon
secretion from α-cells in a paracrine manner or secretion of insulin from β-cells via an autocrine loop through its receptor CRHR2.
In the ventromedial hypothalamus it suppresses food intake.
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Figure 3.23: Expression of GLP1R, CRHR1 and CRHR2 in human PDAC
Plots show expression of individual patients normalized to 18S-rRNA and relative to a pooled organ donor sample. Lines between dots
connect samples from the same patient. GLP1R: glucagon-like peptide 1 receptor; CRHR1: corticotropin-releasing factor receptor 1;
CRHR2: corticotropin-releasing factor receptor 2; * p ஸ 0.05, ** p ஸ 0.01, *** p ஸ 0.001 as determined by two-tailed paired Student’s
t-test.
3.4 Subcutaneous allogra studies
3.4.1 Tbl1x deficiency aenuates growth of established tumors in vivo
Based on the ﬁndings of TBL1X and TBL1XR1 function in cell proliferation a mouse experiment was designed to test
its role in an in vivo seing. Since no eﬀect was observable for TBL1XR1 in any of the metabolic experiments, the focus
was put on TBL1X alone.
To this end, Panc02 cells were used, which are a well-established syngeneic implantation model for C57BL/6 mice
[137]. e cells used in the present study additionally had stable expression of luciferase that had been introduced
previously via lentiviral gene transfer (Prof. Dr. Ana Martin-Villalba’s lab, DKFZ). is made it possible to monitor
tumor growth not only by percutaneous measurement of tumor size but also by means of in vivo bioluminescence
imaging. e cells were injected subcutaneously into 9-week old male C57BL/6N mice as described in section 5.12.5 on
page 61. Four days later, animals were shaved at the site of injection to inspect tumor growth. At this early time point,
tumors were very small (≈ 1mm) and impossible to measure with a digital caliper in a reliable manner. Bioluminescence
imaging, however, gave a weak but well-observable signal. At 6 days aer implantation, tumors were big enough to
be measured with a digital caliper and it was begun to inject 1×108 ifu of adenovirus expressing unspeciﬁc or Tbl1x-
speciﬁc shRNA directly into the tumors every 2–3 days. is treatment was able to slow tumor growth signiﬁcantly 9
days aer the ﬁrst viral injection (ﬁgure 3.24A–B and ﬁgure 3.25 on the next page). Twenty days aer implantation,
the tumors in the control-shRNA-injected animals had reached the maximum size of 15mm that is allowed by German
Protection of Animals Act (Tierschutzgesetz). Mice were then killed and tumors were excised, weighed and cut in
three pieces as depicted in ﬁgure 5.1 on page 62 for histology as well as extraction of RNA and proteins. e mass of
Tbl1x-shRNA-treated tumors was lower than that of control-shRNA-treated ones (ﬁgure 3.24C). A reduction in Tbl1x
was, however, neither observable on mRNA level nor on protein level or in immunohistochemistry (data not shown),
though the adenovirus’ capability to induce Tbl1x-knockdown was tested prior to this mouse study in Panc02 cells in
vitro (ﬁgure 3.26 on page 35). Possible explanations for the lack of detectable knockdown in the established tumors will
be discussed later (section 4.3.1 on page 43).
3.4.2 Tbl1x deficiency sensitizes established tumors towards gemcitabine
Based on the observations in cell culture of TBL1X aﬀecting cellular glucose metabolism it was of interest if deﬁciency of
the protein could render pancreatic cancer cells sensitive to chemotherapeutic agents as has been suggested by previous
work from others [138, 139]. In vitro studies in a collaboration project had shown that knockdown of TBL1X resulted
in increased apoptotic cell death aer treatment with DNA damage-inducing drugs doxorubicin or gemcitabine (Vera
Greiner and Dr. omas Hofmann, DKFZ, unpublished).
erefore, Panc02 cells were infectedwith a lentivirus expressing unspeciﬁc orTbl1x-speciﬁc shRNA and a population
with stable integration of the viral construct was selected (see section 5.16.4 on page 69). Already in vitro, Tbl1x-deﬁcient
cells had a slower growth rate than control-shRNA-transduced cells (20% less EdU positive cells). ese cells were then
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Figure 3.24: Tumor growth of adenovirus-treated subcutaneous Panc02 allogras
Luciferase-expressing Panc02 cells were injected subcutaneously into the right ﬂank of C57BL/6N mice and tumor growth was mon-
itored by percutaneous measurement and bioluminescence as described in section 5.12.5 on page 61. At days 8, 11, 13, 15 and 18
aer implantation, 1×108 ifu of shRNA-expressing adenovirus were injected directly into the tumors as described in section 5.12.8 on
page 61. At day 20 aer implantation, animals were killed and tumors were sampled for further analysis.A: tumor volume;B: tu-
mor luminescence (see also ﬁgure 3.25);C: tumor weight at necropsy. All values ploed as mean ± SEM. n = 3–4 animals per group.
* p ஸ 0.05, ** p ஸ 0.01, *** p ஸ 0.001 as determined by two-way ANOVA with Bonferroni post-test (A,B) or by one-tailed Welch’s
t-test (C).
Figure 3.25: Tumor luminescence of adenovirus-treated subcutaneous Panc02 allogras
Bioluminescence images of two representative mice from the experiment described in ﬁgure 3.24 are shown.
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Figure 3.26: Adenoviral knockdown in Panc02 cells in vitro
Panc02 cells were seeded and the following day infected as described in section 5.16.5 on page 69 with a 1:2 serial dilution series of
adenovirus expressing a negative control (NC) or Tbl1x-speciﬁc shRNA ranging from an MOI of 250 down to 0.244. Cells were lyzed
48 h aer infection and RNA was extracted for quantitative PCR analysis.
implanted subcutaneously into male C57BL/6N mice as before. When tumors had grown to a palpable size, mice were
injected three times per week intraperitoneally with three diﬀerent dosages of gemcitabine (20, 60 and 120mg/kg), which
is the most commonly used chemotherapeutic drug in the treatment of human pancreatic cancer. Tbl1x-knockdown
alone already resulted in reduced growth as was previously also observed in the intratumoral adenovirus-injection
study. Gemcitabine showed a dose-dependent eﬀect on tumor growth as expected. Furthermore, a synergistic eﬀect
of Tbl1x-deﬁciency and chemotherapeutic treatment could be seen. e lowest gemcitabine dosage of 20mg/kg was
already able to provoke a stall of tumor growth in Tbl1x-knockdown tumors whereas in control tumors this was only
achieved with the highest dose of 120mg/kg (ﬁgure 3.27 on the next page). e eﬀect became clearest when ploing the
volume of each tumor relative to its volume on day 7 post implantation (ﬁgure 3.27B) and calculating the area under
curve (ﬁgure 3.27D). e eﬀect of Tbl1x-knockdown and gemcitabine dosage was also reﬂected in ﬁnal tumor weight at
necropsy (ﬁgure 3.27E).
When analyzing mRNA extracted from tumors, a knockdown of Tbl1x between 33 and 48% (ﬁgure 3.28 on the fol-
lowing page) could be measured while knockdown-eﬃciency in Panc02 cells directly before implantation was 75%.
Furthermore, a signiﬁcant reduction in proliferating (Ki-67 expressing) cells could be detected aer Tbl1x knock-
down in the NaCl-treated group. In the group treated with 20mg/kg gemcitabine, the eﬀect of Tbl1x deﬁciency was not
signiﬁcant (p = 0.149), but a trend towards reduced proliferation was visible (ﬁgure 3.29 on page 37).
3.4.3 Tbl1x deficiency leads to reduction of PI3 kinase and downstream eﬀectors
In search of a possible mechanism explaining these observations, the microarray data from Capan-1 cells were exam-
ined and PIK3CA mRNA, encoding for PI3 kinase catalytic subunit p110α, was found to be reduced 1.64-fold in cells
treated with siRNA against TBL1X. When examining protein and RNA samples from Capan-1 cells by immunoblot and
quantitative PCR, the reduction of PI3 kinase could be conﬁrmed (ﬁgure 3.30 on page 37).
Based on these observations, protein expression was evaluated in the subcutaneous tumor allogras and in Panc02
cells directly before implantation. Since the synergistic eﬀect of Tbl1x-knockdown and chemotherapeutic treatment was
most prominent in the animals treated with 20mg/kg gemcitabine, it was decided to focus on these samples (ﬁgure 3.31 on
page 38). First of all, the knockdown of Tbl1x could be conﬁrmed both in allogra tumors and cells prior to injection.
Furthermore, PI3 kinase was reduced in Tbl1x-knockdown samples in accordance to the ﬁndings in Capan-1 cells.
Interestingly, the amounts of downstream eﬀectors of PI3 kinase, namely Akt and Gsk3β (glycogen synthase kinase-3
beta) were also reduced. Levels of phosphorylated Akt were higher relative to total Akt in shTbl1x-tumors compared
to shNC-tumors and in gemcitabine-treated tumors compared to untreated tumors. Phosphorylated Gsk3β was slightly
reduced relative to total Gsk3β in shTbl1x-tumors compared to shNC-tumors and slightly elevated in gemcitabine-
treated tumors relative to untreated tumors. Since PI3 kinase is known to interact with Kras [140, 141], also Kras
downstream eﬀectors Erk-1 and Erk-2 were examined. Levels of total Erk-1 were slightly reduced in gemcitabine-
treated tumors and in shTbl1x-tumors. Erk-2 showed reduction in shTbl1x-tumors. Phosphorylation of Erk-1 and Erk-2
was slightly higher in gemcitabine-treated and in shTbl1x-tumors (ﬁgure 3.31 on page 38 and ﬁgure 3.32 on page 39).
On the other hand, the PI3 kinase antagonist Pten (Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-
speciﬁcity protein phosphatase) was only slightly elevated in gemcitabine-treated shTbl1x-tumors whereas in all other
groups no diﬀerences could be observed. Phosphorylation of Pten was reduced in gemcitabine-treated shTbl1x-tumors
(ﬁgure 3.31 on page 38 and ﬁgure 3.32 on page 39). ese data indicated that Tbl1x regulated the expression of PI3 kinase
and downstream mediators.
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Figure 3.27: Tumor growth of subcutaneous shTbl1x-Panc02 allogras
Panc02 cells with stable expression of Tbl1x-speciﬁc shRNA (via lentiviral gene transfer) were injected subcutaneously into the right
ﬂank of C57BL/6N mice as described in section 5.12.5 on page 61. Starting 7 days aer implantation, site of injection was shaved and
tumor volume was monitored by percutaneous measurement with a digital caliper followed by intraperitoneal injection of 0.9%NaCl
or indicated dosages of gemcitabine in 0.9% NaCl. At day 21 aer implantation, animals were killed and tumors were sampled for
further analysis.A: absolute tumor growth;B: tumor volume relative to day 7 post implantation;C: area under curve of absolute
tumor growth;D: area under curve of tumor volume relative to day 7 post implantation;E: tumor weight at necropsy. All values
ploed as mean ± SEM. n = 4–5 animals per group. For statistical analysis see table H.1 on page 119.
Figure 3.28: mRNA expression of Tbl1x in subcutaneous shTbl1x-Panc02 allogras
Data are ploed as mean ± SEM; *** p ஸ 0.001 vs. shNC determined by two-way ANOVA with Bonferroni post-test.
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Figure 3.29: Proliferation in subcutaneous shTbl1x-Panc02 allogras
Paraﬃn sections from 4–5 tumors per group were stained for expression of the proliferative marker Ki-67 as described in sec-
tion 5.13.3.5 on page 64. Evaluation of Ki-67 positive tumor area was performed as described in section 5.13.4 on page 64. Data
are ploed as mean ± SEM; ** p ஸ 0.01 determined by two-way ANOVA (detailed analysis shown in table H.2 on page 120).
Figure 3.30: Expression of PI3 kinase in siRNA-treated Capan-1 cells
A: Protein samples of Capan-1 cells with siRNA-mediated knockdown of TBL1X were immunobloed. e samples were from the
same experiment as shown in ﬁgure 3.13C on page 26; PI3K p110α: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
alpha isoform; β-actin served as loading control. B: mRNA expression levels for PIK3CA relative to TBP. e samples were from
the same experiment as shown in ﬁgure 3.13A on page 26; PIK3CA: gene encoding for PI3K p110α.
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In the microarray data from siRNA-mediated TBL1X knockdown in Capan-1 cells also the cell cycle regulators CDK2
and CDK4 were downregulated. is was also observed in the subcutaneous tumors and pre-implantation cells ex-
pressing Tbl1x-shRNA, albeit Cdk2 only showed a slight reduction. Since Gsk3β can phosphorylate cyclin D1 and thus
enhance its ubiquitinylation and proteasomal degradation [142], an immunoblot was performed for this protein and it
was found to be reduced in Tbl1x-knockdown tumors and Panc02 cells prior to injection (ﬁgure 3.31 and ﬁgure 3.32 on
the facing page).
Figure 3.31: Protein expression in subcutaneous shTbl1x-Panc02 allogras
A: immunoblots from implanted tumors aer necropsy;B: immunoblots from stable Panc02 cell clones before implantation. PI3K
p110α: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Akt: protein kinase B; Gsk3β: glycogen
synthase kinase-3 beta; Erk: extracellular signal-regulated kinase; Cdk2: cyclin-dependent kinase 2; Cdk4: cyclin-dependent kinase
4; Vcp: valosin-containing protein (loading control).
3.4.4 PI3 kinase is upregulated in human tumors and correlates with TBL1X and TBL1XR1
To test the relevance of PI3 kinase regulation by TBL1X in human PDAC, patient material was analyzed and there was
indeed an increased expression of PIK3CA mRNA in tumors compared to normal tissue and a strong and signiﬁcant
correlation with both TBL1X and TBL1XR1 expression levels (ﬁgure 3.33 on the next page).
3.4.5 TBL1X binds to PI3 kinase promoter region
Data from a previous chromatin immunoprecipitation coupled with massively parallel DNA sequencing (ChIP-Seq)
experiment from mouse liver with TBL1X-antibody (performed by Dr. Xiaoyue Wang in our lab) showed an enrichment
peak in the 20 kbp upstream region of the PIK3CA gene. is region was mapped to the corresponding human region
(ﬁgure 3.34A on page 40) and speciﬁc primers (ﬁgure 3.34B) were designed. Next, a chromatin immunoprecipitation
was performed on Capan-1 cells as described in section 5.18.6 on page 72 with TBL1X-speciﬁc antibody and a 2.3-fold
enrichment of the PIK3CA promoter region peak was detected, indicating a binding of TBL1X upstream of the PIK3CA
gene. is suggested that TBL1X acted as a direct transcriptional (co-)regulator of PI3 kinase.
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Figure 3.32: antification of protein expression in subcutaneous shTbl1x-Panc02 allogras
Immunoblots from implanted tumors aer necropsy were quantiﬁed using Image Lab™ soware (Bio-Rad). Band intensities are
normalized to Vcp and relative to shNC-tumors not treated with gemcitabine. Data ploed as mean ± SEM; * p ஸ 0.05, ** p ஸ 0.01,
*** p ஸ 0.001 as determined by two-way ANOVA with Bonferroni post test.
Figure 3.33: Expression of PI3 kinase in human PDAC and correlation with TBL1X and TBL1XR1
Plots show mRNA expression of individual patients normalized to 18S-rRNA and relative to a pooled organ donor sample. A: Ex-
pression of PIK3CA in tissue from organ donors or healthy and tumor tissue of PDAC patients. Lines between dots connect samples
from the same patient. B: Correlation of PIK3CA mRNA with expression levels of TBL1X and TBL1XR1. BMI: body mass index;
PDAC: pancreatic ductal adenocarcinoma; * p ஸ 0.05, ** p ஸ 0.01, as determined by two-tailed paired Student’s t-test.
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Figure 3.34: TBL1X-binding to PIK3CA promoter region
A: an enrichment peak on mouse chromosome 3 upstream of the PIK3CA gene was identiﬁed with chromatin immunoprecipita-
tion sequencing (ChIP-Seq) with TBL1X-antibody in liver and mapped to the corresponding human region; images were created
with Ensembl genome browser (http://www.ensembl.org).B: Alignment of mouse and human region with the high-homology
core in violet and the primers used for detection in ChIP. Unfortunately, using Primer-Blast (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/) it was not possible to design suitable primers that would bind closer to the high-homology core and at the
same time be speciﬁc for that particular genomic region; alignment was created with Geneious soware [143]. C: Chromatin im-
munoprecipitation was performed from Capan-1 cells with TBL1X-antibody (or histone H3 antibody as positive control) and probed
for PIK3CA promoter region with primers indicated inB. Graph shows results from two independent experiments. * p ஸ 0.05,
** p ஸ 0.01, as determined by one-way ANOVA.
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4.1 Metabolic phenotype of p48 +/Cre; Kras +/LSL-G12D mice on HFD
4.1.1 Male p48 +/Cre; Kras +/LSL-G12D mice are partially protected from diet-induced obesity
In recent years, obesity and type 2 diabetes have been implicated as a risk factor for several forms of cancers, including
PDAC [30–40]. A distinct mechanistic explanation has, however, not been established yet. erefore, it was of interest
to investigate the role of the transcriptional co-regulator TBL1X and TBL1XR1 as a potential link. To this end, the
p48 +/Cre; Kras +/LSL-G12D mouse tumor model was subjected to a high fat diet regime.
Surprisingly, male p48 +/Cre; Kras +/LSL-G12D mice did not gain as much weight as their wild type lier mates, both on
HFD and on LFD (ﬁgure 3.7 on page 21). Females, on the other hand did not show such a diﬀerence between genotypes.
is might at least in part be aributed to exocrine pancreatic insuﬃciency. Feces samples that were collected from
some mice towards the end of the 12-week feeding period suggested that in male p48 +/Cre; Kras +/LSL-G12D mice on HFD
the uptake of dietary lipids was impeded resulting in high fecal triglycerides and free fay acids (table 3.3 on page 22).
To further investigate this hypothesis, it would be worthwhile to collect feces systematically and to measure fecal
triglycerides, free fay acids and elastase as well as levels of pancreatic lipases.
Pancreatic exocrine insuﬃciency has been previously described in p48 +/Cre; Kras +/LSL-G12D mice on HFD [53]. e
authors of this study also observed less weight gain in p48 +/Cre; Kras +/LSL-G12D mice compared to controls (although not
to the same extent as in the present thesis), increased feces production and fecal energy content. Oil red O staining of
stool samples indicated high fat content, but they did not perform a proper lipid extraction and quantiﬁcation of fecal
lipids.
Nevertheless, the fact that this feature was only observed in male animals raises the issue of sex diﬀerences that would
be interesting to further investigate. Also in humans, pancreatic exocrine insuﬃciency seems to bemore frequent inmen
[144]. Probably here lifestyle factors such as cigaree smoking and alcohol consumption play a role. Both behaviors are
more common amongmen than women and can lead to pancreatitis, a known cause of pancreatic exocrine insuﬃciency.
Still the fact that mice show similar sex diﬀerences should make one consider also genetic and/or hormonal diﬀerences
between males and females.
4.1.2 Fay liver development in mice on LFD
Contrary to initial assumptions, male wild type animals on LFD had high liver weights compared to females. Histo-
logically, fay livers could be identiﬁed in all male mice, whereas female wild type mice on LFD rarely developed a
fay liver, and if so, only to a very mild extent. is might be explained by the composition of the HFD and LFD
(table 4.1 on the following page). e diﬀerence in caloric fat content between the diets is balanced by carbohydrates
and here predominantly sucrose and corn starch. Sucrose chemically consists of glucose and fructose, the laer being
metabolized exclusively by the liver, where it is converted to triglycerides. Due to this fact, fructose also stands in the
focus of research for contributing to the global obesity and diabetes pandemic in humans. Studies in mice have shown
that fructose consumption leads to increased adiposity [145]. Additionally, it is known in mice that males are more
susceptible to high fat diet-induced obesity than females [146, 147].
4.2 Moribundity of p48 +/Cre; Kras +/LSL-G12D mice on HFD
ep48DNA-binding subunit of transcription factor PTF1, also known as Ptf1a, is a regulator of pancreatic development.
It becomes active in early pancreatic buds (around day 9.5 of embryonic development in the mouse) and is involved in
determining whether pancreatic bud cells diﬀerentiate to pancreatic progenitors or revert back to a duodenal fate [148].
is fact was exploited by Hingorani et al. [15] when they created the p48 +/Cre; Kras +/LSL-G12D mouse model for PDAC
that was also used in this study.
As described earlier, p48 +/Cre; Kras +/LSL-G12Dmice, especiallymales onHFD, frequently fell moribund during the course
of the feeding experiment (section 3.2.3 on page 20). e observed symptoms of hind leg limping implied the possibility of
neuronal defects. It is indeed known that p48, besides its role in pancreatic development, is also involved in neurogenesis,
especially in the cerebellum [149, 150] which is important for motor control. It might therefore be possible that in some
mice the mutant Kras also becomes active in neurons potentially leading to the observed locomotive defects. Since
the phenomenon occurred most frequently in male p48 +/Cre; Kras +/LSL-G12D mice on HFD, both sex and diet-dependent
factors, such as obesity-related inﬂammatory processes, have to be considered as possible variables.
Another symptom sporadically observed in moribund p48 +/Cre; Kras +/LSL-G12D mice was weight loss and apathy. is
might be due to pancreatic organ failure resulting in impaired food digestion and nutrient uptake. Possible reasons
can be either severe pancreatic exocrine insuﬃciency or obstruction of the main pancreatic and/or bile duct by growing
malignancies. e former can be due to loss of exocrine tissue by transformation to PanIN lesions and cancer cells, while
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Table 4.1: Composition of HFD and LFD
LFD HFD
component weight % kcal % weight % kcal %
fat 4.3 10 34.9 60
protein 19.2 20 26.2 20
carbohydrates 67.3 70 26.3 20
casein 18.96 19.72 25.84 19.72
l-cystine 0.28 0.30 0.39 0.30
corn starch 29.86 31.06 0 0
maltodextrin 10 3.32 3.45 16.15 12.32
sucrose 33.17 34.51 8.89 6.78
cellulose 4.74 0 6.46 0
soybean oil 2.37 5.55 3.23 5.55
lard 1.90 4.44 31.66 54.35
mineral mix 0.95 0 1.29 0
CaHPO4 1.23 0 1.68 0
CaCO3 0.52 0 0.71 0
potassium citrate hydrate 1.56 0 2.13 0
vitamin mix 0.95 0.99 1.29 0.99
choline bitartrate 0.19 0 0.26 0
the laer results in pancreatic juices to back up into the pancreas, further damaging the organ and causing distress in
the animals.
4.3 TBL1X and TBL1XR1 as regulators of tumor cell growth
TBL1X and TBL1XR1 were initially described as components of the SMRT/NCoR/HDAC3 co-repressor complex asso-
ciated with nuclear receptors [86, 87, 89] where they serve as exchange factors [90] (see section 1.3 on page 8). Later
studies then found TBL1XR1 to be upregulated in lung squamous cell carcinoma [100], deleted in ETV6-RUNX1 positive
acute lymphoblastic leukemia [101] or ampliﬁed in breast cancer [102]. While the ﬁrst two studies only made the re-
spective observations, the laer paper also further investigated the function and showed that knockdown of TBL1XR1
in breast cancer cells led to reduced migration and invasion in vitro and diminished tumorigenesis in a nude mouse
xenogra model.
A study published in 2012 found that TBL1XR1 is frequently mutated in central nervous system lymphomas and that
the presence of the mutation correlates with shorter survival [104]. But it was not until very recently, that several other
studies showed the involvement of TBL1XR1 in various cancers, including lung squamous cell carcinoma [151], prostate
cancer [152], acute lymphoblastic leukemia [153, 154], acute promyelocytic leukemia [155], esophageal squamous cell
carcinoma [156], and cervical cancer [157]. Of these studies, three showed a correlation between altered TBL1XR1
expression and decreased survival [156, 157] or disease relapse [153].
e study by Liu et al. [156] showed that TBL1XR1 was upregulated in esophageal squamous cell carcinoma and
positively correlated with disease progression. Patients with a higher TBL1XR1 expression had a shorter overall survival
time. Overexpression of TBL1XR1 promoted lymphangiogenesis and lymphatic metastasis in vitro and in vivo, whereas
downregulation of TBL1XR1 had the opposite eﬀect. is was due to binding of TBL1XR1 to the VEGFC promoter, thus
inducing gene expression.
Wang et al. [157] found that the expression of TBL1XR1 in cervical cancer cell lines and tissues was signiﬁcantly
upregulated at the mRNA and protein level compared to normal cervical cells. TBL1XR1 could be identiﬁed as an
independent prognostic factor that was signiﬁcantly correlated with the clinical stage, survival time and recurrence of
patients. Overexpression of TBL1XR1 in HeLa and Siha cell lines promoted invasion in vitro and in vivo. On the other
hand, knockdown of TBL1XR1 inhibited epithelial-mesenchymal transition in vitro and in vivo.
e present study is the ﬁrst to show a role for TBL1X in cancer and for TBL1XR1 particularly in pancreatic cancer.
e key ﬁndings of TBL1X and TBL1XR1 upregulation in pancreatic cancer, both human and murine, and their eﬀects
on tumor cell growth in vitro and in vivo nicely ﬁt into the overall picture set up by the aforementioned publications.
TBL1X and TBL1XR1 have been described to interact with β-catenin and to be required for Wnt-mediated β-catenin
signaling and target gene expression [92, 93]. Wnt/β-catenin signaling is an important developmental pathway [94, 158]
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that is frequently altered in pancreatic cancer [18, 97–99, 159, 160]. In the microarray data from Capan-1 cells with
siRNA-mediated knockdown of TBL1X or TBL1XR1 a signiﬁcant alteration in the expression of Wnt target genes could,
however, not be seen (data not shown). is indicates, that both co-regulators do not exert their pro-proliferative
function through the Wnt/β-catenin pathway. It is therefore concluded that not Wnt/β-catenin but PI3 kinase signaling,
whichwill be discussed later, is themajormechanism bywhich TBL1X (and potentially also TBL1XR1) exerts its function
in proliferation and chemotherapy resistance in pancreatic cancer.
4.3.1 TBL1X knockdown eﬀiciency in adenovirus-injected subcutaneous allogra tumors
As was shown in section 3.4.1 on page 33, intratumoral injection of adenovirus with TBL1X-speciﬁc shRNA aenuated
tumor growth. Although the functionality of the virus was validated in vitro (ﬁgure 3.26 on page 35), a knockdown of
TBL1X could not be detected in the tumors aer necropsy. is can be aributed to several aspects, namely outgrowth of
infected cells by non-infected cells, degradation of the virus by repeated freeze-thaw cycles, and long intervals between
injections.
It has been previously described by Possemato et al. [161] that knockdown of genes relevant for growth or survival
in an in vivo tumor model by viral approaches can lead to a selection process. Cells infected with shRNA against an
essential gene underwent growth arrest or apoptosis and were thus outgrown by cells that had not been infected with
virus and were therefore not impeded in their growth behavior.
Besides this, also experimental issues have to be considered. e adenovirus used in this experiment was available
in three aliquots. For each injection, one aliquot was thawed, virus was used and the remainder frozen at −80 ∘C. e
number of freeze-thaw cycles for each aliquot was marked on the tube and none was freeze-thawed more than three
times. It can, however, not be excluded that towards the end of the experiment, when all aliquots had already undergone
two freeze-thaw cycles, virus performance was reduced. Furthermore, it was observed that shTBL1X-injected tumors
grew slower during the week when injections were performed every 48 h while making a leap in growth over the
weekend when the time between injections was 72 h.
4.4 PI3 kinase as a downstream target of TBL1X and mediator of chemoresistance
e lipid kinase family of phosphatidylinositol-4,5-bisphosphate 3-kinases (PI3 kinase) are involved in multiple cellular
processes, including cell growth and proliferation, survival, diﬀerentiation and intracellular transport. ey act as
intracellular signal transducers by phosphorylating phosphatidylinositols on the hydroxyl group at position 3 of the
inositol ring.
PI3 kinases are grouped in three classes. Members of class Ⅰ produce phosphatidylinositol-3-phosphate (PI(3)P),
phosphatidylinositol-(3,4)-bisphosphate (PI(3,4)P2), and phosphatidylinositol-(3,4,5)-trisphosphate (PI(3,4,5)P3). ey
are heterodimers consisting of a regulatory and catalytic subunit and are activated by receptor tyrosine kinases (class
ⅠA) or G protein-coupled receptors (class ⅠB). Members of class ⅠA are formed by one of ﬁve isoforms of a p85 or p55
regulatory subunit (p85α, p55α, p50α, p85β, or p55γ) and one of four isoforms of a p110 catalytic subunit (p110α, p110β,
p110γ, p110δ). e PI3 kinase products PI(3,4)P2 and PI(3,4,5)P3 activate Akt by binding to its pleckstrin-homology do-
main. Furthermore, it is known that Ras can interact with and activate PI3 kinase [162–164]. A simpliﬁed overview of
PI3 kinase signaling is given in ﬁgure 4.1 on the next page.
In many cancers, including PDAC, the PI3 kinase catalytic subunit isoform p110α is frequently mutated and consti-
tutively active, oen coinciding with a loss or reduction of the phosphatidylinositol-(3,4,5)-trisphosphate phosphatase
PTEN that antagonizes PI3 kinase signaling [78]. Fresno Vara et al. [165] report that the PI3K/Akt pathway is oen
disturbed in cancer and that Akt activation is related to apoptosis resistance.
Resistance of pancreatic tumors to gemcitabine treatment is still a major issue that also contributes to the poor survival
rates in patients. Several studies have shown that Erk phosphorylation is related to gemcitabine resistance [166, 167].
Inhibition of Erk activity led to a sensitization of cancer cells towards gemcitabine while the expression of a mutant
constitutively active MEK provided resistance to the drug. Application of PI3 kinase inhibitors was also able to increase
gemcitabine-induced apoptosis in pancreatic cancer cell lines [79, 80].
In this study a reduction in PI3 kinase expression aer Tbl1x knockdown could clearly be shown and there was a trend
of increased Erk phosphorylation upon gemcitabine treatment and a reduction of Erk-2 levels (ﬁgure 3.31 on page 38
and ﬁgure 3.32 on page 39) aer Tbl1x-knockdown. is suggested that the reduction of PI3 kinase aer Tbl1x ablation
triggered multiple cellular responses including reduced Erk activity to convey gemcitabine sensitization.
e possibility of a combination treatment of gemcitabine with other drugs to enhance therapy response and patient
survival is a focus of ongoing research. One such combination is sorafenib, a potent multi-kinase inhibitor that can be
applied orally. It targets Raf serine/threonine kinases and diﬀerent receptor tyrosine kinases such as vascular endothe-
lial growth factor receptor (VEGFR), platelet derived growth factor receptor (PDGFR), c-Kit, FLT-3 and RET [168, 169].
In a phase Ⅰ trial of combination treatment of gemcitabine and sorafenib it was well tolerated and 57% of patients ex-
perienced stable disease [170]. A phase Ⅱ trial, however, did not state a signiﬁcant clinical beneﬁt of the combination
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Figure 4.1: PI3 kinase signaling
PI3 kinases of class ⅠA can be directly activated by receptor tyrosine kinases. Alternatively, receptor tyrosine kinases can mediate
the exchange of GDP to GTP on Ras, thus activating it. Active Ras can then in turn activate PI3 kinase p110 catalytic subunit or
the Raf-MAPK-Erk signaling pathway. e deactivation of Ras by hydrolysis of GTP to GDP can be facilitated by GTPase-activating
proteins (GAP). Active PI3 kinase turns phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) to phosphatidylinositol-3,4,5-trisphosphate
(PI(3,4,5)P3) which then activates Akt. is leads to a deactivating phosphorylation of Gsk3β that when active inhibits cell cycle
progression. e phosphatase PTEN can dephosphorylate PI(3,4,5)P3 and thus counteracts PI3 kinase activity.
treatment [171]. erefore, Awasthi et al. [172] combined gemcitabine and sorafenib with endothelial monocyte activat-
ing polypeptide Ⅱ (EMAP), a pro-inﬂammatory cytokine with antiangiogenic and antiendothelial activities. ey could
show that, both in vitro and in vivo, this triple combination provides a beneﬁt over single administration or gemcitabine-
sorafenib combination alone. Administration of gemcitabine with LY293111, an antagonist of the Erk1/2-activating
leukotriene B4 receptor, in an orthotopic implantation model in athymic mice also provided a beer outcome [173]. A
double-blinded, placebo-controlled phase Ⅲ clinical trial conducted in 2007 [174] with gemcitabine and the EGFR in-
hibitor erlotinib resulted in a modest increase in median survival (6.24 vs. 5.91 months) while the 1-year survival rate
with erlotinib and gemcitabine was 23% versus 17% with placebo and gemcitabine.
4.4.1 TBL1X and TBL1XR1 control glucose metabolism in pancreatic tumor cells
One observation that was made in the in vitro studies was a decreased glucose uptake and glycolysis aer TBL1X and
TBL1XR1 knockdown (ﬁgure 3.19 and ﬁgure 3.20 on page 31). is, however, seems to be a chicken-before-egg-problem
of whether glucose consumption is directly regulated by TBL1X/TBL1XR1 or whether it is a secondary consequence of
decreased proliferation. Cancer cells usually have high rates of aerobic glycolysis thusmeeting their demands in building
blocks for new cells. Glycolysis intermediates are shuled to the pentose phosphate pathway ensuring production of
ribose and deoxyribose as components for new RNA and DNA [120, 121]. One explanation could therefore be, that the
decrease in proliferation aer TBL1X/TBL1XR1 knockdown caused a decreased demand for nucleic acid synthesis and
thus a reduction in aerobic glycolysis. On the other hand, it is known that PI3 kinase/Akt signaling is a regulator of
metabolic pathways, including glycolysis (reviewed by DeBerardinis et al. [120] and Mu~noz-Pinedo et al. [121]). Further
studies are therefore required to answer the question whether TBL1X/TBL1XR1 aﬀect glucose metabolism directly via
the PI3 kinase/Akt pathway or indirectly via decreased demand for nucleotide building blocks.
e eﬀect of TBL1X/TBL1XR1 on glucose metabolism is furthermore interesting since cancer cells are more sensitive
to radiation or chemotherapeutics when glycolysis is inhibited [138, 139]. In Kras-transformed cells glucose starvation
has been found to induce cell death via the unfolded protein response [175]. e cellular energy sensor AMPK has
recently been found to negatively regulate aerobic glycolysis and thus suppress tumor growth. Inactivation of AMPK
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led to an increase in aerobic glycolysis and usage of glucose for lipid and biomass production [176]. Hexokinases catalyze
the ﬁrst step of glycolysis, namely the phosphorylation of glucose to glucose-6-phosphate thus preventing its export
out of the cell. Many cancer cells express high levels of hexokinase 2 (HK2) that is otherwise only found in embryonic
development or adipose, skeletal, or heart muscle cells. Ablation of HK2 is able to reduce tumor growth in mouse models
of lung and breast cancer [177]. HK2-negative cells have less ﬂux of glucose carbon to the citric acid cycle as well as
ribonucleotide and fay acid synthesis. erapeutic strategies aiming at tumor cell glucose metabolism are therefore a
potential candidate for future cancer treatments.
4.5 Outlook
Challenging p48 +/Cre; Kras +/LSL-G12D mice with a high fat diet induced structures resembling invasive carcinoma in some
of the animals. orough analysis by an experienced mouse pathologist is, however, still required to conﬁrm and
quantify these ﬁndings. Expression levels of TBL1X/TBL1XR1 (and other transcriptional co-regulators) were not altered
between lean and obese human patients or between LFD- and HFD-fed mice. erefore, other mechanisms may link
obesity and pancreatic tumor development. For further studies, not only mRNA expression should be studied but also
changes on post-transcriptional levels.
A growth-regulating eﬀect of TBL1X in cancer in general and TBL1XR1 on pancreatic cancer in particular has not
previously been described and constitutes an interesting basis for future research. To complement the subcutaneous
allogras studies with an orthotopic model it would be worthwhile to cross p48 +/Cre; Kras +/LSL-G12D mice with Tbl1x ﬂ/ﬂ
or Tbl1xr1ﬂ/ﬂ mice to generate animals with a pancreas-speciﬁc knockout of Tbl1x or Tbl1xr1 in combination with the
tumor-initiating Kras mutation. It would be expected to detect a tumor-preventing eﬀect of Tbl1x and Tbl1xr1 ablation
also under these circumstances.
e so far unobserved regulation of PI3 kinase expression by TBL1X provides a novel and promising new target
mechanism for PDAC treatment regarding gemcitabine resistance. e action of TBL1X on the PI3 kinase promoter
should be further studied with a luciferase reporter gene assay. Also a rescue experiment with ectopic expression of
mutant constitutively active PI3 kinase in TBL1X-depleted cancer cells should be carried out to show that the eﬀects
of TBL1X on tumor cell growth, metabolism and chemosensitivity are indeed largely dependent on PI3 kinase. TBL1X
might nevertheless be an interesting novel drug target upstream of PI3 kinase signaling. is could be done by RNA
nanoparticles [178, 179] since it will probably be very diﬃcult to aﬀect Tbl1x/Tbl1xr1 expression or activity with con-
ventional chemical or protein-based drugs in vivo. Screening of patients for expression levels of TBL1X in their tumors
might help to stratify them to predict therapy response and treatment outcome.
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5 Material and Methods
Material
5.1 Instruments and equipment
instrument / equipment model company
aspiration adapter, 8-channel Neolab (Heidelberg, Germany)
bacterial incubator Heraeus Function Line ermoFisher Scientiﬁc (Schwerte, Germany)
bacterial shaking incubator Multitron Standard Infors HT (Bomingen, Switzerland)
balance EW 2200-2NM Kern & Sohn (Balingen, Germany)
Bunsen burner Labogaz 206 Campingaz (Haersheim, Germany)
cell counter, automated Countess™ Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
cell culture hood Cellgard Class Ⅱ Biolog-
ical Safety Cabinet
IBS Integrad Biosciences (Fernwald, Germany)
CO2 incubator Sanyo (Een Leur, e Netherlands)
counting chamber BLAUBRAND®,
Neubauer improved,
Cat. No. 717805
Brand (Wertheim, Germany)
digital caliper Bochem (Weilburg, Germany)
EchoMRI™ Whole Body Composi-
tion Analyzer
Echo Medical Systems (Houston, TX, USA)
ﬂuorescence lamp for microscope HXP 120C Carl Zeiss (Oberkochen, Germany)
ﬂuorometer bit® 2.0 Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
freezer (−20 ∘C) Liebherr (Biberach, Germany)
freezer, ultra-low temperature
(−80 ∘C)
New Brunswick U101
Innova
Eppendorf (Hamburg, Germany)
freezing container Mr. Frosty™, 5100-0001 ermoFisher Scientiﬁc (Schwerte, Germany)
gas anesthesia system XGI-8 Caliper LifeSciences (Rodgau, Germany)
GeneChip® ﬂuidics station 450 Aﬀymetrix (High Wycombe, United Kingdom)
GeneChip® scanner Aﬀymetrix (High Wycombe, United Kingdom)
glucometer OneTouch® Ultra LifeScan (Neckargemünd, Germany)
immunoblot documentation ChemiDoc™ XRS+
Molecular Imager® with
Image Lab™ Soware
Bio-Rad (München, Germany)
IVIS® Optical Imaging System Lumina Ⅱ Caliper LifeSciences (Rodgau, Germany)
LED ﬂuorescence lamp for Axio
Imager.M2
Colibri.2 Carl Zeiss (Oberkochen, Germany)
Liquidator™ 96 Rainin Pipeing 360∘ Meler Toledo (Gießen, Germany)
magnetic stirrer MR 3001 K Heidolph (Schwabach, Germany)
magnetic stirrer Duomax 1030 Heidolph (Schwabach, Germany)
magnetic stirrer 444-7076 VWR (Darmstadt, Germany)
microinjector IM-6 Narishige (London, UK)
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instrument / equipment model company
microscope Axio Imager.M2 with
AxioCam HRc
Carl Zeiss (Oberkochen, Germany)
microscope Axiovert 40 CFL with
AxioCam ICm1
Carl Zeiss (Oberkochen, Germany)
microscope, automated Olympus Cell^R Olympus (Hamburg, Germany)
microscope, motorized Cell Observer Z1 Carl Zeiss (Oberkochen, Germany)
microplate reader Mithras LB 940 Berthold Technologies (Bad Wildbad, Ger-
many)
micropipee 0.2–2 μl P2 Gilson (Limburg-Oeim, Germany)
micropipee 1–10 μl P10 Gilson (Limburg-Oeim, Germany)
micropipee 2–20 μl P20 Gilson (Limburg-Oeim, Germany)
micropipee 10–100 μl P100N Gilson (Limburg-Oeim, Germany)
micropipee 50–200 μl P200 Gilson (Limburg-Oeim, Germany)
micropipee 100–1000 μl P1000 Gilson (Limburg-Oeim, Germany)
micropipee, 8-channel, 0.5–10 μl Research plus Eppendorf (Hamburg, Germany)
micropipee, 8-channel, 10–100 μl Research Eppendorf (Hamburg, Germany)
microtome RM2245 Leica (Wetzlar, Germany)
microwave 700W Severin (Sundern, Germany)
Mini-PROTEAN R 3 Cell 165-3301 Bio-Rad (München, Germany)
Mini-PROTEAN R Tetra Cell 165-8004 Bio-Rad (München, Germany)
Mini Trans-Blot® Cell 170-3930 Bio-Rad (München, Germany)
mouse cage, 335 cm2 H-TEMP™
Polysulfon
1144B-00SU Tecniplast (Hohenpeißenberg, Germany)
mouse cage system Green Line IVC SealSafe
Plus
Tecniplast (Hohenpeißenberg, Germany)
mouse housing cabinet, ventilated Tecniplast (Hohenpeißenberg, Germany)
multistep pipee Multipee® plus Eppendorf (Hamburg, Germany)
multistep pipee Multipee® M4 Eppendorf (Hamburg, Germany)
Nanodrop ND-1000 ermoFisher Scientiﬁc (Schwerte, Germany)
orbital shaker Duomax 1030 Heidolph (Schwabach, Germany)
pH-meter Qph 70 GHM Messtechnik, Greisinger (Regenstauf,
Germany)
pipetboy acu Integra (Fernwald, Germany)
power supply for gel electrophore-
sis
PowerPac Basic™ Bio-Rad (München, Germany)
power supply for Axio Imager.M2 232 Carl Zeiss (Oberkochen, Germany)
precision balance M-power AZ124 Sartorius (Göingen, Germany)
real-time PCR system StepOnePlus Life Technologies™, Applied Biosystems®
(Darmstadt, Germany)
refrigerator (2–8 ∘C) Liebherr (Biberach, Germany)
rotating wheel Neolab (Heidelberg, Germany)
scintillation counter, Tri-Carb Liq-
uid Scintillation analyzer
2200CA Packard Instruments (Meriden, CT, USA)
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instrument / equipment model company
sonicator Bioruptor® Plus Diagenode (Seraing, Belgium)
tabletop centrifuge Mikro 22 R Heich (Newport Pagnell, United Kingdom)
tabletop centrifuge Heraeus Fresco 17 ermoFisher Scientiﬁc (Schwerte, Germany)
tabletop centrifuge Heraeus Biofuge pico ermoFisher Scientiﬁc (Schwerte, Germany)
tabletop centrifuge Heraeus Biofuge Primo ermoFisher Scientiﬁc (Schwerte, Germany)
ermomixer comfort Eppendorf (Hamburg, Germany)
thermocycler T3000 biometra (Göingen, Germany)
tissue grinder, all-glass Dounce 7ml Kimble Chase (Meiningen, Germany)
Tissue Lyser MM400 Retsch (Haan, Germany)
tissue processor for dehydration ASP 300 Leica (Wetzlar, Germany)
tissue embedding center EG1150H Leica (Wetzlar, Germany)
titer plate shaker ermoFisher Scientiﬁc (Schwerte, Germany)
vortex mixer Genie Scientiﬁc Industries (Bohemia, NY, USA)
water bath P-D Industriegesellscha (Dresden, Germany)
water ﬁlter system TKA xCAD ermoFisher Scientiﬁc (Schwerte, Germany)
XF96 Extracellular Flux Analyzer Seahorse Bioscience (Copenhagen, Denmark)
XF Prep Station Seahorse Bioscience (Copenhagen, Denmark)
5.2 Consumable lab ware
product company Cat. No.
biopsy foam pad Simport (Belœil, ébec, Canada) M476-1
cell scraper Corning (Wiesbaden, Germany) 3010
chamber slide, 8-well, Nunc Lab-Tek ermoFisher Scientiﬁc (Schwerte, Ger-
many)
177445
CHROMA SPIN™ 100 columns Clontech (Saint-Germain-en-Laye,
France)
0.2ml Combitips advanced® Eppendorf (Hamburg, Germany) 0030 089.413
0.5ml Combitips advanced® Eppendorf (Hamburg, Germany) 0030 089.421
0.5ml Combitips advanced®, sterile Eppendorf (Hamburg, Germany) 0030 089.634
5ml Combitips advanced® Eppendorf (Hamburg, Germany) 0030 089.456
5ml Combitips advanced®, sterile Eppendorf (Hamburg, Germany) 0030 089.669
10ml Combitips advanced® Eppendorf (Hamburg, Germany) 0030 089.464
10ml Combitips advanced®, sterile Eppendorf (Hamburg, Germany) 0030 089.667
Countess™ cell counting chamber slides Life Technologies™, Invitrogen™ (Darm-
stadt, Germany)
C10283
cover slips, 24 × 60mm #1 Menzel (Braunschweig, Germany) BB024060A1
2ml cryogenic vial StarLab (Hamburg, Germany) E3110-6122
1.5ml DNA LoBind tubes Eppendorf (Hamburg, Germany) 0030 108.051
500ml ﬁlter system 0.22 μm, polystyrene,
nonpyrogenic
Corning (Wiesbaden, Germany) 430758
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product company Cat. No.
10 μl ﬁlter tip, graduated StarLab (Hamburg, Germany) S1121-3810
20 μl ﬁlter tip, beveled StarLab (Hamburg, Germany) S1120-1810
100 μl ﬁlter tip, beveled StarLab (Hamburg, Germany) S1120-1840
200 μl ﬁlter tip, graduated StarLab (Hamburg, Germany) S1120-8810
1000 μl ﬁlter tip StarLab (Hamburg, Germany) S1126-7810
folded ﬁlters Munktell (Bärenstein, Germany) 4.303.240
gas cartridge (propane) for Bunsen burner Campingaz (Haersheim, Germany) C 206 Super
GeneChip®HumanGenomeU133 Plus 2.0
Array
Aﬀymetrix (High Wycombe, United King-
dom)
900466
glucose test stripes, OneTouch® Ultra LifeScan (Neckargemünd, Germany) –
histology cassees Neolab (Heidelberg, Germany) 7-0014
imaging plate , 96-well clear boom black
wall
BD Falcon™ (Heidelberg, Germany) 353219
injection needle Sterican® 0.4 × 20mm
(27G)
B. Braun (Melsungen, Germany) 4657705
inoculation loops, 1 μl Sarstedt (Nümbrecht, Germany) 86.1567.050
insulin syringes, Micro-Fine™+ Demi,
0.3ml
BD Medical (Heidelberg, Germany) 324826
MicroAmp® Fast Optical 96-well Reaction
Plate for quantitative PCR
Life Technologies™, Applied Biosystems®
(Darmstadt, Germany)
4346906
MicroAmp® Optical Adhesive Film for
quantitative PCR
Life Technologies™, Applied Biosystems®
(Darmstadt, Germany)
4311971
micro hematocrit capillaries, heparin-
coated
Brand (Wertheim, Germany)
microscope slide, SuperFrost® Plus,
25 × 75mm, 1.0mm thick
VWR (Darmstadt, Germany) 631-0108
microtiter plate, 96-well (Nunc F96) ermoFisher Scientiﬁc (Schwerte, Ger-
many)
260836
Millex®-GV ﬁlter unit PVDF 0.22 μm Merck KGaA (Darmstadt, Germany) SLGV033RS
Millex®-HV ﬁlter unit PVDF 0.45 μm Merck KGaA (Darmstadt, Germany) SLHV033RS
Millex®-HA ﬁlter unit mixed cellulose es-
ters 0.45 μm
Merck KGaA (Darmstadt, Germany) SLHA033SS
nitrocellulose membrane, Protran BA 85,
0.45 μm
GE Healthcare (Solingen, Germany) 10401196
Paraﬁlm® M Bemis® (Neenah WI, USA) PM-996
Pasteur pipee, glass, long WU Mainz (Bamberg, Germany)
PCR tubes, 8-strip, 0.2ml Greiner Bio-one (Frickenhausen, Ger-
many)
673210
PCR tube lids, ﬂat, 8-strip Greiner Bio-one (Frickenhausen, Ger-
many)
373250
petri dish for Agar plates Greiner Bio-one (Frickenhausen, Ger-
many)
632180
200 μl pipee tips, LTS, for Liquidator™ Steinbrenner Laborsysteme (Wiesenbach,
Germany)
SL-LT-L200
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product company Cat. No.
10 μl pipee tip StarLab (Hamburg, Germany) S1111-3700
200 μl pipee tip Steinbrenner Laborsysteme (Wiesenbach,
Germany)
TipTower Reﬁll System
1000 μl pipee tip Steinbrenner Laborsysteme (Wiesenbach,
Germany)
TipTower Reﬁll System
0.1–10 μl pipee tips, epT.I.P.S.® LoReten-
tion
Eppendorf (Hamburg, Germany) 0030 072.006
0.5–20 μl pipee tips, epT.I.P.S.® LoReten-
tion
Eppendorf (Hamburg, Germany) 0030 072.014
1–200 μl pipee tips, epT.I.P.S.® LoReten-
tion
Eppendorf (Hamburg, Germany) 0030 072.022
50–1000 μl pipee tips, epT.I.P.S.® LoRe-
tention
Eppendorf (Hamburg, Germany) 0030 072.030
15ml polypropylene centrifuge tubes Greiner Bio-one (Frickenhausen, Ger-
many)
188271
50ml polypropylene centrifuge tubes Greiner Bio-one (Frickenhausen, Ger-
many)
227261
1.5ml reaction tubes, black Carl Roth (Karlsruhe, Germany) AA80
1.5ml RNase-free centrifuge tubes, Mµlti®
Safe Seal
Carl Roth (Karlsruhe, Germany) 7080
14ml round-boom snap-cap tubes, poly-
propylene
BD Falcon™ (Heidelberg, Germany) 352059
1.5ml safe-lock tube Eppendorf (Hamburg, Germany) 0030 120.086
2ml safe-lock tube Eppendorf (Hamburg, Germany) 0030 120.094
5ml safe-lock tube Eppendorf (Hamburg, Germany) 0030 119.460
scalpel, disposable, sterile, No. 21 Feather (Osaka, Japan)
scintillation tubes, LDPE Carl Roth (Karlsruhe, Germany) 5404.1
5ml serological pipee BD Falcon™ (Heidelberg, Germany) 357543
10ml serological pipee BD Falcon™ (Heidelberg, Germany) 357551
25ml serological pipee BD Falcon™ (Heidelberg, Germany) 357525
50ml serological pipee BD Falcon™ (Heidelberg, Germany) 357550
5ml skirted tube VWR (Darmstadt, Germany) 216-0153
stainless steel beads, 5mm Qiagen (Hilden, Germany) 69989
1ml syringe, So-Ject® Tuberkulin Henke Sass Wolf (Tulingen, Germany) 5010-200V0
5ml syringe BD (Heidelberg, Germany) 309050
20ml syringe BD (Heidelberg, Germany) 300629
50ml syringe BD (Heidelberg, Germany) 300865
10 cm tissue culture plate BD Falcon™ (Heidelberg, Germany) 353003
15 cm tissue culture plate BD Falcon™ (Heidelberg, Germany) 353025
tissue culture plate, 6-well BD Falcon™ (Heidelberg, Germany) 353046
tissue culture plate, 12-well Corning (Wiesbaden, Germany) 3512
tissue culture plate, 24-well BD Falcon™ (Heidelberg, Germany) 353047
tissue culture plate, 48-well BD Falcon™ (Heidelberg, Germany) 353230
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product company Cat. No.
tissue culture plate , 96-well BD Falcon™ (Heidelberg, Germany) 353072
Venoﬁx® A 0.4 × 10mm (27G) B. Braun (Melsungen, Germany) 4056388
waste bags, 200 × 300mm Carl Roth (Karlsruhe, Germany) E706.1
weigh boats 41 × 41mm Neolab (Heidelberg, Germany) 1-1124
weigh boats 89 × 89mm Neolab (Heidelberg, Germany) 1-1125
Whatman™ paper GE Healthcare (Solingen, Germany) 3030 917
10–100 μl wide bore tips Gilson (Limburg-Oeim, Germany) DFL10ST
XF96 FluxPak 4-port measurement car-
tridges
Seahorse Bioscience (Copenhagen, Den-
mark)
102310-001
XF96 Polystyrene Cell Culture Mi-
croplates
Seahorse Bioscience (Copenhagen, Den-
mark)
101085-004
5.3 Kits
product company Cat. No.
BioArray HighYield® RNA transcript labeling
kit
Enzo Life Sciences (Lörrach, Germany) ENZ-42655
Cell Proliferation Kit (BrdU Assay) GE Healthcare (Solingen, Germany) RPN20
Click-iT® EdU Imaging Kit Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
C10338
DNase Set, RNase-free Qiagen (Hilden, Germany) 1023460
First strand cDNA Synthesis Kit, Fermentas ermoFisher Scientiﬁc (Schwerte, Germany) K1612
Glucose (HK) Assay Kit Sigma-Aldrich (München, Germany) GAHK20-1KT
HIV-1 p24 ELISA Assay XpressBio (urmont, MD, USA) XB-1000
HR Series NEFA-HR (2) kit Wako Diagnostics (Neuss, Germany) 999-34691
MinElute PCR puriﬁcation kit Qiagen (Hilden, Germany) 28004
Mouse Insulin ELISA Mercodia (Uppsala, Sweden) 10-1247-01
NEFA Standard Solution Wako Diagnostics (Neuss, Germany) 276-76491
Pierce® BCA Protein Assay Kit ermoFisher Scientiﬁc (Schwerte, Germany) 23225
PureLink® HiPure Plasmid Maxiprep Kit Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
K2100-06
QIAprep Spin Miniprep Kit Qiagen (Hilden, Germany) 27104
QIAquick Gel Extraction Kit Qiagen (Hilden, Germany) 28704
bit® dsDNA HS Assay Kit Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
Q32854
RNeasy® Mini Kit Qiagen (Hilden, Germany) 74106
Serum Triglyceride Determination Kit Sigma-Aldrich (München, Germany) TR0100
SuperScript®Choice System for cDNA Synthe-
sis
Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
18090-019
VECTASTAIN Elite ABC Kit Vector Laboratories (Burlingame, CA, USA) PK-6100
XF Cell Mito Stress Test Kit Seahorse Bioscience (Copenhagen, Denmark) 101706-100
XF Glycolysis Stress Test Kit Seahorse Bioscience (Copenhagen, Denmark) 102194-100
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5.4 Enzymes
enzyme company Cat. No.
micrococcal nuclease New England Bioloabs® Inc., (Ipswich, MA,
USA)
M0247S
proteinase K ermoFisher Scientiﬁc (Schwerte, Germany) EO0491
RNase A 10mg/ml ermoFisher Scientiﬁc (Schwerte, Germany) EN0531
5.5 Plasmids
plasmid company Cat. No.
pLKO.1-shRNA-Mm Tbl1x Sigma-Aldrich (München, Germany) SHCLNG-NM 020601
pLKO.1-shRNA-scrambled Addgene (Cambridge, MA, USA) 1864
pMD2.G Addgene (Cambridge, MA, USA) 12259
psPAX2 Addgene (Cambridge, MA, USA) 12260
5.6 Antibodies
5.6.1 Primary antibodies
protein company Cat.-No. origin usage
AKT Cell Signaling 9272 rabbit IB
Ⓟ-AKT Ser-473 Cell Signaling 9271 rabbit IB
AMPK Cell Signaling 2532 rabbit IB
Ⓟ-AMPKr-172 Cell Signaling 2535 rabbit IB
CDK2 Santa Cruz sc-163 rabbit IB
CDK4 Cell Signaling 2906 mouse IB
Cyclin D1 Cell Signaling 2926 mouse IB
ERK-1/2 Cell Signaling 9102 rabbit IB
Ⓟ-ERK-1/2 r-202/Tyr-204 Cell Signaling 9101 rabbit IB
GSK3β Cell Signaling 9315 rabbit IB
Ⓟ-GSK3β Ser-9 Cell Signaling 9336 rabbit IB
Histone H3 Cell Signaling 4620 rabbit ChIP
IRS1 Cell Signaling 3407 rabbit IB
Ⓟ-IRS1 Tyr-895 Cell Signaling 3070 rabbit IB
Ⓟ-IRS1 Ser-1101 Cell Signaling 2385 rabbit IB
Ki-67 Dako M7249 mouse IHC
PI3K p110α Cell Signaling 4249 rabbit IB
PTEN Cell Signaling 9552 rabbit IB
Ⓟ-PTEN Ser-380 / r-382/383 Cell Signaling 9549 rabbit IB
TBL1X Abcam ab24548 rabbit IB, IHC, ChIP
TBL1X Abcam ab2243 goat IHC
TBL1XR1 Novus Biologicals NB600-270 rabbit IB
TBL1XR1 Abnova H00079718-M01 mouse IHC
β-actin Sigma A5441 mouse IB
VCP Abcam 11433 mouse IB
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5.6.2 Secondary antibodies
antibody company Cat.-No. origin usage
anti-goat IgG (H+L), biotinylated KPL, Inc. 71-00-37 rabbit IHC
anti-mouse IgG (whole molecule) Sigma-Aldrich M8642 goat IHC
anti-rat IgG, biotinylated, mouse adsorbed Vector Laboratories BA-4001 rabbit IHC
anti-mouse IgG (H+L)-Cy3, MinX Dianova 715-165-150 donkey BrdU assay
anti-mouse IgG (H+L)-HRP Bio-Rad 170-6516 goat IB
anti-rabbit IgG (H+L)-HRP Bio-Rad 172-1019 goat IB
EnVision™+ anti-mouse HRP labeled polymer Dako K4001 IHC
EnVision™+ anti-rabbit HRP labeled polymer Dako K4003 IHC
Normal Rabbit IgG Cell Signaling 2729 rabbit ChIP
10% Normal Rabbit Serum KPL, Inc. 71-00-28 rabbit IHC
5.7 Chemicals and reagents
product company Cat. No.
acetic acid Sigma-Aldrich (München, Germany) 45731
acrylamide/bisacrylamide 37.5:1, 40% (Roti-
phorese® Gel 40 (37.5:1))
Carl Roth (Karlsruhe, Germany) T802.1
agarose Carl Roth (Karlsruhe, Germany) 3810
Alexa Fluor® 555 azide, triethylammonium salt Life Technologies™, Molecular Probes®
(Darmstadt, Germany)
A20012
AllStars Negative control siRNA coupled 3’ to
Alexa Fluor® 488 on sense-strand
Qiagen (Hilden, Germany) 1027292
ampicillin sodium salt Sigma-Aldrich (München, Germany) A9518
Antibody Diluent, Background Reducing Dako (Hamburg, Germany) S3022
APS (ammonium persulfate) Carl Roth (Karlsruhe, Germany) 9592
β-mercaptoethanol Sigma-Aldrich (München, Germany) M7154
Biotin-Blocking System (0.1% avidin solution
and 0.01% biotin solution)
Dako (Hamburg, Germany) X0590
boric acid (H3BO3) Sigma-Aldrich (München, Germany) 31146
bromophenol blue, sodium salt Sigma-Aldrich (München, Germany) 114405
BSA for cell culture: Albumin solution from
bovine serum, 30% in DPBS, sterile-ﬁltered
Sigma-Aldrich (München, Germany) A9576
BSA for immunobloing and EdU assay: albu-
min bovine Fraction Ⅴ
biomol (Hamburg, Germany) 01400.100
BSA for BrdU assay, fay acid free Sigma-Aldrich (München, Germany) A8806
BSA for immunohistochemistry Sigma-Aldrich (München, Germany) A7030
CaCl2 (calcium chloride) Carl Roth (Karlsruhe, Germany) CN93
chloroform (CHCl3) Carl Roth (Karlsruhe, Germany) 3313
CuSO4 (copper (Ⅱ) sulfate pentahydrate) Sigma-Aldrich (München, Germany) 209198
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2-deoxy-d-glucose Sigma-Aldrich (München, Germany) D8375-5G
1,2-3H-2-deoxy-d-glucose PerkinElmer (Rodgau, Germany) NET549001MC
DEPC (diethylpyrocarbonate) Sigma-Aldrich (München, Germany) D5758
DMEMHighGlucose Pyruvate (+ l-glutamine) Life Technologies™, Gibco® (Darmstadt, Ger-
many)
41966-029
DMEM Low Glucose Pyruvate (+ l-glutamine) Life Technologies™, Gibco® (Darmstadt, Ger-
many)
31885-023
DMSO (dimethyl sulfoxide), sterile for cell cul-
ture
Sigma-Aldrich (München, Germany) D2650
DNA marker, GeneRuler 100 bp ermoFisher Scientiﬁc (Schwerte, Germany) SM0241
DPBS, no CaCl2, no MgCl2 Life Technologies™, Gibco® (Darmstadt, Ger-many)
14190-094
DPBS 10×, no CaCl2, no MgCl2 Life Technologies™, Gibco® (Darmstadt, Ger-many)
14200-067
DTT (dithiothreitol) Applichem (Darmstadt, Germany) A2948
ECL™ Western Bloing Detection Reagent GE Healthcare (Solingen, Germany) RPN2106
ECL™ Prime Western Bloing Detection
Reagent
GE Healthcare (Solingen, Germany) RPN2232
EDTA (ethylenediaminetetraacetic acid disodi-
um salt dihydrate)
Sigma-Aldrich (München, Germany) E5134
EdU (5-ethynyl-2’-deoxyuridine) Life Technologies™, Molecular Probes®
(Darmstadt, Germany)
A10044
EGTA (Ethylene glycol-bis(2-aminoethyl-
ether)-N,N,N’,N’-tetraacetic acid)
Sigma-Aldrich (München, Germany) E4378
ethanol ≥ 99.8%, denatured with approx. 1%
methyl ethyl ketone (for histology)
Carl Roth (Karlsruhe, Germany) K928
eosin G Carl Roth (Karlsruhe, Germany) 7089
ethanol, absolute Sigma-Aldrich (München, Germany) 32205
ethidium bromide solution 1% / 10mg/ml Carl Roth (Karlsruhe, Germany) 2218
fetal bovine serum (FBS), Dialyzed, US-Origin Life Technologies™, Gibco® (Darmstadt, Ger-
many)
26400-036
fetal bovine serum (FBS), aliﬁed, E.U. Ap-
proved, South America Origin
Life Technologies™, Gibco® (Darmstadt, Ger-
many)
10270-106
Fluorescent Mounting Medium Dako (Hamburg, Germany) S3023
formaldehyde solution 37% J. T. Baker (Deventer, e Netherlands) 7040
formamide Merck KGaA, Calbiochem (Darmstadt, Ger-
many)
344206
forskolin Sigma-Aldrich (München, Germany) F3917
gemcitabine 40mg/ml solution HEXAL® –
d-glucose anhydrous Applichem (Darmstadt, Germany) A0883
100× l-glutamine 200mm Life Technologies™, Gibco® (Darmstadt, Ger-
many)
25030-024
glycerol Sigma-Aldrich (München, Germany) 15523
glycine Sigma-Aldrich (München, Germany) 33226
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HEPES buﬀer solution 1m Life Technologies™, Gibco® (Darmstadt, Ger-
many)
15630-056
H2O2 (hydrogen peroxide) 30% solution Merck KGaA (Darmstadt, Germany) 1.07209
HCl (hydrochloric acid) 37% Sigma-Aldrich (München, Germany) 30721
Hoechst 33342, trihydrochloride trihydrate,
10mg/ml
Life Technologies™, Molecular Probes®
(Darmstadt, Germany)
H3570
IGEPAL® CA-630 (NP-40 substitute) Sigma-Aldrich (München, Germany) 56741
imidazole Merck KGaA (Darmstadt, Germany) 4716
insulin human recombinant expressed in yeast Sigma-Aldrich (München, Germany) I2643
isoﬂurane Baxter (Unterschleißheim, Germany) I7403
KCl (potassium chloride) Carl Roth (Karlsruhe, Germany) A137
KH2PO4 (potassium dihydrogen phosphate) Carl Roth (Karlsruhe, Germany) 3904
LB-Agar (Luria/Miller) Carl Roth (Karlsruhe, Germany) X969
LB-Medium (Luria/Miller) Carl Roth (Karlsruhe, Germany) X968
LiCl (lithium chloride) Carl Roth (Karlsruhe, Germany) 3739
Lipofectamine® 2000 Transfection Reagent Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
11668-019
Liquid DAB+ Chromogen and Substrate Buﬀer Dako (Hamburg, Germany) K3468
d-luciferin ﬁreﬂy, potassium salt Biosynth (Staad, Switzerland) L-8220
d-mannitol Sigma-Aldrich (München, Germany) M4125
1-14C-d-mannitol PerkinElmer (Rodgau, Germany) NEC314050UC
Mayer’s hemalum solution (hematoxylin) Merck KGaA (Darmstadt, Germany) 1.09249
methanol Sigma-Aldrich (München, Germany) 32213
MgCl2 ⋅ 6H2O (magnesium chloride hexahy-drate)
Sigma-Aldrich (München, Germany) M9272
MgSO4 ⋅ 7H2O (magnesium sulfate heptahy-drate)
Applichem (Darmstadt, Germany) A4101
milk powder, skim milk extra grade Gerbu (Heidelberg, Germany) 1602
MOPS (3-(N -morpholino)propanesulfonic
acid)
Sigma-Aldrich (München, Germany) M3183
Na2HPO4 ⋅ 2H2O (di-sodium hydrogen phos-
phate dihydrate)
Sigma-Aldrich (München, Germany) 30412
Na2MoO4 ⋅ 2H2O (sodium molybdate dihy-
drate)
Sigma-Aldrich (München, Germany) M1003
Na3VO4 (sodium orthovanadate) Sigma-Aldrich (München, Germany) S6508
NaCl (sodium chloride) Sigma-Aldrich (München, Germany) 31434
NaF (sodium ﬂuoride) Sigma-Aldrich (München, Germany) S1504
NaHCO3 ⋅ 10H2O (sodium carbonate decahy-
drate)
Merck KGaA (Darmstadt, Germany) 6391
NaOH (sodium hydroxide) Sigma-Aldrich (München, Germany) 30620
Opti-MEM® Ⅰ Reduced Serum Medium Life Technologies™, Gibco® (Darmstadt, Ger-
many)
31985-047
Orange G Sigma-Aldrich (München, Germany) O3756
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PageRuler™ prestained protein ladder ermoFisher Scientiﬁc (Schwerte, Germany) 26616
penicillin-streptomycin, liquid, 100× Life Technologies™, Gibco® (Darmstadt, Ger-
many)
15140-122
Permount Mounting Medium ermoFisher Scientiﬁc (Schwerte, Germany) 50-277-97
phenol red solution 0.5% in DPBS, sterile for
cell culture
Sigma-Aldrich (München, Germany) P0290
PMSF (phenylmethanesulfonyl ﬂuoride) Sigma-Aldrich (München, Germany) P7626
polybrene (hexadimethrine bromide) Sigma-Aldrich (München, Germany) H9268
poly-l-lysine hydrobromide Sigma-Aldrich (München, Germany) P2636
Ponceau S solution 0.1% in 5% acetic acid Sigma-Aldrich (München, Germany) P7170
Power Block™ Universal Blocking Reagent,
10× concentrated
BioGenex (Fremont, CA, USA) HK085-5KE
Power SYBR® Green PCR Master Mix Life Technologies™, Applied Biosystems®
(Darmstadt, Germany)
4367659
PrestoBlue® cell viability reagent Life Technologies™, Molecular Probes®
(Darmstadt, Germany)
A13261
protease inhibitor cocktail Sigma-Aldrich (München, Germany) P8340
protease inhibitor cOmplete Roche (Mannheim, Germany) 04693116001
protease inhibitor cOmplete, EDTA-free Roche (Mannheim, Germany) 04693132001
protein G agarose beads, ChIP-grade Cell Signaling (Leiden, e Netherlands) 9007S
puromycin Sigma-Aldrich (München, Germany) P8833
100× pyruvate 100mm Life Technologies™, Gibco® (Darmstadt, Ger-
many)
11360-039
RNAlater™ RNA Stabilization Reagent Qiagen (Hilden, Germany) 76106
Roti®-Histoﬁx 4% acid free (pH 7.0)
phosphate-buﬀered formaldehyde solution
Carl Roth (Karlsruhe, Germany) P087
Roticlear® Carl Roth (Karlsruhe, Germany) A538
Rotiszint® eco plus LSC-Universalcocktail Carl Roth (Karlsruhe, Germany) 0016
RPMI amino acids solution (50×) Sigma-Aldrich (München, Germany) R7131
SDS (sodium dodecyl sulfate) Sigma-Aldrich (München, Germany) 62862
sodium acetate anhydrous Applichem (Darmstadt, Germany) A1522
(+)-sodium l-ascorbate Sigma-Aldrich (München, Germany) A4034
sodium deoxycholate Sigma-Aldrich (München, Germany) D6750
sodium tartrate dibasic dihydrate Sigma-Aldrich (München, Germany) 71994
spermidine Sigma-Aldrich (München, Germany) S0266
spermine Sigma-Aldrich (München, Germany) S4264
sucrose Sigma-Aldrich (München, Germany) S1888
sulforhodamine B sodium salt (SRB) Sigma-Aldrich (München, Germany) S9012
TaqMan® Gene Expression Master Mix Life Technologies™, Applied Biosystems®
(Darmstadt, Germany)
4369016
TEMED (N,N,N’,N’-tetramethylethane-1,2-
diamine)
Carl Roth (Karlsruhe, Germany) 2367
Tris (tris(hydroxymethyl)aminomethane) Sigma-Aldrich (München, Germany) T1503
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Triton®X-100 Applichem (Darmstadt, Germany) A1388
trypan blue solution 0.4% Life Technologies™, Invitrogen™ (Darmstadt,
Germany)
T10282
0.25% Trypsin-EDTA (1×), Phenol Red Life Technologies™, Gibco® (Darmstadt, Ger-
many)
25200-056
Tween® 20 Sigma-Aldrich (München, Germany) P9416
water, nuclease-free Life Technologies™, Gibco® (Darmstadt, Ger-
many)
10977-035
XF Calibrant Seahorse Bioscience (Copenhagen, Denmark) 100840-000
xylene Merck KGaA (Darmstadt, Germany) 1.08681
5.8 Animal food
product company Cat. No.
standard chow diet Kliba Nafag (Kaiseraugst, Switzerland) 3437
low fat diet (LFD), 10% calories from fat, γ-irradiated Research Diets, Inc. (New Brunswick,
NJ, USA)
D12450Bi
high fat diet (HFD), 60% calories from fat, γ-irradiated Research Diets, Inc. (New Brunswick,
NJ, USA)
D12492i
5.9 Buﬀers and solutions
Buﬀers and solutions, including electrophoresis gels, are listed in alphabetical order and subsequently referred to by the
names given here. Buﬀer concentrations are 1× unless stated otherwise.
Citrate buﬀer 10mm tri-sodium citrate dihydrate; adjust to pH 6.0 with HCl; add 0.05% Tween® 20
ChIP buﬀer 50mm Tris, pH 8.0; 140mm NaCl; 1mm EDTA; 1% Triton®X-100; 0.1mm sodium deoxycholate; 0.1%
SDS; 1× protease inhibitor cOmplete (Roche); always prepare fresh
ChIP elution buﬀer 50mm Tris, pH 8.0; 1mm EDTA; 1% SDS; 50mm NaHCO3; always prepare fresh
ChIP sucrose buﬀer A 320mm sucrose; 15mm HEPES, pH 7.9; 60mm KCl; 2mm EDTA; 0.5mm EGTA; 0.5% BSA;
0.5mm spermidine; 0.15mm spermine; 0.5mm DTT; pH adjusted to 7.2; always prepare fresh
ChIP sucrose buﬀer B 416mm sucrose; 15mm HEPES, pH 7.9; 60mm KCl; 2mm EDTA; 0.5mm EGTA; 0.5mm sper-
midine; 0.15mm spermine; 0.5mm DTT; pH adjusted to 7.2; always prepare fresh
ChIP swelling buﬀer 25mm HEPES, pH 7.2; 1mm MgCl2; 10mm KCl; 0.1% IGEPAL (NP-40); 1mm DTT; 0.5mmPMSF; 1× protease inhibitor cOmplete (Roche); always prepare fresh
ChIP wash buﬀer A 50mm Tris; 140mm NaCl; 1mm EDTA; 1% Triton®X-100; 0.1% sodium deoxycholate; 0.1%
SDS; always prepare fresh
ChIP wash buﬀer B 50mm Tris; 500mm NaCl; 1mm EDTA; 1% Triton®X-100; 0.1% sodium deoxycholate; 0.1%
SDS; always prepare fresh
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ChIPwash buﬀer C 20mm Tris; 250mm LiCl; 1mm EDTA; 0.5% IGEPAL (NP-40); 0.1% sodium deoxycholate; always
prepare fresh
DEPC-treated water 1ml of DEPC was added to 1 l of distilled water, shaken vigorously, incubated over night at
room temperature to inactivate RNases and then autoclaved to degrade DEPC. Store at room temperature.
DMEM basic medium 1 vial of DME Base (8.3 g, Sigma, Cat. No. D5030) was dissolved in ddH2O and supplemented
with 3.7 g NaHCO3 and 1.85 g NaCl. pH was adjusted to 7.2, volume ﬁlled up to 1 l and medium was 0.22 μm ﬁlter-
sterilized. Phenol red was added to 15mg/l as well as 1mm pyruvate, 2mm l-glutamine and 10% dialyzed FBS. Store at
4 ∘C.
For glucose-withdrawal experiments, 4.5mg/ml (25mm) d-glucose was added or le out.
Eosin solution 0.1% eosin G; 63% ethanol; 1% acetic acid; store at room temperature protected from light
LB agar plates 40 g/l LB Agar (Carl Roth) in water, autoclaved, cooled down in water bath to 56 ∘C, antibiotics added
to desired concentration and poured into petri dishes (≈ 20ml per plate); store at 4 ∘C for up to 4 weeks
LB medium 25 g/l in water, autoclaved; store at room temperature
Krebs-Ringer-Henseleit (KRH) buﬀer 118.5mm NaCl; 24.65mm NaHCO3; 4.74mm KCl; 1.18mmMgSO4; 1.184mmKH2PO4; 2.5mm CaCl2; pH 7.4; 0.22 μm ﬁlter-sterilized; store at 4 ∘C
MNase digestion buﬀer 50mm Tris, pH 7.4; 25mm KCl; 4mm MgCl2; 1mm CaCl2; 1× EDTA-free protease inhibitorcOmplete (Roche); always prepare fresh
MOPS buﬀer, 10× 200mmMOPS; 50mm sodium acetate; 10mm EDTA; pH 7.0; store at 4 ∘C
Orange G buﬀer, 6× 70% glycerol; 10mm EDTA; 1mg/ml Orange G; store at 4 ∘C
PBS 137mm NaCl; 2mm KH2PO4; 10mm Na2HPO4; 2.7mm KCl; pH 7.0; store at room temperature
PBS-T 137mmNaCl; 2mm KH2PO4; 10mmNa2HPO4; 2.7mm KCl; 0.1% Tween® 20; pH 7.0; store at room temperature
Phosphatase inhibitor cocktail, 100× 200mm imidazole; 100mm NaF; 115mm Na2MoO4; 100mm Na3VO4; 400mm
sodium tartrate; store in aliquots at −20 ∘C
Protein extraction buﬀer 50mm Tris; 1mm EDTA; 10mm NaF; 2mm Na3VO4; 1mm DTT; 1× protease inhibitor
cocktail (Sigma, Cat. No. P8340); 1× phosphatase inhibitor cocktail; always prepare fresh
Protein extraction supplement buﬀer 150mm NaCl; 10% IGEPAL® (NP-40); store at 4 ∘C
RIPA buﬀer 50mm Tris; 250mm NaCl; 2% IGEPAL® (NP-40); 2.5 μm EDTA; 0.1% SDS; 0.5% sodium deoxycholate;
1× protease inhibitor cocktail (Sigma, Cat. No. P8340); 1× phosphatase inhibitor cocktail; store in aliquots at −20 ∘C
RNA loading buﬀer for 100 μl use 0.5 μl of 10mg/ml ethidium bromide; 5 μl MOPS buﬀer; 50 μl formamide; 17.5 μl of
37% formaldehyde; 16.7 μl orange G buﬀer; 10.3 μl RNase-free water; always prepare fresh
SDS loading dye, 5× 12.5% β-mercaptoethanol; 10% SDS; 1mg/ml bromophenol blue; 300mm Tris-HCl pH 6.8; 5mm
EDTA; 50% glycerol; store in aliquots at −20 ∘C
SDS-polyacrylamide separating gel 8 / 10 / 12% acrylamide/bisacrylamide (37.5:1); 375mm Tris-HCl pH 8.8; 0.1%
SDS; 2.66mm TEMED; 0.1% APS
SDS-polyacrylamide stacking gel 5 % 5% acrylamide/bisacrylamide (37.5:1); 125mm Tris-HCl pH 6.8; 0.1% SDS;
6.67mm TEMED; 0.1% APS
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SDS running buﬀer 200mm glycine; 25mm Tris; 0.1% SDS; store at room temperature
SDS transfer buﬀer 25mm Tris; 190mm glycine; store at 4 ∘C
Seahorse Assay Medium 1 vial of DME Base (8.3mg/ml, Sigma, Cat. No. D5030) was dissolved in 1 l of ddH2O; pH
was adjusted to 7.4 and medium was 0.22 μm ﬁlter-sterilized and stored at 4 ∘C
For the Glycolysis Stress Test Kit, medium was freshly supplemented with 15mg/l phenol red and 2mm l-glutamine.
For theMito Stress Test Kit, mediumwas freshly supplementedwith 15mg/l phenol red, 2mm l-glutamine, 1mm pyruvate
and 4.5mg/ml (25mm) d-glucose.
SRB fixation buﬀer 5% acetic acid; 95% ethanol; store at −20 ∘C
SRB solution 0.4% (w/v) sulforhodamine B; 1% (v/v) acetic acid; store at room temperature protected from light
TBE 45mm Tris; 45mm boric acid; 1mm EDTA; pH 8.0; store at room temperature
TBS 20mm Tris; 137mm NaCl; pH 7.6; store at room temperature
TBS-T 20mm Tris; 137mm NaCl; 0.1% Tween® 20; pH 7.6; store at room temperature
TE 10mm Tris pH 8.0; 1mm EDTA; store at room temperature
5.10 Nomenclature of genes and proteins
Genes, mRNA and cDNA transcripts of genes and genotypes of mouse strains are addressed using italicized characters
(e. g. Tbl1x). Proteins are addressed using upright characters (e. g. Tbl1x). Mouse proteins as well as genes and corre-
sponding mRNA and cDNA transcripts are assigned by upper case ﬁrst leer and subsequent lower case leers (e. g.
Tbl1x, Tbl1x) whereas human orthologs are assigned by upper case leers (e. g. TBL1X, TBL1X).
Methods
5.11 Human patients
Pancreatic tissue from surgical resection of cancer and chronic pancreatitis patients as well as samples from healthy
organ donors were provided by Dr. Oliver Strobel from the European Pancreas Center at the Chirurgische Klinik of the
University of Heidelberg. Wrien informed consent was obtained from all patients. In case of cancer patients, tumor
tissue and healthy tissue was provided for intra-individual comparison of expression levels. Details on the individual
patients are summarized in table D.1 on page 86 in appendix D. RNA was extracted as described in section 5.17.1 on
page 69 and reverse-transcribed to cDNA. Proteins were extracted according to section 5.18.1 on page 72.
5.12 Animal experiments
5.12.1 Animal models
p48 +/Cre; Kras +/LSL-G12Dmice [15] use a knock-in of the KrasG12D allele, a mutant variant of Kraswhere glycine at position
12 is substituted by aspartic acid which compromises both its intrinsic and extrinsic GTPase activity and results in con-
stitutive downstream signaling of Ras eﬀector pathways. e allele was introduced with an upstream LoxP-Stop-LoxP
(LSL) cassee via homologous recombination. Crossing with p48+/Cre mice expressing Cre-recombinase under control
of the pancreas-speciﬁc p48 promoter resulted in p48 +/Cre; Kras +/LSL-G12D animals expressing the mutant KrasG12D allele
in pancreatic cells at the same level as the endogenous gene thus mimicking the acquisition of such activating point
mutations in human PDACs.
p48 +/Cre; Kras +/LSL-G12Dmice were bred in a C57BL/6N background at the IBF (Interfakultäre Biomedizinische Forschung-
seinrichtung) of Heidelberg University by Dr. Oliver Strobel and genotyped as described [15].
Wild type C57BL/6N mice were obtained from Charles River Laboratories at the age of 7–9 weeks.
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5.12.2 Housing of animals
e animals were housed according to international standards with a 12 h dark / 12 h light cycle and unrestricted access
to diet. Animal handling and experimentation was performed in accordance with the German Protection of Animals
Act (Tierschutzgesetz) and approved by local authorities (Regierungspräsidium Karlsruhe).
5.12.3 EchoMRI™ measurement
EchoMRI™ analysis allows the determination of whole body fat mass, lean mass and free water in mice. Animals were
weighed and then subjected to measurement according to the manufacturer’s instructions.
5.12.4 Feeding experiments in p48 +/Cre; Kras +/LSL-G12D mice
At 3–10 weeks of age, p48 +/Cre; Kras +/LSL-G12D mice and wild type lier mates were transferred from Heidelberg Univer-
sity IBF to DKFZ central animal facility and housed in a Green Line IVC SealSafe Plus Mouse Cage system (Tecniplast)
with ad libitum access to standard chow diet and water. Aer 1 week of adaptation, food was changed to high fat diet
(60% calories from fat) or low fat diet (10% calories from fat) for a duration of 12weeks with ad libitum access. Weight of
mice was checked weekly. EchoMRI™ (Echo Medical Systems, Houston, TX, USA) measurement was performed before
the start of the diet as well as 3, 7 and 11 weeks aerwards. Four and 8 weeks aer start of the diet, animals were fasted
over night for 16–18 h and then blood glucose was measured with a OneTouch® Ultra glucometer. Blood was collected
with heparin-coated micro hematocrit capillaries, stored on ice until all animals were assessed, centrifuged for 1 h at
855 ×g and plasma was used for ELISA measurement of insulin (Mercodia). At the end of the 12-week period, animals
were weighed, then killed by cervical dislocation followed by decapitation. Blood glucose was measured from trunk
blood with a OneTouch® Ultra glucometer and then collected, stored on ice until all animals were prepared, centrifuged
for 1 h at 855 ×g and serum was used for ELISA measurement of insulin (Mercodia). A small piece from the pancreatic
tail was taken for protein and RNA extraction and snap-frozen in liquid nitrogen. e rest of the organ was ﬁxed in
formalin and embedded in paraﬃn as described in section 5.13.1 on the following page. Liver, heart, perigonadal white
adipose tissue, inguinal white adipose tissue, scapular brown adipose tissue, gastrocnemius muscle, and small intestine
were cut into small pieces in PBS, snap-frozen in liquid nitrogen and stored in cryogenic vials or 5ml skirted tubes at
−80 ∘C.
5.12.5 Subcutaneous tumor cell implantation
Animals were housed in groups of 4 in 335 cm2 H-TEMP™ Polysulfon cages (Tecniplast) in a ventilated moue housing
cabinet (Tecniplast) with ad libitum access to standard chow diet and water.
Luciferase-expressing Panc02 cells (see section 5.14.1 on page 64) were grown to suﬃcient numbers, trypsinized, resus-
pended in DPBS and counted. Concentration was adjusted to 2×106 cells/ml with DPBS and cells were kept on ice. 100 μl
of cell suspension containing 2×105 cells were injected subcutaneously into the right hind ﬂank of C57BL/6N mice.
5.12.6 Tumor size measurement
Starting at day 4–7 aer implantation, the site of injection was shaved and tumor volume was determined by percuta-
neous measurement with digital a caliper. Tumor volume was calculated by the ellipsoid formula:
V = 43π ⋅ ቆ
width
2 ቇ
2
⋅ ቆ
length
2 ቇ
5.12.7 Bioluminescence imaging
Animals were injected intraperitoneally with 10 μl per g body weight of 15mg/ml d-luciferin in DPBS using insulin
syringes (BD Medical). Aer 4–6 min, animals were put in a narcotic chamber connected to an XGI-8 Gas Anesthesia
System (Caliper LifeSciences). Narcosis was induced with 3% isoﬂurane and maintained with 1.5% isoﬂurane. 10 min
aer d-luciferin injection, animals were placed in an IVIS® Lumina Ⅱ (Caliper LifeSciences) under 1.5% isoﬂurane and
bioluminescence was measured for 5 min. Data were visualized and analyzed with Living Image soware.
5.12.8 Intratumoral injection of adenovirus
Adenovirus was kindly provided by Dr. Maria Rohm from our lab (production described in [180, p77–79] and [181]).
Virus was diluted to 1×108 infectious particles per 15–20 μl in DPBS with 10% glycerol and loaded to a 27G Venoﬁx® A
injection hose connected to a microinjector (Narishige). 1×108 infectious particles were injected into each tumor.
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5.12.9 Subcutaneous tumor preparation
At necropsy, tumors were taken out, freed from surrounding skin and other tissue and cut in three pieces as shown in
ﬁgure 5.1.
Figure 5.1: Cuing of subcutaneous tumor allogras
e upper half of the tumor (formerly facing the skin) was taken for histology. e cuing surface was placed on a biopsy foam pad
in a histology cassee so that aer embedding the ﬁrst sections would be from the middle of the tumor. e lower half (formerly
facing towards the peritoneum) was cut longitudinally and the two halves were separately snap-frozen in liquid nitrogen for later
extraction of RNA or proteins.
5.13 Histology
Tissues were prepared as described below and imaged on an Axio Imager.M2 with AxioCam HRc (Zeiss).
5.13.1 Paraﬀin embedding and sectioning of tissue
Upon dissection, organs were placed on a biopsy foam pad in a histology cassee and submerged in Roti®-Histoﬁx for
24 to maximum 48 h, then washed in running deionized water (VE-Wasser) for 2 h and stored in 70% ethanol for up to
6 weeks. Samples were then dehydrated in a Leica ASP 300 (70% ethanol 40 min; 95% ethanol 40 min; 100% ethanol
35 min; 2 × 100% ethanol 40 min; 100% ethanol 60 min; xylene 45 min; xylene 60 min; xylene 75 min; 3 × paraﬃn wax
60 min) and embedded in paraﬃn blocks with a Leica EG 1150H. Sections of 4 μm were prepared with a Leica RM2245
microtome, placed on glass cover slides and dried.
5.13.2 Hematoxylin eosin (H&E) staining
Sections were de-paraﬃnized (3 × 10 min Roticlear®, 3 × 3 min 100% ethanol, 3 min 96% ethanol, 10 min 70% ethanol,
2 min 50% ethanol, 2 min distilled water), stained for 2 min in Mayer’s hemalum solution, washed for 15 min under
running tap water, counterstained for 7 sec in eosin solution, brieﬂy washed in distilled water and dehydrated (5 sec
70% ethanol, 3 min 96% ethanol, 2 × 3 min 100% ethanol, 3 × 5 min Roticlear®) and mounted in Permount Mounting
Medium.
5.13.3 Immunohistochemistry staining
Sections were de-paraﬃnized (3 × 10 min Roticlear®, 3 × 10 min 100% ethanol, 10 min 95% ethanol, 10 min 75% eth-
anol, 10 min 50% ethanol, 10 min distilled water) and then processed as indicated below.
5.13.3.1 TBL1X (human tissue)
Antigen retrieval was done by heating in the microwave at 500W for 10 min in citrate buﬀer pH 6.0 followed by air-
cooling for 15 min and seling down to distilled water for 10 min. Endogenous peroxidases were inactivated with 3%
H2O2 in methanol for 10 min followed by incubation in distilled water for 10 min and washing 2 × 10 min in TBS with
0.1% BSA. Slides were blocked with Power Block™ Universal Blocking Reagent for 1 h at room temperature. Primary
antibody (rabbit polyclonal to TBL1X, Abcam, Cat. No. ab24548) was applied 1:400 in Dako Antibody Diluent over night
at 4 ∘C in a humid chamber, then washed 2 × 10 min in TBS with 0.1% BSA and once for 10 min in TBS with 0.1%
BSA and 0.05% Tween® 20. Secondary antibody (EnVision™+ anti-rabbit HRP, Dako) was added undiluted for 45 min at
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room temperature in a humid chamber, then washed 2 × in TBS with 0.1% BSA and once for 10 min in TBS with 0.1%
BSA and 0.05% Tween® 20. Color reaction was performed for 15 sec with Dako Liquid DAB+ Chromogen diluted 1:100
in DAB Substrate Buﬀer, then stopped with distilled water. Slides were counterstained for 12 sec in Mayer’s hemalum
solution, washed with running tap water for 10 min and then dehydrated (5 min 70% ethanol, 5 min 95% ethanol, 3 ×
5 min 100% ethanol, 3 × 5 min Roticlear®) and mounted in Permount Mounting Medium.
5.13.3.2 Tbl1x (mouse tissue)
Antigen retrieval was done by heating in the microwave at 750W for 10 min in citrate buﬀer pH 6.0 followed by in-
cubation in water bath for 30 min at 96 ∘C. Slides were then air-cooled for 15 min and incubated in distilled water for
10 min. Endogenous peroxidases were inactivated with 3% H2O2 in methanol for 10 min followed by incubation in
distilled water for 5 min and washing 2 × 5 min in TBS with 0.1% BSA. Slides were blocked with 10% Normal Rabbit
Serum for 45 min at room temperature, then 0.1% avidin for 20 min at 37 ∘C in the dark, washed 2 × 5 min in TBS with
0.1% BSA, blocked with 0.01% biotin for 20 min at 37 ∘C in the dark and washed 2 × 5 min in TBS with 0.1% BSA.
Primary antibody (goat polyclonal to TBL1X, Abcam, Cat. No. ab2243) was applied 1:1000 in Dako Antibody Diluent
over night at 4 ∘C in a humid chamber, then washed 3 × 5 min in TBS with 0.1% BSA and 0.05% Tween® 20. Secondary
antibody (biotinylated rabbit anti-goat, KPL) was added undiluted for 45 min at room temperature in a humid chamber,
then ﬂushed once in TBS with 0.1% BSA and 0.05% Tween® 20, washed 2 × 5 min in TBS with 0.1% BSA and 0.05%
Tween® 20 and once for 5 min in TBS with 0.1% BSA. Signal was enhanced with ABC reagent from the VECTASTAIN
Elite ABC Kit (Vector Laboratories; prepare mixture 30 min before use) for 45 min at room temperature, then washed
2 × 5 min in TBS with 0.1% BSA. Color reaction was performed for 50 sec with Dako Liquid DAB+ Chromogen di-
luted 1:100 in DAB Substrate Buﬀer, then stopped with distilled water. Slides were counterstained for 6 sec in Mayer’s
hemalum solution, washed with running tap water for 10 min and then dehydrated (5 min 70% ethanol, 5 min 95%
ethanol, 3 × 5 min 100% ethanol, 3 × 5 min Roticlear®) and mounted in Permount Mounting Medium.
5.13.3.3 TBL1XR1 (human tissue)
Antigen retrieval was done by heating in the microwave at 500W for 10 min in citrate buﬀer pH 6.0 followed by air-
cooling for 15 min and seling down to distilled water for 10 min. Endogenous peroxidases were inactivated with
3% H2O2 in methanol for 10 min followed by incubation in distilled water for 10 min and washing 2 × 10 min in TBS
with 0.1% BSA. Slides were blocked with Power Block™ Universal Blocking Reagent for 1 h at room temperature.
Primary antibody (TBL1XR1 monoclonal antibody (M01), clone 3G7, Abnova, Cat. No. H00079718-MO1) was applied
1:1000 in Dako Antibody Diluent over night at 4 ∘C in a humid chamber, then washed 2 × 10 min in TBS with 0.1%
BSA and once for 10 min in TBS with 0.1% BSA and 0.05% Tween® 20. Secondary antibody (EnVision™+ anti-mouse
HRP, Dako) was added undiluted for 45 min at room temperature in a humid chamber, then washed 2 × in TBS with
0.1% BSA and once for 10 min in TBS with 0.1% BSA and 0.05% Tween® 20. Color reaction was performed for 15 sec
with Dako Liquid DAB+ Chromogen diluted 1:100 in DAB Substrate Buﬀer, then stopped with distilled water. Slides
were counterstained for 12 sec in Mayer’s hemalum solution, washed with running tap water for 10 min and then
dehydrated (5 min 70% ethanol, 5 min 95% ethanol, 3 × 5 min 100% ethanol, 3 × 5 min Roticlear®) and mounted in
Permount Mounting Medium.
5.13.3.4 Tbl1xr1 (mouse tissue)
Antigen retrieval was done by heating in the microwave to the boil in citrate buﬀer pH 6.0, cooling for 5 min, microwav-
ing at 350W for 3 min and incubating in water bath for 20 min at 96 ∘C. Slides were then air-cooled for 15 min and
incubated in distilled water for 10 min. Endogenous peroxidases were inactivated with 3%H2O2 in methanol for 10 min
followed by incubation in distilled water for 5 min and washing 2 × 5 min in TBS with 0.1% BSA. Slides were blocked
with 1mg/ml goat anti-mouse IgG (Sigma) in 0.9% NaCl for 1 h at room temperature, then with Power Block™ Universal
Blocking Reagent for 1 h at room temperature. Primary antibody (TBL1XR1 monoclonal antibody (M01), clone 3G7,
Abnova, Cat. No. H00079718-MO1) was applied 1:500 in Dako Antibody Diluent over night at 4 ∘C in a humid chamber,
then washed 2 × 5 min in TBSwith 0.1% BSA and 2 × 5 min in TBSwith 0.1% BSA and 0.05% Tween® 20. Secondary an-
tibody (EnVision™+ anti-mouse HRP, Dako) was added undiluted for 45 min at room temperature in a humid chamber,
then washed 2 × 5 min in TBS with 0.1% BSA. Color reaction was performed for 30 sec with Dako Liquid DAB+ Chro-
mogen diluted 1:100 in DAB Substrate Buﬀer, then stopped with distilled water. Slides were counterstained for 9 sec in
Mayer’s hemalum solution, washed with running tap water for 10 min and then dehydrated (5 min 70% ethanol, 5 min
95% ethanol, 3 × 5 min 100% ethanol, 3 × 5 min Roticlear®) and mounted in Permount Mounting Medium.
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5.13.3.5 Ki-67 (mouse tissue)
Antigen retrieval was done by heating in the microwave to the boil in citrate buﬀer pH 6.0 followed by incubation in
water bath for 30 min at 96% before air-cooling for 15 min and incubating in distilled water for 10 min. Endogenous
peroxidases were inactivated with 3% H2O2 in methanol for 10 min followed by incubation in distilled water for 5 min
and washing 2 × 5 min in TBS with 0.1% BSA. Slides were blocked with 10% Normal Rabbit Serum for 45 min at
room temperature, then 0.1% avidin for 20 min at 37 ∘C in the dark, washed 2 × 5 min in TBS with 0.1% BSA, blocked
with 0.01% biotin for 20 min at 37 ∘C in the dark and washed 2 × 5 min in TBS with 0.1% BSA. Primary antibody
(Monoclonal mouse anti-rat Ki-67, Dako, Cat. No. M7249) was applied 1:5000 in Dako Antibody Diluent over night at
4 ∘C in a humid chamber, then ﬂushed in 5 min in TBS with 0.1% BSA and 0.05% Tween® 20, washed 3 × 5 min in TBS
with 0.1% BSA and 0.05% Tween® 20. Secondary antibody (biotinylated rabbit anti-rat IgG antibody, mouse adsorbed,
Vector Laboratories) was added at 1 μg/ml in Dako Antibody Diluent for 45 min at room temperature in a humid chamber,
then ﬂushed once in TBS with 0.1% BSA and 0.05% Tween® 20, washed 2 × 5 min in TBS with 0.1% BSA and 0.05%
Tween® 20 and once for 5 min in TBS with 0.1% BSA. Signal was enhanced with ABC reagent from the VECTASTAIN
Elite ABC Kit (Vector Laboratories; prepare mixture 30 min before use) for 45 min at room temperature, then washed
2 × 5 min in TBS with 0.1% BSA. Color reaction was performed for 40 sec with Dako Liquid DAB+ Chromogen diluted
1:100 in Substrate Buﬀer, then stopped with distilled water. Slides were counterstained for 6 sec in Mayer’s hemalum
solution, washed with running tap water for 10 min and then dehydrated (5 min 70% ethanol, 5 min 95% ethanol, 3 ×
5 min 100% ethanol, 3 × 5 min Roticlear®) and mounted in Permount Mounting Medium.
5.13.4 antification of Ki-67 staining
Entire paraﬃn sections stained for Ki-67 were imaged with a Cell Observer Z1 (Zeiss) with a 20× objective. Images
were stitched together with the ZEN soware provided with the microscope. Non-tumor tissue such as adhering skin
or subcutaneous fat was removed from the image. For ease of processing, the stitched image was sliced into individual
images of approximately 1000 × 1000 pixels using ImageJ. ese were then loaded to ilastik soware which was trained
to discriminate background (white), Ki-67 positive nuclei (brown), and counterstained cytoplasm and Ki-67 negative
nuclei (blue, hematoxylin-stained). Cell Proﬁler was then used to quantify the area occupied by tumor cells and by
Ki-67 positive nuclei.
5.14 Cell culture
5.14.1 Cell lines
Capan-1, Capan-2, AsPC-1 BxPC-3 and HEK293T cells were obtained from ATCC. Panc02 cells with stable lentivirus-
mediated expression of luciferase were kindly provided by Dr. Ana Martin-Villalba (DKFZ).
5.14.2 Cultivation of cells
All cells were cultured on 15 cm-dishes in 20ml DMEM High Glucose Pyruvate (+ l-glutamine) supplemented with
10% FBS and 1% penicillin/streptomycin (all from Gibco®) in a humidiﬁed incubator at 37 ∘C and 5% CO2. For sub-
culturing, cells were washedwith 10mlDPBS (Gibco®) and detached from culture plate with 3ml 0.25% trypsin (Gibco®)
for 5–10 min at 37 ∘C. Trypsin was stopped by adding 10ml of culture medium. Cells were washed from the plate,
centrifuged for 3 min at 550 ×g, re-suspended in culture medium and seeded on a new 15 cm-dish. Cell morphology was
monitored with an Axiovert 40 CFL microscope (Zeiss).
For experiments, aer the last re-suspension step in culture medium, an aliquot of 10 μl was taken, diluted with
10 μl trypan blue solution. Cells were counted in a Neubauer counting chamber or Countess™ automated cell counter.
Concentration of cells was calculated and appropriate amounts of cells were seeded.
5.14.3 Detection of cell culture contamination
1×106–1×107 cells were harvested, transferred to a 1.5ml safe-lock tube and pelleted by centrifugation at 2, 500 rpm for
5 min. e pellet was resuspended in 100 μl DPBS and placed at 95 ∘C for 15 min. Lysate was centrifuged at 10, 000 rpm
for 10 min to remove cellular debris. e supernatant was transferred to a new 1.5ml safe-lock tube and stored at −20 ∘C
before submission to the company Multiplexion. Multiplexion validated the purity of the cell lines using Multiplex Cell
Contamination Test (McCT) [182]. Only non-contaminated cells were used.
5.14.4 Freezing of cells
Cells were washed with 10ml DPBS (Gibco®) and detached from culture plate with 3ml 0.25% trypsin (Gibco®) for
5–10 min at 37 ∘C. Trypsin was stopped by adding 10ml of culture medium. Cells were washed from the plate, cen-
64
5.15 Cell-based assays
trifuged for 3 min at 550 ×g and re-suspended in culture medium. An aliquot was taken, diluted in trypan blue solution
and cells were counted in a Neubauer counting chamber or Countess™ automated cell counter. Cell density was ad-
justed to 2×106 cells/ml with culture medium. FBS and sterile DMSO were added to reach a ﬁnal mixture of 50% culture
medium, 40% FBS, 10% DMSO. Cells were aliquoted at 1ml in cryogenic vials, put into a Mr. Frosty™ freezing con-
tainer (ermoFisher Scientiﬁc) and placed at −80 ∘C. e following day, tubes were transferred to a liquid nitrogen
storage tank.
5.14.5 Thawing of cells
Cells were taken out of liquid nitrogen storage tank and thawed in a 37 ∘C water bath, then transferred to 9ml culture
medium, centrifuged for 3 min at 550 ×g, re-suspended in 1ml culture medium and plated out in 20ml culture medium
on a 15 cm-dish.
5.14.6 Nutrient withdrawal
Capan-1 cells were plated at 5×103 cells per well on 96-well clear boom black wall plates in antibiotic-free culture
medium (DMEM High Glucose Pyruvate (+ l-glutamine) with 10% FBS). On the following day siRNA transfection was
done as described in section 5.14.7. 24 h aer application of siRNA, medium was changed to DMEM basic medium
(59) with or without 4.5mg/ml d-glucose. Cells were grown for another 48 h before subjecting to EdU assay (see sec-
tion 5.15.2 on the following page).
5.14.7 siRNA transfection
An overview of the siRNAs used is given in table 5.10. AllStars Negative control siRNA coupled 3’ to Alexa Fluor® 488
on sense-strand (Qiagen, Cat. No. 1027292) was used as a non-silencing control and to assess transfection eﬃciency via
green ﬂuorescence. For transfection, cells were plated in antibiotic-free culture medium (DMEMHigh Glucose Pyruvate
(+ l-glutamine) with 10% FBS) to reach 30–50% conﬂuence the following day. For each siRNA to be transfected, 0.5 pmol
siRNA per 1000 cells plated were dissolved in 1/10 volume Opti-MEM® Ⅰ (relative to the amount of culture medium on the
cells). In case of double transfections, the ﬁnal amount of siRNA was ﬁlled up with AllStars Negative control siRNA to
guarantee equal amounts of total siRNA in each group. In a second tube, Lipofectamine® 2000 was dissolved to 3% in
the same amount of Opti-MEM® Ⅰ. e two mixes were combined and incubated for 20 min at room temperature before
adding drop-wise to the culture medium. Aer 24 h incubation at 37 ∘C the medium was changed to fresh antibiotic-free
culture medium for further culturing or live cell measurements or cells were harvested for RNA or protein extraction.
Table 5.10: Overview on GeneSolution siRNAs from Qiagen
Gene Species RefSeq ID Cat.-No. Sequence
TBL1X human NM 001139466 SI04329514 target TGCGTTAGAGTGTACTCTGAA
sense GCUUAGAGUGUACUCUGAATT
antisense UUCAGAGUACACUCUAACGCA
TBL1XR1 human NM 024665 SI03025925 target TTGTTTGATGGTCGACCAATA
sense GUUUGAUGGUCGACCAAUATT
antisense UAUUGGUCGACCAUCAAACAA
5.15 Cell-based assays
5.15.1 BrdU assay
Cell proliferation was assayed with the Cell Proliferation Kit from GE Healthcare. is assay makes use of the base
analogue BrdU that is incorporated into the DNA of proliferating cells instead of thymine and can be detected with a
speciﬁc antibody. Capan-1 cells were seeded at a density of 1.5×104 cells per well on an 8-chamber LabTech Microscopy
Slide and subjected to the indicated treatment. Medium was then replaced by fresh pre-warmed medium with 1:1000
Labelling Reagent from the kit and incubated for 1 h at 37 ∘C. Labelling Reagent medium was then removed and cells
were brieﬂywashedwithDPBS before ﬁxing for 30 min in 90% ethanol / 5% acetic acid / 5%water at room temperature.
Subsequently, cells were rehydrated by washing 3 times 3–5 min with DPBS and 75–100μl reconstituted nuclease/anti-
BrdU antibody from the kit was applied for 1 h at room temperature. Cells were then washed 3 times 3–5 min with
DPBS before incubating in 100 μl Cy™3-conjugated anti-mouse IgG (Dianova) diluted 1:800 in DPBS with 1% BSA
supplemented with 100 ng/ml Hoechst 33342 for 1 h at room temperature protected from light. Finally, cells were washed
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3 times 3–5 minwith DPBS protected from light andmounted in Fluorescent MountingMedium (Dako) aer thoroughly
aspirating excess DPBS. Microscopy slides were stored at 4 ∘C before imaging with Cy3 and DAPI channel using an
Axio Imager.M2 (Zeiss). Total nuclei (Hoechst 33258 stained) and BrdU-positive nuclei were counted using CellProﬁler
soware [183–185].
5.15.2 EdU assay
Cell proliferation was assayed with a customized modiﬁcation of the Click-iT® EdU Imaging Kit from Invitrogen™.
is assay makes use of the base analogue EdU that is incorporated into the DNA of proliferating cells instead of
thymine. With the click reaction performed here, the EdU is covalently coupled to the ﬂuorescent dye Alexa Fluor®-555.
Proliferating cells can then be identiﬁed by ﬂuorescence microscopy.
Capan-1 cells were seeded at a density of 1.5×104 cells per well on 8-chamber LabTech Microscopy Slide or at 6×103
cells per well on 96-well clear-boom black wall microtiter plates and subjected to indicated treatment. Panc02 cells
with stable integration of shNC or shTbl1x were seeded at 1×103 cells per well on 96-well clear-boom black wall
microtiter plates and grown for 24 h. On the day of assay, 1/2 volume of medium was aspirated and replaced with an
equal amount of fresh pre-warmed medium supplemented with EdU at 20 μm (resulting in a ﬁnal EdU concentration of
10 μm) and incubated at 37 ∘C for 45 min (Capan-1) or 30 min (Panc02). Medium was aspirated and cells were ﬁxed with
100¹ or 250 μl² Roti®-Histoﬁx (4% formaldehyde, phosphate-buﬀered) for 15 min at room temperature, then aspirated
and washed twice with 100 or 250 μl of 3% BSA in DPBS before permeabilizing in 100 or 250 μl of 0.5% Triton®X-100 in
DPBS for 20 min at room temperature. Aer aspirating and washing twice with 100 or 250 μl of 3% BSA in DPBS, cells
were incubated in 40 or 100 μl Click-iT® reaction cocktail (see table 5.11) for 30 min protected from light. e cocktail
was then aspirated, cells were washed once with 100 or 250 μl of 3% BSA in DPBS, then once with 100 or 250 μl DPBS
before incubating in 50 or 125 μl of 5 μg/ml Hoechst 33342 for 30 min at room temperature protected from light. Finally,
cells were washed twice with 100 or 250 μl DPBS and (in case of chamber slides) mounted in Fluorescent Mounting
Medium (Dako) or (in case of 96-well plates) le in 100 μl DPBS. Cells were imaged in Cy3 and DAPI channel using an
Olympus Cell^R automated microscope (Olympus, Hamburg, Germany) with xcellence soware. Total nuclei (Hoechst
33258 stained) and EdU-positive nuclei were counted using CellProﬁler soware [183–185].
Table 5.11: Click-iT® reaction cocktail for EdU assay
It is important to add the components in the exact order listed here and to use the mixture within 15 min aer adding sodium
ascorbate. e fast and easy reaction is catalyzed by Cu(Ⅰ) ions but Cu(Ⅰ) salts are mostly insoluble in water or react with atmospheric
oxygen and are thus tricky to handle. erefore, the easily water soluble Cu(Ⅱ) salt copper sulfate (CuSO4) is used instead. e Cu(Ⅱ)
ions therein are then reduced in situ by ascorbate to Cu(Ⅰ) ions that then catalyze the reaction. When le standing too long, however,
the Cu(Ⅰ) ions are being oxidized back to Cu(Ⅱ) by atmospheric oxygen and can no longer catalyze the reaction.
Volume
Reaction component chamber slide 96-well plate
1× Click-iT® reaction buﬀer (87.5mm Tris-HCl pH 7.4, component D) 85.00 μl 34.00 μl
100mm CuSO4 (component E) 5.00 μl 2.00 μl
1.5mm Alexa Fluor® 555 azide (component B) 0.25 μl 0.10 μl
1× reaction buﬀer additive (100mm sodium ascorbate, component F) 10.00 μl 4.00 μl
Σ 100.00 µl 40.00 µl
5.15.3 PrestoBlue® cell viability assay
PrestoBlue® is a cell-permeable resazurin derivative that is metabolized by living cells to resazurin. 1/10 volume of
PrestoBlue® solution was added to cell culture media and incubated for 2 h at 37 ∘C and 5% CO2 before reading ﬂuores-
cence at 550 nm excitation / 610 nm emission.
5.15.4 Seahorse extracellular flux measurement
Capan-1 cells were seeded at 1.5×104 per well in XF96 Polystyrene Cell Culture Microplates. No cells were plated in
the four edge wells (A1, A12, H1, H12) since these served as background-reference. siRNA-mediated knockdown was
performed the following day as described under section 5.14.7 on the previous page. 24 h aer knockdown, medium was
¹96-well plate
²chamber-slide
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changed to fresh culture medium and cells were grown for another 24 h. An XF96 FluxPak 4-port measurement cartridge
was equilibrated over night in the CO2-free incubator of the XF Prep Station at 37 ∘C in 150 μl per well XF Calibrant.
On the day of assay, medium was carefully aspirated, cells were washed once with 100 μl pre-warmed Seahorse Assay
Medium and then incubated in 150 μl pre-warmed Seahorse AssayMedium (see page 60) in the CO2-free incubator of the
XF Prep Station at 37 ∘C for 1 h. Meanwhile, assay chemicals from either Mito Stress Test Kit or Glycolysis Stress Test
Kit were dissolved in Seahorse Assay Medium and were applied to the ports of the equilibrated measurement cartridge
according to table 5.12. e loaded cartridgewas insertedwith the XFCalibrant into the XF96 Extracellular Flux analyzer.
Aer completion of calibration the XF Calibrant plate was ejected by the machine and the plate containing the cells was
inserted, equilibrated and the measurements were performed according to the protocol in table 5.13. Aer completion
of the assay the medium was aspirated and the cells were ﬁxed for sulforhodamine B staining (see section 5.15.5). Cell
number determined by sulforhodamine B staining for each well was divided by average cell number of all wells to obtain
relative cell number. Measurement values were then divided by this relative cell number.
Table 5.12: Compound setup for Seahorse Assays
Mito Stress Test Kit
compound port conc. in port volume in port conc. on cells
oligomycin A 14 μm 25 μl 2 μm
FCCP B 4.0 μm 25 μl 0.5 μm
antimycin A + rotenone C 9 μm each 25 μl 1 μm each
Seahorse Assay Medium D – 25 μl –
Glycolysis Stress Test Kit
compound port conc. in port volume in port conc. on cells
d-glucose A 70mm 25 μl 10mm
oligomycin B 16 μm 25 μl 2 μm
2-deoxy-d-glucose C 900mm 25 μl 100mm
Seahorse Assay Medium D – 25 μl –
Table 5.13: Protocol for Seahorse Assays
1. Calibrate
2. Equilibrate
3. Mix 3 min
4. Measure 3 min ቋ 4 ×
5. Inject port A
6. Mix 3 min
7. Measure 3 min ቋ 3 ×
8. Inject port B
9. Mix 3 min
10. Measure 3 min ቋ 3 ×
11. Inject port C
12. Mix 3 min
13. Measure 3 min ቋ 4 ×
5.15.5 Sulforhodamine B staining
Aer Seahorse Extracellular Flux measurement, medium was aspirated and cells were ﬁxed with 100 μl ice cold SRB
ﬁxation buﬀer and incubated for at least 30 min at −20 ∘C. Cells were washed twice with water before incubating with
50 μl of SRB solution for 30 min at room temperature protected from light with mild shaking on a titer plate shaker.
Aerwards, sulforhodamine B was removed and cells were washed four times with 1% (v/v) acetic acid. For the ﬁrst
wash step, the wells were ﬁlled entirely while the following steps were done with 200 μl per well. Sulforhodamine B
was resolved from cells by applying 100 μl of 10mm un-buﬀered Tris and incubating for 5–10 min at room temperature
protected from light with vigorous shaking on a titer plate shaker. Finally, absorbance was measured at 550 nm and
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converted to cell number using a standard curve that was determined by seeding deﬁned amounts of cells, allowing
them to aach for 5 h and then subjecting them to the staining procedure.
log(cell number) = 4.632 − log⎛⎜
⎝
3.859 − 0.005015
∆OD − 0.005015 − 1
1.324
⎞
⎟
⎠
∆OD is the blank-corrected OD of sulforhodamine-stained cells.
5.15.6 Glucose consumption assay
1×105 Capan-1 cells were plated in 1ml of DMEMHigh Glucose Pyruvate (+ l-glutamine) with 10% FBS in 12-well plates
in 3 replicates per condition. e following day, cells were transfected with siRNA as described in section 5.14.7 on
page 65. 24 h later, medium was changed to fresh DMEM High Glucose Pyruvate (+ l-glutamine) with 10% FBS and
cells were grown for another 48 h. Media was then taken and glucose concentration was determined with the Glucose
(HK) Assay Kit (Sigma) following manufacturer’s instructions. Glucose consumption was calculated by subtracting cell
supernatant concentration from that of fresh media (DMEM High Glucose Pyruvate (+ l-glutamine) with 10% FBS).
Cells were trypsinized and counted for normalization.
5.15.7 2-deoxyglucose uptake assay
1×105 Capan-1 cells were plated in 1ml of DMEM High Glucose Pyruvate (+ l-glutamine) with 10% FBS in 12-well
plates in 6 replicates per condition. e following day, cells were transfected with siRNA as described in section 5.14.7 on
page 65. 24 h later, mediumwas changed to fresh DMEMHigh Glucose Pyruvate (+ l-glutamine) with 10% FBS and cells
were grown for another 24 h. Media was then changed to pre-gassed and pre-warmed Krebs-Ringer-Henseleit buﬀer
(see page 59) supplemented with 1mm HEPES (pH 7.4), 25mm d-glucose, 0.1% BSA, 1× RPMI amino acids (Sigma-
Aldrich), 1mm pyruvate, 2mm l-glutamine, 8mm d-mannitol and cells were incubated at 37 ∘C and 5% CO2 for 2 h.
Aer that, cells were incubated for exactly 15 min in tracer media (pre-gassed and pre-warmed Krebs-Ringer-Henseleit
buﬀer supplemented with 1mm HEPES (pH 7.4), 25mm d-glucose, 0.1% BSA, 1× RPMI amino acids (Sigma-Aldrich),
1mm pyruvate, 2mm l-glutamine, 8mm d-mannitol, 14C-d-mannitol, 1mm 2-deoxy-d-glucose, 3H-2-deoxy-d-glucose).
Tracing was stopped by removing tracer media and immediately adding ice cold pre-incubation media. Cells were then
lyzed in 300 μl RIPA buﬀer with protease inhibitors. 200 μl lysate as well as tracer media (to calculate the speciﬁc activity
of 3H-2-deoxy-d-glucose and 14C-d-mannitol) and lysis buﬀer (for background radiation) were mixed each with 4ml
Rotiszint® eco plus in 5ml LDPE scintillation tubes and scintillation was counted (3H and 14C dual decay per minute).
10 μl of lysate was used in duplicates for protein determination by Pierce® BCA Protein Assay Kit. 2-deoxy-d-glucose
uptake rates were calculated based on incorporation of 3H counts into cells versus the speciﬁc activity of 3H-2-deoxy-
d-glucose in the media with correction for the extracellular space by d-mannitol³ tracing, divided by time of assay,
multiplied by correction factor (200 μl lysate for scintillation counting out of 300 μl total lysate) and divided by total
protein amount in well (protein concentration in μg/μl × 300 μl).
5.16 Virus work
5.16.1 Lentiviral shRNA vectors
Lentiviral pLKO.1 vector containing shRNA against murine Tbl1xwas purchased as bacterial glycerol stock from Sigma-
Aldrich (TRCN0000109356, Cat. No. SHCLNG-NM 020601). Control vector pLKO.1 with scrambled shRNA (Cat. No.
1864) as well as lentiviral packaging vectors pMD2.G (Cat. No. 12259) and psPAX2 (Cat. No. 12260) were obtained as
stab cultures via Addgene. Bacterial stocks were streaked with sterile inoculation loops on LB agar plates containing
50 μg/ml ampicillin and grown at 37 ∘C over night. Next day, 5ml LB medium with 50 μg/ml ampicillin were inoculated in
round-boom snap-cap tubes with some material from glycerol stock or a colony from an LB agar plate using a sterile
inoculation loop and grown for 8 h shaking at 37 ∘C. 200 μl of this pre-culture was inoculated into 200ml of LB medium
with 50 μg/ml ampicillin in a 500ml Erlenmeyer ﬂask and grown over night at 37 ∘C shaking at ≈180 rpm before isolating
plasmids with the PureLink® HiPure Plasmid Maxiprep Kit from Invitrogen™ following manufacturer’s instructions.
5.16.2 Lentivirus production
HEK293T cells were plated in 6-well plates at 2.5×105 cells per well. On the following day, pLKO.1 vectors with scrambled
or Tbl1x-speciﬁc shRNAs were transfected as follows:
³d-mannitol can not be taken up by mammalian cells
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Table 5.14: shRNAs for lentiviral vectors
Gene RefSeq ID TRC Number Sequence
scrambled – – Age Ⅰ sense loop/Xho Ⅰ antisense termination
(NC) CGGTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTG
Tbl1x NM 020601.2 TRCN0000109356 Age Ⅰ sense loop/Xho Ⅰ antisense termination
CCGGGCGAGGATATGGAACCTTAATCTCGAGATTAAGGTTCCATATCCTCGCTTTTTG
For each cell culture well, 1 μg shRNA vector, 1 μg psPAX2 and 100 ng pMD2.G were diluted in 200 μl of Opti-MEM® Ⅰ,
mixed with 200 μl of Opti-MEM® Ⅰ supplemented with 2.5% Lipofectamine® 2000 and incubated for 30 min at room
temperature. e plasmid-Lipofectamine mixture (400 μl) was added to the cells drop-wise. On the next day, culture
medium was changed to DMEM High Glucose Pyruvate (+ l-glutamine) supplemented with 10% FBS and 1.1% BSA
(Sigma). 48 h later, supernatant was collected, centrifuged for 3 min at 600 ×g and aliquots were stored at −80 ∘C. Virus
titer of supernatant was determined with HIV-1 p24 ELISA.
5.16.3 Lentivirus titer determination
Titer determination was done with the HIV-1 p24-ELISA (XpressBio). Viral supernatants were diluted 1:5000–1:10, 000
and processed following manufacturer’s instructions. Resulting concentration of p24 was multiplied by the dilution
factor and factor 100 to obtain transducing units per ml.
5.16.4 Lentivirus transduction
3×104 cells per well of Panc02 were plated in 12-well plates with antibiotic-free culture medium. On the following
day, medium was changed to 200 μl of antibiotic-free culture medium with 8 μg/ml polybrene. An equal volume of Opti-
MEM® Ⅰ with 8 μg/ml polybrene plus lentivirus was added at an MOI of 10–100. 12–14 h later, medium was changed to
fresh antibiotic-free culture medium and cells were cultured for additional 24 h. Cells were then trypsinized and 1/10
of the cells were plated onto 6-well plates in antibiotic-free culture medium with 1.5 μg/ml puromycin. Cells were sub-
cultured when almost conﬂuent and expanded under constant selective pressure. RNA was isolated (see section 5.17.2),
reverse-transcribed to cDNA (see section 5.17.4 on the following page) and knockdown eﬃciency was measured with
TaqMan® quantitative PCR (see section 5.17.5 on the next page).
5.16.5 Adenovirus infection of cells
Adenovirus was generated previously by Dr. Maria Rohm from our lab (see [180, p77–79] and [181]). Sequences were
as follows: Tbl1x: GCGAGGATATGGAACCTTAAT, unspeciﬁc shRNA: GATCTGATCGACACTGTAATG. Virus was diluted at
desired MOI in DMEM High Glucose Pyruvate (+ l-glutamine) without FBS or antibiotics and with 0.5 μg/ml poly-l-
lysine. Culture medium was aspirated and replaced with 1/4 volume of virus-containing media. Aer 90 min medium
was ﬁlled up to the usual volume with DMEM High Glucose Pyruvate (+ l-glutamine) supplemented with 10% FBS and
1% penicillin/streptomycin. Cells were kept in presence of virus for 48 h before lyzing for RNA or protein extraction.
5.17 RNA methods
5.17.1 RNA extraction from tissue samples
Tissue samples were either snap-frozen in liquid nitrogen or submerged in RNAlater™ buﬀer (Qiagen) and stored at
−80 ∘C. Snap-frozen samples were cut into pieces with a disposable scalpel on dry ice whereas RNAlater™ tissue was
thawed and cut with a disposable scalpel at room temperature. Approximately 30mg were homogenized in 600 μl RLT
buﬀer (RNeasy Mini Kit, Qiagen) supplemented with 1% β-mercaptoethanol by shaking with a stainless steel bead for
2–5 min at 30Hz in a Tissue Lyser. Aerwards, the corresponding instructions of the RNeasy Mini Kit (Qiagen) were
followed including on-column DNase digest. RNA concentration was measured photometrically with a NanoDrop at
260 and 280 nm.
5.17.2 RNA extraction from cell culture samples
Cells were washed once with DPBS (Gibco®), lyzed on plate with 350 μl per well RLT buﬀer (RNeasy Mini Kit, Qiagen)
supplementedwith 1% β-mercaptoethanol in a 6- or 12-well format and either processed immediately or stored at −80 ∘C
until further use. Lysate was collected from the wells, transferred to a 1.5ml-tube and passaged 5 times through a 20G
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needle. Aerwards, the corresponding instructions of the RNeasy Mini Kit (Qiagen) were followed including on-column
DNase digest. RNA concentration was measured photometrically with a NanoDrop at 260 and 280 nm.
5.17.3 RNA gel electrophoresis
When necessary, RNA integrity was checked by separating 500–1000 ng RNA on a 1% agarose gel in 1× TBE (prepared
in DEPC-treated water). Prior to electrophoresis, RNA was mixed with 10 μl RNA loading buﬀer, denatured for 10 min
at 65 ∘C on a ermomixer (Eppendor) and cooled on ice for 2 min. RNA quality was considered good when the 28S
ribosomal RNA band was twice as intense as the 18S band and no smear from degraded RNA was visible.
5.17.4 Reverse transcription of RNA
0.5–2 μg RNA were reverse transcribed to single stranded cDNA in a 20 μl reaction with random hexamer primers using
the Fermentas First strand cDNA Synthesis Kit following manufacturer’s instructions. Finally, single stranded cDNA
was diluted in nuclease-free water (Gibco®) resulting in equivalents of 10 ng/μl of initial RNA.
5.17.5 TaqMan® quantitative PCR
PCR reactions were set up in 20 μl per well in MicroAmp® Fast Optical 96-well Reaction Plates with duplicates for each
sample as follows:
commercial TaqMan® probes self-designed primers and probes
10 ng/μl cDNA 2–5 μl 10 ng/μl cDNA 2–5 μl
10 μm forward primer 1 μl
10 μm reverse primer 1 μl
TaqMan® probe 0.5 μl 5 μm self-designed probe 0.5 μl
TaqMan® Gene Expression Master Mix 10 μl TaqMan® Gene Expression Master Mix 10 μl
nuclease-free water 7.5–4.5 μl nuclease-free water 5.5–2.5 μl
total 20 µl total 20 µl
e plate was sealed with MicroAmp® Optical Adhesive Film, brieﬂy centrifuged and then ampliﬁcation was done in
a StepOne Plus (Applied Biosystems®) as follows: 2 min at 50 ∘C, 10 min at 95 ∘C followed by 40–45 cycles of 15 sec at
95 ∘C, 1 min at 60 ∘C plus data acquisition. CT values were determined by the StepOne soware.
CT values of the gene of interest were subtracted form CT values of a reference gene (TBP or 18S-rRNA) from the same
sample, resulting in a ∆CT value. is ∆CT was then converted to gene expression relative to TBP or 18S-rRNA using
the formula Relative expression = 2−∆CT .
5.17.6 Gene Expression Microarrays
Microarray experiments were performed by Maria Muciek and analyzed by Dr. Carsten Sticht from University Clinic
Mannheim. Gene expression proﬁling was performed using GeneChip® arrays of HGU-133 Plus 2.0 type from Aﬀyme-
trix. cDNA synthesis was done using the SuperScript® Choice System (Life Technologies™) according to manufacturer’s
protocol. Biotin-labeled cRNA was produced using ENZO BioArray HighYield® RNA transcript labeling kit. Standard
protocol from Aﬀymetrix with 3.3 μl of cDNA was used for the in vitro transcription (IVT). Cleanup of the IVT product
was done using CHROMA SPIN-100 columns (Clontech). Spectrophotometric analysis was used for quantiﬁcation of
cRNA with acceptable A260/A280 ratio of 1.9 to 2.1. Aer that, the cRNA was fragmented using Aﬀymetrix deﬁned
protocol. Labeled and fragmented cRNA was hybridized to Aﬀymetrix HGU-133 Plus 2 microarrays for 16 h at 45 ∘C
using Aﬀymetrix deﬁned protocol. Microarrays were washed using a GeneChip® ﬂuidics station 450 and stained initially
with streptavidinphycoerytherin. For each sample the signal was further enhanced by incubation with biotinylated
goat anti-streptavidin antibody followed by a second incubation with streptavidinphycoerytherin and a second round
of intensities were measured. Microarrays were scanned with GeneChip® scanner controlled by Aﬀymetrix Microarray
Suite soware.
A Custom CDF Version 14 with Entrez based gene deﬁnitions was used to annotate the arrays. e Raw ﬂuorescence
intensity values were normalized applying quantile normalization. Diﬀerential gene expression was analyzed based on
loglinear mixed model ANOVA [186, 187], using a commercial soware package SAS JMP7 Genomics, version 5, from
SAS Institute (Cary, NC, USA). A false positive rate of α = 0.05with FDR correction was taken as the level of signiﬁcance.
e overrepresentation analysis (ORA) is a microarray data analysis that uses predeﬁned gene sets to identify a
signiﬁcant overrepresentation of genes in data sets [188, 189]. Pathways belonging to various cell functions such as cell
cycle or apoptosis were obtained from public external databases (KEGG, http://www.genome.jp/kegg/). A Fisher’s
exact test was performed to detect the signiﬁcantly regulated pathways.
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Table 5.15: Commercial probes for TaqMan® quantitative PCR
Gene Species Entrez Gene ID TaqMan® Assay ID
ACLY human 47 Hs00982738 m1
CARM1 (PRMT4) human 10498 Hs00406354 m1
CDK2 human 1017 Hs01548894 m1
CPT1A human 1374 Hs00912671 m1
CPT1B human 1375 Hs00992664 m1
CRHR1 human 1394 Hs00366363 m1
CRHR2 human 1395 Hs00266401 m1
CRTC2 (TORC2) human 200186 Hs01064500 m1
FASN human 2194 Hs01005622 m1
G6PD human 2539 Hs00166169 m1
GLP1R human 2740 Hs00157705 m1
GLS2 human 27165 Hs00203158 m1
GLUT1 (SLC2A1) human 6513 Hs00892681 m1
GLUT2 (SLC2A2) human 6514 Hs01096904 m1
KIF3B human 9371 Hs01122781 m1
LDHa human 3939 Hs00855332 g1
MEST human 4232 Hs00853380 g1
NRIP1 (RIP140) human 8204 Hs00534035 s1
PDK1 human 5163 Hs01561850 m1
PDK4 human 5166 Hs01037712 m1
PFKFB3 human 5209 Hs00998700 m1
PGC1α (PPARGC1A) human 10891 Hs00173304 m1
PIK3CA human 5290 Hs00907957 m1
SCD1 human 6319 Hs01682761 m1
TBP human 6908 Hs00427620 m1
TBL1X human 6907 Hs00183329 m1
TBL1XR1 human 79718 Hs01037550 m1
TSC22D4 human 81628 Hs00229526 m1
Table 5.16: Self-designed primers and probes for TaqMan® quantitative PCR
Gene Species Entrez Gene ID Sequence
Tbp mouse 21374 Forward TTGACCTAAAGACCATTGCACTTC
Reverse TTCTCATGATGACTGCAGCAAA
Probe FAM-5’-TGCAAGAAATGCTGAAT-
ATAATCCCAAGCG-3’-TAMRA
Tbl1x mouse 21372 Forward ACGAGGTGAACTTTCTGGTATATCG
Reverse GGACTGGCTAATGTGACTTTCGA
Probe FAM-5’-ATCAGGTTTTTCCCACTC-
TGCCTTCACG-3’-TAMRA
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Gene Set Enrichment Analysis (GSEA), was used to determine whether deﬁned lists (or sets) of genes exhibit a statis-
tically signiﬁcant bias in their distribution within a ranked gene list (see http://www.broadinstitute.org/gsea/
for details [188].
Analyses were done in the R version 2.15 environments [190]. e ICC calculation was done using the irr-package.
5.18 Protein methods
5.18.1 Protein extraction from tissue
Tissue samples were snap-frozen in liquid nitrogen and stored at −80 ∘C. Pieces were cut on dry ice with a disposable
scalpel and approximately 30mg were homogenized in 400 μl protein extraction buﬀer by shaking with a stainless steel
bead for 2–3 min at 30Hz in a Tissue Lyser. Aerwards, 1/10 volume of protein extraction supplement buﬀer was added
and samples were mixed for 1 h on a turning wheel at 4 ∘C and 7 rpm. Lysate was transferred to a new tube, centrifuged
for 20 min at 13, 000 rpm and supernatant was stored at −80 ∘C until further use.
5.18.2 Protein extraction from cell culture
Medium was aspirated, cells were washed once with DPBS and lyzed in 15–20 μl/cm2 RIPA buﬀer with protease and
phosphatase inhibitors. If required, cells were frozen aer this step at −80 ∘C until further processing. Cells were
scraped oﬀ the culture plate in RIPA buﬀer with a cell scraper, lysate was transferred to a 1.5ml-tube and sonicated
for 30 sec at low intensity in a Bioruptor® Plus sonicator. Finally, lysates were centrifuged at 13, 000 rpm and 4 ∘C for
10 min and supernatant was transferred to a new tube and stored at −80 ∘C until further use.
5.18.3 Determination of protein concentration
Protein concentration was determined with the Pierce® BCA Protein Assay Kit on 96-well microtiter plates (Nunc F96).
Protein samples were diluted 1:2 to 1:5 fold to not exceed the linear range of the standard curve. 10 μl of BSA standard
(0.025–2 μg/μl) or diluted protein lysate were probed in duplicates with 200 μl of assay reagent per well.
5.18.4 SDS-polyacrylamide gel electrophoresis
10–20 μg of protein were mixed with water and 5× SDS loading dye to obtain a loading dye concentration of 1×, then
denatured for 10 min at 95 ∘C before separating with SDS-polyacrylamide gels (8, 10 or 12% separation gel) in SDS run-
ning buﬀer at 90–120V for 90–120 min using a Mini-PROTEAN® 3 cell or Mini-PROTEAN R Tetra Cell with PowerPac
Basic™ (Cat. No. 164-5050) from Bio-Rad. PageRuler™ prestained protein ladder was used as a size standard.
5.18.5 Immunobloing
Transfer was done using a wet blot system. Aer separation, gels were carefully removed from glass plates and sub-
merged in SDS transfer buﬀer. Meanwhile, a sandwich array with all components previously soaked in SDS transfer
buﬀer was assembled in the transfer cassee: sponge pad, 1 gel-sized Whatman™ paper, gel-sized nitrocellulose mem-
brane, gel, 1 gel-sized Whatman™ paper, sponge pad. Transfer was performed for 1:10 h at 80V or 2:30 h at 70V in
SDS transfer buﬀer using a Mini Trans-Blot® Cell. e transfer sandwich was disassembled and the membrane was
brieﬂy stained with Ponceau S solution to assess quality of transfer. Staining was removed by 2–3 brief washes with
TBS-T or PBS-T until no color remained. Subsequently, the membranes were blocked for 1 h at room temperature in
corresponding blocking solution followed by incubation of primary antibody (see table 5.17 on the facing page) at 4 ∘C
over night. en, blots were washed 3 times for 5–10 min in TBS-T or PBS-T before adding HRP-conjugated secondary
antibody (see table 5.18 on the next page) for 1 h at room temperature. Finally, blots were washed another 3 times for
5–10 min in TBS-T or PBS-T. ECL™ Western Bloing Detection Reagent mixture was applied to the membranes, in-
cubated for 5 min, then membranes were put between to transparent plastic foils and chemoluminescence was imaged
with a ChemiDoc™ XRS+ System with Image Lab™ soware (Cat. No. 170-8265) from Bio-Rad.
5.18.6 Chromatin immunoprecipitation
Cross-linking: Capan-1 cells were seeded on ﬁve 15 cm-plates and grown to 80–90% conﬂuence within 2–3 days.
Medium was then exchanged to 27ml of regular culture medium, 3ml of 3.7% formaldehyde solution was added for
cross-linking and mixed immediately. Plates were incubated on an orbital shaker at low speed for exactly 15 min.
Reactionwas stoppedwith 3ml of 1.375m glycine, mixed immediately and incubated on an orbital shaker at low speed for
5 min. Plates were then placed on ice, medium was removed and washed twice with 20ml of ice-cold DPBS (completely
removing wash from culture dish each time). Next, 2ml of ice cold DPBS with 0.5m PMSF was added, cells were scraped
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Table 5.17: Incubation conditions for primary antibodies in immunobloing
protein company Cat.-No. diluent dilution origin mouse human
AKT Cell Signaling 9272 5% BSA in TBS-T 1:1000 rabbit 60 kDa 60 kDa
Ⓟ-AKT Ser-473 Cell Signaling 9271 5% BSA in TBS-T 1:1000 rabbit 60 kDa 60 kDa
AMPK Cell Signaling 2532 5% BSA in TBS-T 1:1000 rabbit 64 kDa 62 kDa
Ⓟ-AMPKr-172 Cell Signaling 2535 5% BSA in TBS-T 1:1000 rabbit 64 kDa 62 kDa
CDK2 Santa Cruz sc-163 5% BSA in TBS-T 1:1000 rabbit 39 kDa 34 kDa
CDK4 Cell Signaling 2906 5% BSA in TBS-T 1:1000 mouse 34 kDa 34 kDa
Cyclin D1 Cell Signaling 2926 5% BSA in TBS-T 1:1000 mouse 33 kDa 34 kDa
ERK-1/2 Cell Signaling 9102 5% BSA in TBS-T 1:1000 rabbit 42 kDa 42 kDa
44 kDa 44 kDa
Ⓟ-ERK-1/2 Cell Signaling 9101 5% BSA in TBS-T 1:1000 rabbit 42 kDa 42 kDa
r-202/Tyr-204 44 kDa 44 kDa
GSK3β Cell Signaling 9315 5% BSA in TBS-T 1:1000 rabbit 46 kDa 46 kDa
Ⓟ-GSK3β Ser-9 Cell Signaling 9336 5% BSA in TBS-T 1:1000 rabbit 46 kDa 46 kDa
IRS1 Cell Signaling 3407 5% BSA in TBS-T 1:500 rabbit 180 kDa 180 kDa
Ⓟ-IRS1 Tyr-895 Cell Signaling 3070 5% BSA in TBS-T 1:500 rabbit 180 kDa 180 kDa
Ⓟ-IRS1 Ser-1101 Cell Signaling 2385 5% BSA in TBS-T 1:500 rabbit 180 kDa 180 kDa
PI3K p110α Cell Signaling 4249 5% BSA in TBS-T 1:1000 rabbit 110 kDa 110 kDa
PTEN Cell Signaling 9552 5% BSA in TBS-T 1:1000 rabbit 54 kDa 54 kDa
Ⓟ-PTEN Cell Signaling 9549 5% BSA in TBS-T 1:1000 rabbit 54 kDa 54 kDa
Ser-380 / r-382/383
TBL1X Abcam ab24548 5% milk or 5% BSA 1:1000 rabbit 57 kDa 64 kDa
in PBS-T or TBS-T
TBL1XR1 Novus Biologicals NB600-270 5% milk or 5% BSA 1:1000 rabbit 56 kDa 56 kDa
in PBS-T or TBS-T
β-actin Sigma A5441 5% milk or 5% BSA 1:5000 mouse 42 kDa 42 kDa
in PBS-T or TBS-T
VCP Abcam 11433 5% milk or 5% BSA 1:5000 mouse 90 kDa 90 kDa
in PBS-T or TBS-T
Table 5.18: Incubation conditions for secondary antibodies in immunobloing
antibody manufacturer Cat. No. diluent dilution
goat anti-mouse IgG (H+L)-HRP Bio-Rad 170-6516 5% milk or 5% BSA in 1:5000
TBS-T or PBS-T
goat anti-rabbit IgG (H+L)-HRP Bio-Rad 172-1019 5% milk or 5% BSA in 1:5000
TBS-T or PBS-T
oﬀ, resuspended in the liquid and the material from all ﬁve cell culture dishes was pooled into one 15ml-tube. Cells
were centrifuged at 1500 rpm for 5 min at 4 ∘C.
Nuclei purification and chromatin fragmentation: e pellet was resuspended in 5ml of ice cold ChIP swelling
buﬀer, incubated on ice for 10 min, then homogenized by 10–20 up-down movements in a Dounce tissue grinder until
no large visible particles remained. Homogenate was transferred to a new 15ml-tube, incubated for 10 min at 4 ∘C to
release the nuclei and then centrifuged at 2000 rpm for 5 min at 4 ∘C. e supernatant was removed, the pellet resus-
pended in 5ml of ChIP Sucrose buﬀer A and homogenized by 10 up-down movements in a Dounce tissue grinder. e
resulting nuclear suspension was then carefully layered over 5ml of ChIP Sucrose buﬀer B and centrifuged at 3000 rpm
for 15 min at 4 ∘C. Supernatant was carefully removed in 1ml-steps, the nuclear pellet resuspended in 1ml of MNase
digestion buﬀer (EDTA-free) and transferred to a 1.5ml DNA LoBind® tube (Eppendor) using LoRetention pipee tips
(Eppendor). e pellet was centrifuged at 3000 rpm for 5 min at 4 ∘C, supernatant removed and resuspended in MNase
digestion buﬀer to an OD260 of 0.2 (for measurement, 5 μl of nuclei were diluted in 1ml of 1m NaOH and analyzed using
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a NanoDrop). For chromatin fragmentation, 8 μl of micrococcal nuclease (2000 gel units/µl, NEB) were added, inverted
several times, incubated for 20 min at 37 ∘C and mixed by inverting every 3–5 min. e reaction was stopped by adding
EDTA to a ﬁnal concentration of 10mm and puing the tube on ice. Nuclei were pelleted by centrifuging at 13, 000 rpm
for 1 min at 4 ∘C, supernatant discarded and resuspended in 1ml of ChIP buﬀer (with protease inhibitors and 0.5mm
PMSF) and incubated on ice for 10 min. Lysis was checked under microscope (mix 10 μl nuclear suspension with 10 μl of
0.4% trypan blue in PBS and put on coverslip). If lysis was not complete, samples were sonicated in a Bioruptor® Plus
sonicator at high intensity for 3 cycles of 30 sec ON / 30 sec OFF. Sample was centrifuged at 13, 000 rpm for 15 min at
4 ∘C and the chromatin-containing supernatant was transferred to a fresh 1.5ml DNA LoBind® tube using LoRetention
pipee tips. An aliquot of 50 μl was taken to check chromatin fragmentation, the remainder was snap-frozen in liquid
nitrogen and stored at −80 ∘C until further use.
Analysis of chromatin digestion and concentration determination: e 50 μl sample was diluted with 100 μl of
nuclease-free water and supplementedwith 6 μl of 5mNaCl and 2 μl RNase A (ermoFischer Scientiﬁc). e sample was
vortexed and then incubated at 37 ∘C for 30 min. en 2 μl of≈ 20mg/ml proteinase Kwere added, vortexed and incubated
at 55 ∘C for 2 h. e DNA was then puriﬁed with the MinElute PCR puriﬁcation kit (Qiagen) with 50 μl elution volume
and a 10 μl sample was analyzed on a 1% agarose gel with 100 bp DNA marker (Fermentas). DNA fragments were
between 150–900 bp corresponding to 1–5 nucleosomes.
Immunoprecipitation: e concentration of fragmented cross-linked chromatin was measured with a bit® 2.0
Fluorometer (Invitrogen™) using thebit® dsDNA HS Assay Kit (Invitrogen™) following manufacturer’s instructions.
For all subsequent steps DNA LoBind® tubes were used as well as LoRetention pipee tips for all steps where chromatin
had to be pipeed. 10 μg of chromatin was used for each precipitation and ﬁlled up to a ﬁnal volume of 500 μlwith ChIP
buﬀer plus protease inhibitors. As the 10% input control, 1 μg of chromatin was dissolved in a total volume of 50 μl
with ChIP buﬀer plus protease inhibitors and stored at −20 ∘C until further use.
Lysates were pre-cleared with 30 μl of ChIP-grade protein G agarose beads (pipeed with wide bore tips) and 4 μg
Normal Rabbit IgG (Cell Signaling, Cat. No. 2729) for at least 2 h on a rotating wheel at 4 ∘C. Tubes were centrifuged at
6000 rpm for 1 min at 4 ∘C and supernatant was transferred to a new tube. Antibodies were added (negative control 1 μg
Normal Rabbit IgG (Cell Signaling, Cat. No. 2729); positive control 10 μl Histone H3 antibody (Cell Signaling, Cat. No.
4620); sample: 10 μl TBL1X-antibody (Abcam, Cat. No. ab24548)) and incubated over night at 4 ∘C on a rotating wheel.
e next morning, 30 μl ChIP-grade protein G agarose beads (pipeed with wide bore tips) were added and incubated
for 2 h on a rotating wheel at 4 ∘C, then centrifuged at 6000 rpm for 1 min at 4 ∘C. Supernatant was aspirated and the
beads were washed twice with 1ml of ChIP wash buﬀer A, twice with 1ml of ChIP wash buﬀer B, twice with 1ml of
ChIP wash buﬀer C and twice with 1ml 1× TE with a 5 min rotation at room temperature for each washing step. Aer
the last wash, beads were washed once more and the wash buﬀer was removed carefully and as completely as possible.
IP elution and reversal of crosslinks: DNA was eluted twice by adding 100 μl ChIP elution buﬀer, incubating at
65 ∘C and 1200 rpm on a shaking heating block for 15 min followed by centrifugation at 13, 000 rpm for 1 min at room
temperature. Both supernatants were collected and stored at −20 ∘C until further use. e 10% input control was thawed
and ﬁlled up to 200 μl with ChIP elution buﬀer. To all samples, 8 μl of 5m NaCl was added and incubated at 65 ∘C over
night at 950 rpm on a shaking heating block. Next morning, proteinase K was added to a ﬁnal concentration of 1mg/ml
and incubated at 56 ∘C for 2 h at 950 rpm on a shaking heating block. Finally, RNase A was added to a ﬁnal concentration
of 100 μg/ml and incubated at 37 ∘C for 1 h followed by inactivation at 95 ∘C for 10 min.
DNApurification and PCR analysis: DNAwas extracted with the MinElute PCR puriﬁcation kit (Qiagen) following
manufacturer’s instructions. Enrichment of PIK3CA promoter fragment was performed on a StepOnePlus Real-Time
PCR System. ChIP DNA was diluted 1:2 and 1 μl was mixed with 8.4 μl water, 0.3 μl 10 μm forward primer, 0.3 μl 10 μm
reverse primer (see table 5.19) and 10 μl Power SYBR® Green PCR Master Mix. Samples were ampliﬁed using standard
SYBR® Green protocol of the StepOne Soware (10 min 95 ∘C; 40 cycles of 15 sec 95 ∘C, 1 min 60 ∘C; followed by 15 sec
95 ∘C, 1 min 60 ∘C, melt curve in 0.3 ∘C increments until 95 ∘C).
Table 5.19: ChIP primers for SYBR® Green quantitative PCR on human PIK3CA promoter
Primer Sequence
Forward TGTCAATTTTGTCCTTTGGGAACA
Reverse CAGGACCTGAAAGGTTGCCT
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5.19 Lipid methods
5.19.1 Lipid extraction from feces
Lipids were extracted from fecal maer by a modiﬁed version of Folch et al. [191]. Approximately 100mg of frozen
material was weighed into a 2ml Safe-Lock tube (Eppendor) and 1.5ml of a chloroform/methanol mixture (2:1 ratio)
pre-cooled to −80 ∘C was added together with a similarly pre-cooled stainless steel bead (Qiagen). e sample was
homogenized in a Tissue Lyser for 1–2 min at 30Hz until no visible large particles remained and then mixed for 20 min
at room temperature on a rotating wheel. e homogenate was transferred to a fresh tube and centrifuged at 13, 000 rpm
for 30 min at 20 ∘C. e liquid phase was transferred to a fresh tube and 1/5 volume of 150mmNaCl was added and mixed
followed by centrifugation at 2000 rpm for 5 min at 20 ∘C. e lower phasewas carefully transferred to a fresh tube, while
avoiding contamination from the upper phase, and stored at −80 ∘C until further use. 40 μl of a chloroform/Triton®X-100
mixture (1:1 ratio) were placed in a fresh tube and mixed with 200 μl of the organic lipid extract. e chloroform was
evaporated with an air-blow drier at room temperature until the weight of the tube did not change any more. 200 μl of
water were added, mixed well by vortexing and the extract was stored in a glass vial at −20 ∘C until further use.
5.19.2 Triglyceride measurement
Triglycerides from fecal extracts were determined with the Serum Triglyceride Determination Kit (Sigma) that cleaves
triglycerides into glycerol and fay acids using the enzyme lipase. e Free Glycerol Reagent was dissolved with 40ml
of water and the Triglyceride Reagent with 10ml of water, both without shaking or vortexing, and stored in dark boles
protected from light.
2 μl of lipid extract, or water, or Glycerol Standard dilutions (Sigma) were placed in two series of duplicates on a 96-
well microtiter plate. e ﬁrst series of duplicates was mixed with 100 μl of blank solution (4 volumes of Free Glycerol
Reagent + 1 volume of water). e second series of duplicates was mixed with 100 μl of assay solution (4 volumes of
Free Glycerol Reagent + 1 volume of Triglyceride Reagent). e plate was incubated for 5 min at 37 ∘C before measuring
absorbance at 550 nm. Absorbances were converted to concentrations with the standard curves. Absorbance values
of the blank solution (endogenous free glycerol in the samples) were subtracted from values measured with the assay
solution (glycerol generated by the enzymatic reaction of the assay) to calculate triglyceride concentration, taking into
account the initial sample weight and the dilution steps during the lipid extraction procedure.
5.19.3 Free fay acid measurement
Determination of free fay acids was done with the HR Series NEFA-HR (2) kit (Wako Diagnostics). e assay is based
on a three-step enzymatic reaction:
R−COOH (free fay acid) + ATP + CoA−SH acyl-CoA synthetase−−−−−−−−−−−−−−−−−−−−→ acyl-CoA + AMP + PPi
acyl-CoA + O2
acyl-CoA oxidase−−−−−−−−−−−−−−−−−→ 2,3-trans-enoyl-CoA + H2O2
2H2O2 + 4-aminophenazone + 3-methyl-N -ethyl-N -(β-hydroxyethyl)aniline
peroxidase−−−−−−−−−−−→ quinoneimine + 4H2O
4 μl of lipid extract or water or serial dilutions of NEFA standard solution were pipeed in duplicates on a 96-well
microtiter plate. 50 μl of color reagent solution A were added, mixed well and incubated for 10 min at 37 ∘C. Next, 100 μl
of color reagent solution B were added, mixed well and incubated for 10 min at 37 ∘C before measuring absorbance at
550 nm.
5.20 Statistics
Statistics was done with Microso Excel (Student’s t-test and Welch’s t-test), GraphPad Prism version 5.04 for Win-
dows (linear and non-linear regression models, one-way and two-way ANOVA) or SigmaPlot (two-way and three-way
ANOVA). Data ploed in ﬁgures are mean ± standard error of the mean (SEM) unless stated otherwise.
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5.21 Soware
soware source
AxioVision SE64 Rel 4.8 for Axio Imager.M2 Carl Zeiss (Oberkochen, Germany)
BibDesk http://bibdesk.sourceforge.net/
Bioconductor Fred Hutchinson Cancer Research Center (Seale, WA, USA)
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi
CellProﬁler cell image analysis soware Broad Institute (Cambridge, MA, USA) [183–185]
Geneious Biomaers, Ltd. (Auckland, New Zealand) [143]
GraphPad Prism version 5.04 for Windows GraphPad Soware, Inc. (La Jolla, CA, USA)
GSEA http://www.broadinstitute.org/gsea/
ilastik v0.5.12 http://www.ilastik.org/ [192]
Illustrator Adobe Systems (San Jose, CA, USA)
ImageJ Wayne Rasband (NIH), Bethesda (MD, USA)
Image Lab™ Bio-Rad (München, Germany)
KEGG http://www.genome.jp/kegg/
Living Image Caliper LifeSciences (Rodgau, Germany)
Microarray Suite Aﬀymetrix (High Wycombe, United Kingdom)
Microso Oﬃce Microso (Redmond, WA, USA)
MikroWin 2000 for Mithras LB 940 Berthold Technologies (Bad Wildbad, Germany)
Papers version 2.7.3 Mekentosj B.V. (Dordrecht, e Netherlands)
Photoshop Adobe Systems (San Jose, CS, USA)
Primer-BLAST http://www.ncbi.nlm.nih.gov/tools/primer-blast/
Pubmed http://www.ncbi.nlm.nih.gov/pubmed
R version 2.15 http://www.r-project.org/ [190]
SAS® JMP 7 SAS® Institute (Cary, NC, USA)
SigmaPlot version 12.5 Systat Soware, Inc. (Erkrath, Germany)
StepOnePlus™ system soware Life Technologies™, Applied Biosystems® (Darmstadt, Ger-
many)
TEXShop http://pages.uoregon.edu/koch/texshop/
TEXstudio http://texstudio.sourceforge.net/
xcellence for Cell^R automated microscope Olympus (Hamburg, Germany)
XF96 System Soware for XF96 Extracellular
Flux Analyzer
Seahorse Biosciences (Copenhagen, Denmark)
XƎLATEX typeseing soware http://www.xelatex.org/
ZEN for Cell Observer Z1 Carl Zeiss (Oberkochen, Germany)
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A Maps on global obesity and diabetes prevalence
Figure A.1: Global prevalence of obesity and hyperglycemia
images obtained from [193] and [194]
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B Sequence homology of human and murine TBL1X and TBL1XR1
Figure B.1: Sequence alignment of human and murine TBL1X and TBL1XR1
red: LisH domain; purple: F-box-like domain; blue: WD40-repeat domain. Alignment and ﬁgure created with Geneious soware
[143].
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C Tumor Stages
Table C.1: Tumor staging according to TNM classification of malignant tumors
“T” describes the size of the tumor and whether it has invaded nearby tissue; “N” describes regional lymph nodes that are involved;
“M” describes distant metastasis; “G” describes the diﬀerentiation grade of the tumor cells; “R” describes the residual tumor aer
resection; Use of an “x” instead of a number or other suﬃx means that the parameter was not or could not be evaluated.
Stage Description
Tis carcinoma/tumor in situ, tumor has not yet invaded other tissues
T1 tumor ≤2 cm in size
T2 tumor >2 cm and ≤5 cm in size
T3 tumor >5 cm in size
T4 tumor exceeds organ boundary
N0 tumor cells absent from regional lymph nodes
N1 regional lymph node metastasis present; (at some sites: tumor spread to closest or small
number of regional lymph nodes)
N2 tumor spread to an extent between N1 and N3 (N2 is not used at all sites)
N3 tumor spread to more distant or numerous regional lymph nodes (N3 is not used at all sites)
M0 no distant metastasis
M1 metastasis to distant organs (beyond regional lymph nodes)
G1 low grade, cells are well diﬀerentiated
G2 intermediate grade, cells are moderately diﬀerentiated
G3 high grade, cells are poorly diﬀerentiated
G4 anaplastic
R0 no residual tumor
R1 microscopic residual tumor
R2 macroscopic residual tumor
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D Patient Data
Figure D.1: Statistic parameters of human patients
A: age distribution of organ donors, CP and PDAC patients; B: BMI distribution of normal-weight and obese patients; C: sex
distribution of organ donors, CP and PDAC patients;D: distribution of tumor grading of PCAD patients. Lines and error bars in
A–B: median with interquartile range. CP: chronic pancreatitis, BMI: body mass index, PDAC: pancreatic ductal adenocarcinoma.
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Table D.1: Details of human patients
organ donors (n = 8)
ID age at explantation sex
1166 63 ♂
1207 19 ♀
1220 38 ♂
1234 63 ♀
1242 7 ♂
1348 52 ♂
1366 59 ♂
1384 59 ♂
Chronic pancreatitis (n = 15)
ID age at surgery sex operation degree of pancreatitis
335 55 ♀ pancreatic segmental resection severe
346 45 ♂ DPPHR severe
359 31 ♂ DPPHR medium
475 76 ♂ Whipple mild
477 56 ♂ DPPHR severe
481 43 ♀ DPPHR severe
490 73 ♀ pp-Whipple mild
513 34 ♂ pp-Whipple medium
527 59 ♂ pp-Whipple medium/severe
528 46 ♂ pp-Whipple severe
546 44 ♂ DPPHR medium/severe
642 43 ♀ DPPHR severe
348 44 ♂ DPPHR severe
366 58 ♂ resection severe
401 41 ♀ DPPHR severe
cancer patients, BMI ≤ 25 (n = 9)
ID age at surgery sex BMI tumor classiﬁcation
418 82 ♀ 24.65 T3N0M0 G3 R0
584 40 ♀ 21.97 T3N1M0 G2 R0
872 67 ♂ 24.91 T3N1M0 G2 R0
1157 65 ♀ 21.88 T3N1M1 G2 R1
1161 65 ♂ 21.22 T3N1M0 G3 R0
1201 59 ♂ 24.62 T3N1M0 G3 R0
1385 81 ♀ 22.27 T3N1M0 G2 R0
2979 63 ♀ 23.92 T3N1M0 G4
3054 58 ♂ 21.56 T3N0M0 G2 R1
cancer patients, BMI ≥ 30 (n = 9)
ID age at surgery sex BMI tumor classiﬁcation
297 68 ♀ 30.82 T3N1M0 G1 R0
476 75 ♂ 34.11 T3N1M0 G3
744 67 ♂ 30.49 T3N1M0 G3 R0
1108 76 ♂ 32.79 T3N1M1 G2 R0
1640 73 ♀ 33.73 T3N1M0 G3 R1
1255 51 ♀ 31.62 T3N1M0 G2 R0
1544 71 ♀ 31.23 T3N1M0 G2 R0
1594 76 ♂ 31.70 T3N1M0 G3 R0
3060 63 ♀ 35.16 T3N1M1 G3 R1
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Table D.2: Statistic parameters of human patients
organ donors
parameter age at explantation
mean 44.25
standard deviation 21.45
minimum 7
1ˢᵗ quartile 32
median 55
3ʳᵈ quartile 59
maximum 63
chronic pancreatitis
parameter age at surgery
mean 49.50
standard deviation 12.52
minimum 31
1ˢᵗ quartile 43
median 44.50
3ʳᵈ quartile 57.50
maximum 76
cancer patients, BMI ≤ 25
parameter age at surgery BMI
mean 63.89 23.04
standard deviation 12.42 1.42
minimum 40 21.22
1ˢᵗ quartile 58 21.90
median 64 22.85
3ʳᵈ quartile 66 24.44
maximum 81 24.91
cancer patients, BMI ≥ 30
parameter age at surgery BMI
mean 68.44 32.33
standard deviation 7.88 1.52
minimum 51 30.49
1ˢᵗ quartile 67 31.24
median 71 31.66
3ʳᵈ quartile 75 33.73
maximum 75 35.16
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Figure D.2: Correlation of mRNA expression of TBL1X and metabolic genes in human patients
Plots show correlation of mRNA expression of TBL1X with metabolic genes from ﬁgure 3.6 on page 18. Each dot represents one
sample from either organ donor (•), non-tumor tissue from cancer patient (•) or tumor tissue from cancer patient (•). Expression
is normalized to 18S-rRNA and relative to a pooled organ donor sample. ACLY: ATP citrate lyase; CPT1A: carnitine palmitoyl
transferase 1, liver isoform; CPT1B: carnitine palmitoyl transferase 1, muscle isoform; FASN: fay acid synthase; G6PD: glucose-6-
phosphate dehydrogenase; GLS2: glutaminase 2; GLUT1: glucose transporter 1 (SLC2A1); GLUT2: glucose transproter 2 (SLC2A2);
LDHa: l-lactate dehydrogenase A chain; PDK1: pyruvate dehydrogenase kinase 1; PDK4: pyruvate dehydrogenase kinase 4; SCD1:
stearyl-CoA desaturase. R2: correlation coeﬃcient of linear regression; p signiﬁcance level for slope of regression line diﬀerent from
zero.
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Figure D.3: Correlation of mRNA expression of TBL1XR1 and metabolic genes in human patients
Plots show correlation of mRNA expression of TBL1XR1 with metabolic genes from ﬁgure 3.6 on page 18. Each dot represents one
sample from either organ donor (•), non-tumor tissue from cancer patient (•) or tumor tissue from cancer patient (•). Expression
is normalized to 18S-rRNA and relative to a pooled organ donor sample. ACLY: ATP citrate lyase; CPT1A: carnitine palmitoyl
transferase 1, liver isoform; CPT1B: carnitine palmitoyl transferase 1, muscle isoform; FASN: fay acid synthase; G6PD: glucose-6-
phosphate dehydrogenase; GLS2: glutaminase 2; GLUT1: glucose transporter 1 (SLC2A1); GLUT2: glucose transproter 2 (SLC2A2);
LDHa: l-lactate dehydrogenase A chain; PDK1: pyruvate dehydrogenase kinase 1; PDK4: pyruvate dehydrogenase kinase 4; SCD1:
stearyl-CoA desaturase. R2: correlation coeﬃcient of linear regression; p signiﬁcance level for slope of regression line diﬀerent from
zero.
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E Details of HFD study on p48 +/Cre; Kras +/LSL-G12D mice
Table E.1: Age and lifespan of mice on LFD/HFD study
†: animal was killed; ‡: animal died spontaneously; ♦: scheduled end of experiment; mor.: moribund; inv.: investigatory
animal age at time on age at reason
number genotype diet sex start diet end of death
76 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 9w 5d 11w 6d 21w 4d ♦, †
235 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 6w 5d 12w 18w 5d ♦, †
396 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 7w 5d 12w 19w 5d ♦, †
1741 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 6w 5d 12w 18w 5d ♦, †
167 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 6w 6d 1w 1d 8w mor., †
74 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 9w 5d 2w 3d 12w 1d mor., †
345 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 10w 2d 2w 3d 12w 5d mor., †
382 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 7w 6d 2w 6d 10w 5d mor., †
385 p48 +/Cre; Kras +/LSL-G12D HFD ♂ 7w 6d 5w 1d 13w mor., ‡
209 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 6w 6d 12w 18w 6d ♦, †
337 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 10w 2d 12w 22w 2d ♦, †
347 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 8w 5d 12w 20w 5d ♦, †
1639 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 8w 2d 12w 20w 2d ♦, †
1642 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 8w 1d 12w 20w 1d ♦, †
1922 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 8w 8w 16w inv., †
1968 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 4w 6d 8w 12w 6d inv., †
346 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 8w 5d 4w 2d 13w mor., †
399 p48 +/Cre; Kras +/LSL-G12D HFD ♀ 7w 1d 10w 17w 1d mor., †
1665 p48 +/Cre; Kras +/LSL-G12D LFD ♂ 7w 6d 12w 19w 6d ♦, †
1667 p48 +/Cre; Kras +/LSL-G12D LFD ♂ 7w 6d 12w 19w 6d ♦, †
1970 p48 +/Cre; Kras +/LSL-G12D LFD ♂ 4w 6d 12w 16w 6d ♦, †
376 p48 +/Cre; Kras +/LSL-G12D LFD ♂ 7w 6d 2w 6d 10w 5d mor., †
416 p48 +/Cre; Kras +/LSL-G12D LFD ♂ 6w 1d 8w 2d 14w 3d mor., †
69 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 9w 5d 11w 6d 21w 4d ♦, †
71 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 9w 5d 11w 6d 21w 4d ♦, †
73 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 9w 5d 11w 6d 21w 4d ♦, †
373 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 7w 6d 12w 19w 6d ♦, †
412 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 6w 1d 12w 18w 1d ♦, †
1758 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 6w 2d 12w 18w 2d ♦, †
380 p48 +/Cre; Kras +/LSL-G12D LFD ♀ 7w 6d 11w 18w 6d mor., †
63 wt HFD ♂ 11w 2d 12w 23w 2d ♦, †
81 p48 +/Cre HFD ♂ 9w 5d 11w 6d 21w 4d ♦, †
82 wt HFD ♂ 9w 5d 11w 6d 21w 4d ♦, †
168 wt HFD ♂ 6w 6d 12w 18w 6d ♦, †
233 wt HFD ♂ 6w 5d 12w 18w 5d ♦, †
344 p48 +/Cre HFD ♂ 10w 2d 12w 22w 2d ♦, †
397 Trp53 +/LSL-R172H HFD ♂ 7w 5d 12w 19w 5d ♦, †
1486 wt HFD ♂ 11w 12w 23w ♦, †
1488 wt HFD ♂ 11w 12w 23w ♦, †
1673 p48 +/Cre HFD ♂ 7w 5d 12w 19w 5d ♦, †
1742 Kras +/LSL-G12D HFD ♂ 6w 5d 12w 18w 5d ♦, †
383 wt HFD ♂ 7w 6d 8w 15w 6d ♦, †
384 wt HFD ♂ 7w 6d 8w 15w 6d ♦, †
49 wt HFD ♀ 11w 6d 12w 23w 6d ♦, †
50 wt HFD ♀ 11w 6d 12w 23w 6d ♦, †
Table continued on next page
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E Details of HFD study on p48 +/Cre; Kras +/LSL-G12D mice
Table E.1 continued: Age and lifespan of mice on LFD/HFD study
†: animal was killed; ♦: scheduled end of experiment; wt: wild type
animal age at time on age at reason
number genotype diet sex start diet end of death
51 wt HFD ♀ 11w 6d 12w 23w 6d ♦, †
339 p48 +/Cre HFD ♀ 10w 2d 12w 22w 2d ♦, †
366 Trp53 +/LSL-R172H HFD ♀ 8w 12w 20w ♦, †
1640 wt HFD ♀ 8w 2d 12w 20w 2d ♦, †
1643 wt HFD ♀ 8w 1d 12w 20w 1d ♦, †
375 wt LFD ♂ 7w 6d 12w 19w 6d ♦, †
417 wt LFD ♂ 6w 1d 12w 18w 1d ♦, †
1487 wt LFD ♂ 11w 12w 23w ♦, †
1489 wt LFD ♂ 11w 12w 23w ♦, †
1664 wt LFD ♂ 7w 6d 12w 19w 6d ♦, †
1666 Kras +/LSL-G12D LFD ♂ 7w 6d 12w 19w 6d ♦, †
1971 Kras +/LSL-G12D LFD ♂ 4w 6d 12w 16w 6d ♦, †
52 wt LFD ♀ 11w 6d 12w 23w 6d ♦, †
53 wt LFD ♀ 11w 6d 12w 23w 6d ♦, †
54 wt LFD ♀ 11w 6d 12w 23w 6d ♦, †
72 wt LFD ♀ 9w 5d 11w 6d 21w 4d ♦, †
340 p48 +/Cre LFD ♀ 10w 2d 12w 22w 2d ♦, †
350 p48 +/Cre LFD ♀ 8w 5d 12w 20w 5d ♦, †
1759 wt LFD ♀ 6w 2d 12w 18w 2d ♦, †
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Table E.2: Statistical analysis of area under curve for body weight change
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 143 824.403 143 824.403 7.345 0.010
genotype 1 75 209.485 75 209.485 3.841 0.057
diet 1 950 387.994 950 387.994 48.534 < 0.001
sex × genotype 1 78 675.438 78 675.438 4.018 0.051
sex × diet 1 879.985 879.985 0.045 0.833
genotype × diet 1 88 552.126 88 552.126 4.522 0.039
sex × genotype × diet 1 4 706.425 4 706.425 0.240 0.626
Residual 43 842 027.450 19 582.034
Total 50 2 868 950.889 57 379.018
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 114.231 2.710 0.010
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 82.604 1.960 0.057
diet LFD vs. HFD 293.642 6.967 < 0.001
diet within wt LFD vs. HFD 383.274 7.734 < 0.001
diet within p48 +/Cre; Kras +/LSL-G12D LFD vs. HFD 204.009 2.991 0.005
genotype within LFD wt vs. p48 +/Cre; Kras +/LSL-G12D 7.028 0.113 0.910
genotype within HFD wt vs. p48 +/Cre; Kras +/LSL-G12D 172.237 3.017 0.004
power of performed test with α = 0.05 for sex 0.698
power of performed test with α = 0.05 for genotype 0.362
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for sex × genotype 0.382
power of performed test with α = 0.05 for sex × diet 0.050
power of performed test with α = 0.05 for genotype × diet 0.438
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Table E.3: Statistical analysis of body weight change in male animals
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
time 11 83 314.110 7 574,010 49.740 < 0.001
genotype 1 13 925.054 13 925.054 91.448 < 0.001
diet 1 46 239.191 46 239.191 303.659 < 0.001
time × genotype 11 4 255.250 386.841 2.540 0.004
time × diet 11 6 006.143 546.013 3.586 < 0.001
genotype × diet 1 5 566.478 5 566.478 36.556 < 0.001
time × genotype × diet 11 923.647 83 968 0.551 0.867
Residual 282 42 941.108 152.273
Total 329 291 357.113 885.584
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 14.651 9.563 < 0.001
diet LFD vs. HFD 26.698 17.426 < 0.001
diet within wt LFD vs. HFD 35.961 21.309 < 0.001
diet within p48 +/Cre; Kras +/LSL-G12D LFD vs. HFD 17.435 6.817 < 0.001
genotype within LFD wt vs. p48 +/Cre; Kras +/LSL-G12D 5.388 2.306 0.022
genotype within HFD wt vs. p48 +/Cre; Kras +/LSL-G12D 23.914 12.066 < 0.001
genotype at week 1 wt vs. p48 +/Cre; Kras +/LSL-G12D 2.190 0.473 0.636
genotype at week 2 wt vs. p48 +/Cre; Kras +/LSL-G12D 3.945 0.817 0.415
genotype at week 3 wt vs. p48 +/Cre; Kras +/LSL-G12D 7.027 1.395 0.165
genotype at week 4 wt vs. p48 +/Cre; Kras +/LSL-G12D 9.407 1.797 0.073
genotype at week 5 wt vs. p48 +/Cre; Kras +/LSL-G12D 9.587 1.831 0.068
genotype at week 6 wt vs. p48 +/Cre; Kras +/LSL-G12D 12.511 2.390 0.018
genotype at week 7 wt vs. p48 +/Cre; Kras +/LSL-G12D 16.649 3.011 0.003
genotype at week 8 wt vs. p48 +/Cre; Kras +/LSL-G12D 20.160 3.646 < 0.001
genotype at week 9 wt vs. p48 +/Cre; Kras +/LSL-G12D 21.175 3.797 < 0.001
genotype at week 10 wt vs. p48 +/Cre; Kras +/LSL-G12D 23.000 4.124 < 0.001
genotype at week 11 wt vs. p48 +/Cre; Kras +/LSL-G12D 24.328 4.362 < 0.001
genotype at week 12 wt vs. p48 +/Cre; Kras +/LSL-G12D 28.835 4.632 < 0.001
diet at week 1 LFD vs. HFD 7.526 1.626 0.105
diet at week 2 LFD vs. HFD 12.529 2.594 0.010
diet at week 3 LFD vs. HFD 18.727 3.709 < 0.001
diet at week 4 LFD vs. HFD 24.094 4.603 < 0.001
diet at week 5 LFD vs. HFD 24.044 4.593 < 0.001
diet at week 6 LFD vs. HFD 28.278 5.402 < 0.001
diet at week 7 LFD vs. HFD 32.588 5.894 < 0.001
diet at week 8 LFD vs. HFD 35.944 6.510 < 0.001
diet at week 9 LFD vs. HFD 33.246 5.961 < 0.001
diet at week 10 LFD vs. HFD 33.922 6.082 < 0.001
diet at week 11 LFD vs. HFD 34.440 6.175 < 0.001
diet at week 12 LFD vs. HFD 34.986 6.273 < 0.001
power of performed test with α = 0.05 for time 1.000
power of performed test with α = 0.05 for genotype 1.000
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for time × genotype 0.788
power of performed test with α = 0.05 for time × diet 0.972
power of performed test with α = 0.05 for genotype × diet 1.000
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Table E.4: Statistical analysis of body weight change in female animals
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
time 11 73 776.009 6 706.910 26.748 < 0.001
genotype 1 18.486 18.486 0.0737 0.786
diet 1 59 945.730 59 945.730 239.075 < 0.001
time × genotype 11 164.709 14.974 0.060 1.000
time × diet 11 18 390.886 1 671.899 6.668 < 0.001
genotype × diet 1 2 977.714 2. 977.714 11.876 < 0.001
time × genotype × diet 11 689.547 62 686 0.250 0.993
Residual 303 75 974.254 250.740
Total 350 230 531.738 658.662
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 0.463 0.272 0.786
diet LFD vs. HFD 26.381 15.462 < 0.001
diet within wt LFD vs. HFD 32.261 13.636 < 0.001
diet within p48 +/Cre; Kras +/LSL-G12D LFD vs. HFD 20.501 8.337 < 0.001
genotype within LFD wt vs. p48 +/Cre; Kras +/LSL-G12D 6.343 2.578 0.010
genotype within HFD wt vs. p48 +/Cre; Kras +/LSL-G12D 5.416 2.291 0.023
genotype at week 1 wt vs. p48 +/Cre; Kras +/LSL-G12D 0.051 0.009 0.993
genotype at week 2 wt vs. p48 +/Cre; Kras +/LSL-G12D 2.871 0.502 0.616
genotype at week 3 wt vs. p48 +/Cre; Kras +/LSL-G12D 0.996 0.174 0.862
genotype at week 4 wt vs. p48 +/Cre; Kras +/LSL-G12D 0.741 0.130 0.897
genotype at week 5 wt vs. p48 +/Cre; Kras +/LSL-G12D 1.571 0.271 0.787
genotype at week 6 wt vs. p48 +/Cre; Kras +/LSL-G12D 0.447 0.077 0.939
genotype at week 7 wt vs. p48 +/Cre; Kras +/LSL-G12D 2.015 0.348 0.728
genotype at week 8 wt vs. p48 +/Cre; Kras +/LSL-G12D 2.032 0.351 0.726
genotype at week 9 wt vs. p48 +/Cre; Kras +/LSL-G12D 0.944 0.157 0.875
genotype at week 10 wt vs. p48 +/Cre; Kras +/LSL-G12D 0.471 0.076 0.939
genotype at week 11 wt vs. p48 +/Cre; Kras +/LSL-G12D 1.231 0.195 0.845
genotype at week 12 wt vs. p48 +/Cre; Kras +/LSL-G12D 1.226 0.194 0.846
diet at week 1 LFD vs. HFD 5.546 0.970 0.333
diet at week 2 LFD vs. HFD 10.855 1.898 0.059
diet at week 3 LFD vs. HFD 12.042 2.105 0.036
diet at week 4 LFD vs. HFD 16.615 2.905 0.004
diet at week 5 LFD vs. HFD 16.602 2.865 0.004
diet at week 6 LFD vs. HFD 18.932 3.267 0.001
diet at week 7 LFD vs. HFD 26.404 4.556 < 0.001
diet at week 8 LFD vs. HFD 32.939 5.684 < 0.001
diet at week 9 LFD vs. HFD 33.408 5.533 < 0.001
diet at week 10 LFD vs. HFD 41.653 6.732 < 0.001
diet at week 11 LFD vs. HFD 47.177 7.480 < 0.001
diet at week 12 LFD vs. HFD 54.401 8.626 < 0.001
power of performed test with α = 0.05 for time 1.000
power of performed test with α = 0.05 for genotype 0.050
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for time × genotype 0.050
power of performed test with α = 0.05 for time × diet 1.000
power of performed test with α = 0.05 for genotype × diet 0.927
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Table E.5: Statistical analysis of area under curve for body fat
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 9 567.586 9 567.586 2.903 0.096
genotype 1 72 904.245 72 904.245 22.122 < 0.001
diet 1 247 170.743 247 170.743 75.000 < 0.001
sex × genotype 1 2 532.970 2 532.970 0.769 0.386
sex × diet 1 12.277 12.277 0.004 0.952
genotype × diet 1 8 008.070 8 008.070 2.430 0.127
sex × genotype × diet 1 576.014 576.014 0.175 0.678
Residual 42 138 415 3 295.597
Total 49 591 708.284 12 075.679
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 29.643 1.704 0.096
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 81.827 4.703 < 0.001
diet LFD vs. HFD 150.668 8.660 < 0.001
power of performed test with α = 0.05 for sex 0.255
power of performed test with α = 0.05 for genotype 0.998
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for sex × genotype 0.050
power of performed test with α = 0.05 for sex × diet 0.050
power of performed test with α = 0.05 for genotype × diet 0.201
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Table E.6: Statistical analysis of body fat in male animals
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
time 3 5 958.696 1986.232 89.207 < 0.001
genotype 1 1 432.148 1 432.148 64.322 < 0.001
diet 1 3 012.171 3 012.171 135.285 < 0.001
time × genotype 3 337 768 112.589 5.057 0.003
time × diet 3 1 023.139 341.046 15.317 < 0.001
genotype × diet 1 20.847 20.847 0.936 0.336
time × genotype × diet 3 26.054 8.685 0.390 0.760
Residual 95 2 115.207 22.265
Total 110 19 768.469 179.713
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 8.023 8.020 < 0.001
diet LFD vs. HFD 11.635 11.631 < 0.001
diet within wt LFD vs. HFD 35.961 21.309 < 0.001
diet within p48 +/Cre; Kras +/LSL-G12D LFD vs. HFD 17.435 6.817 < 0.001
genotype at week 0 wt vs. p48 +/Cre; Kras +/LSL-G12D 1.893 0.980 0.330
genotype at week 3 wt vs. p48 +/Cre; Kras +/LSL-G12D 7.575 3.923 < 0.001
genotype at week 7 wt vs. p48 +/Cre; Kras +/LSL-G12D 11.338 5.664 < 0.001
genotype at week 11 wt vs. p48 +/Cre; Kras +/LSL-G12D 11.286 5.292 < 0.001
diet at week 0 LFD vs. HFD 0.485 0.251 0.802
diet at week 3 LFD vs. HFD 13.539 7.012 < 0.001
diet at week 7 LFD vs. HFD 17.871 8.928 < 0.001
diet at week 11 LFD vs. HFD 14.646 6.868 < 0.001
power of performed test with α = 0.05 for time 1.000
power of performed test with α = 0.05 for genotype 1.000
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for time × genotype 0.837
power of performed test with α = 0.05 for time × diet 1.000
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.7: Statistical analysis of body fat in female animals
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
time 3 4 183.448 1 394.483 37.147 < 0.001
genotype 1 909.901 909.901 24.238 < 0.001
diet 1 4 520.685 4 520.685 120.423 < 0.001
time × genotype 3 184.831 61.610 1.641 0.185
time × diet 3 1 854.806 618.269 16.470 < 0.001
genotype × diet 1 246.921 246.921 6.578 0.012
time × genotype × diet 3 24.675 8.255 0.219 0.883
Residual 96 3 603.847 37.540
Total 111 15 508.330 139.715
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 5.735 4.923 < 0.001
diet LFD vs. HFD 12.782 10.974 < 0.001
diet within wt LFD vs. HFD 15.770 9.630 < 0.001
diet within p48 +/Cre; Kras +/LSL-G12D LFD vs. HFD 9.765 5.911 < 0.001
genotype within LFD wt vs. p48 +/Cre; Kras +/LSL-G12D 2.747 1.661 0.100
genotype within HFD wt vs. p48 +/Cre; Kras +/LSL-G12D 8.722 5.318 < 0.001
diet at week 0 LFD vs. HFD 0.822 0.360 0.719
diet at week 3 LFD vs. HFD 10.758 4.720 < 0.001
diet at week 7 LFD vs. HFD 15.875 6.965 < 0.001
diet at week 11 LFD vs. HFD 23.675 9.568 < 0.001
power of performed test with α = 0.05 for time 1.000
power of performed test with α = 0.05 for genotype 0.999
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for time × genotype 0.175
power of performed test with α = 0.05 for time × diet 1.000
power of performed test with α = 0.05 for genotype × diet 0.649
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Table E.8: Statistical analysis of perigonadal fat weight
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 0.837 0.837 1,737 0.195
genotype 1 3.117 3.117 6.469 0.015
diet 1 23.225 23.225 48.207 < 0.001
sex × genotype 1 0.052 0.052 0.109 0.743
sex × diet 1 2.697 2.697 5.599 0.023
genotype × diet 1 0.018 0.018 0.038 0.847
sex × genotype × diet 1 1.289 1.289 2.676 0.110
Residual 41 19.752 0.482
Total 48 55.740 1.161
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 0.280 1.318 0.195
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 0.541 2.543 0.015
diet LFD vs. HFD 1.477 6.943 < 0.001
sex within LFD ♂ vs. ♀ 0.784 2.495 0.017
sex within HFD ♂ vs. ♀ 0.223 0.777 0.442
diet within ♂ LFD vs. HFD 0.974 3.104 0.003
diet within ♀ LFD vs. HFD 1.980 6.891 < 0.001
power of performed test with α = 0.05 for sex 0.125
power of performed test with α = 0.05 for genotype 0.627
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for sex × genotype 0.050
power of performed test with α = 0.05 for sex × diet 0.547
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.9: Statistical analysis of relative perigonadal fat weight
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 50.257 50.257 0.327 0.571
genotype 1 845.489 845.489 5.501 0.024
diet 1 7 788.314 7 788.314 50.669 < 0.001
sex × genotype 1 193.738 193.738 1.260 0.268
sex × diet 1 2 202.455 2 202.455 14.329 < 0.001
genotype × diet 1 56.502 56.502 0.368 0.548
sex × genotype × diet 1 901.734 901.734 5.866 0.020
Residual 41 6 302.085 153.709
Total 48 19 612.242 408.588
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 2.173 0.572 0.571
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 8.911 2.345 0.024
diet LFD vs. HFD 27.047 7.118 < 0.001
ree-way interaciton term analysis
Evaluated diet × sex across levels of genotype:
diet × sex interaction in wt: p = 0.007
diet × sex interaction in p48 +/Cre; Kras +/LSL-G12D: p = 0.356
Simple, simple main eﬀect in wt
e diﬀerence in the mean values among the diﬀerent levels of diet evaluated within ♀ wt is
greater than would be expected by chance (p < 0.001).
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex within LFD wt ♂ vs. ♀ 21.493 3.243 0.002
sex within HFD wt ♂ vs. ♀ 25.679 4.284 < 0.001
diet within ♀ wt LFD vs. HFD 48.329 7.293 < 0.001
Simple main eﬀect tests in p48 +/Cre; Kras +/LSL-G12D
e diﬀerence in the mean values among the diﬀerent levels of diet evaluated within p48 +/Cre; Kras +/LSL-G12D
(averaging over levels of sex) is greater than would be expected by chance (p < 0.001).
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
diet within p48 +/Cre; Kras +/LSL-G12D LFD vs. HFD 29.350 4.775 < 0.001
power of performed test with α = 0.05 for sex 0.050
power of performed test with α = 0.05 for genotype 0.538
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for sex × genotype 0.075
power of performed test with α = 0.05 for sex × diet 0.961
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.10: Statistical analysis of liver weight
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 5.604 5.604 26.627 < 0.001
genotype 1 1.876 1.876 8.915 < 0.001
diet 1 1.098 1.098 5.219 0.027
sex × genotype 1 1.577 1.577 7.494 0.009
sex × diet 1 0.347 0.347 1.649 0.206
genotype × diet 1 0.152 0.152 0.722 0.400
sex × genotype × diet 1 0.510 0.510 2.422 0.127
Residual 42 8.840 0.210
Total 49 27.516 0.562
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 0.717 5.160 < 0.001
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 0.415 2.986 0.005
diet LFD vs. HFD 0.318 2.284 0.027
sex within wt ♂ vs. ♀ 1.098 6.641 < 0.001
sex within p48 +/Cre; Kras +/LSL-G12D ♂ vs. ♀ 0.337 1.507 0.139
genotype within ♂ wt vs. p48 +/Cre; Kras +/LSL-G12D 0.796 3.838 < 0.001
genotype within ♀ wt vs. p48 +/Cre; Kras +/LSL-G12D 0.035 0.186 0.853
power of performed test with α = 0.05 for sex 1.000
power of performed test with α = 0.05 for genotype 0.798
power of performed test with α = 0.05 for diet 0.510
power of performed test with α = 0.05 for sex × genotype 0.708
power of performed test with α = 0.05 for sex × diet 0.115
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.11: Statistical analysis of relative liver weight
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 303.498 303.498 6.024 0.018
genotype 1 86.769 86.769 1.722 0.197
diet 1 784.813 784.813 15.578 < 0.001
sex × genotype 1 352.281 352.281 6.993 0.011
sex × diet 1 297.683 297.683 5.909 0.019
genotype × diet 1 2.579 2.579 0.051 0.822
sex × genotype × diet 1 177.426 177.426 3.522 0.068
Residual 42 2 115.941 50.380
Total 49 4 685.693 95.626
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 5.280 2.454 0.018
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 2.823 1.312 0.197
diet LFD vs. HFD 8.490 3.947 < 0.001
sex within wt ♂ vs. ♀ 10.968 4.288 < 0.001
sex within p48 +/Cre; Kras +/LSL-G12D ♂ vs. ♀ 0.409 0.118 0.907
sex within LFD ♂ vs. ♀ 0.051 0.016 0.987
sex within HFD ♂ vs. ♀ 10.508 3.581 < 0.001
genotype within ♂ wt vs. p48 +/Cre; Kras +/LSL-G12D 8.511 2.653 0.011
genotype within ♀ wt vs. p48 +/Cre; Kras +/LSL-G12D 2.865 1.000 0.323
diet within ♂ LFD vs. HFD 3.261 1.017 0.315
diet within ♀ LFD vs. HFD 13.719 4.786 < 0.001
power of performed test with α = 0.05 for sex 0.588
power of performed test with α = 0.05 for genotype 0.123
power of performed test with α = 0.05 for diet 0.974
power of performed test with α = 0.05 for sex × genotype 0.670
power of performed test with α = 0.05 for sex × diet 0.577
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.12: Statistical analysis of fasting glucose at 4 weeks
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 33.995 33.995 0.056 0.814
genotype 1 2 910.365 2 910.365 4.766 0.034
diet 1 9 214.140 9 214.140 15.098 < 0.001
sex × genotype 1 135.904 135.904 0.223 0.639
sex × diet 1 586.829 586.829 0.961 0.332
genotype × diet 1 230.635 230.635 0.378 0.542
sex × genotype × diet 1 199.940 199.940 0.327 0.057
Residual 50 30 532.799 610.656
Total 57 48 576.224 852.214
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 1.636 0.236 0.814
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 15.136 2.183 0.034
diet LFD vs. HFD 26.931 3.884 < 0.001
power of performed test with α = 0.05 for sex 0.050
power of performed test with α = 0.05 for genotype 0.466
power of performed test with α = 0.05 for diet 0.971
power of performed test with α = 0.05 for sex × genotype 0.050
power of performed test with α = 0.05 for sex × diet 0.050
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.13: Statistical analysis of fasting glucose at 8 weeks
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 1 396.657 1 396.657 5.326 0.026
genotype 1 4 321.869 4 321.869 16.482 < 0.001
diet 1 11 077.399 11 077.399 42.245 < 0.001
sex × genotype 1 1 393.664 1 393.664 5.315 0.026
sex × diet 1 1 748.876 1 748.876 6.670 0.013
genotype × diet 1 2 523.466 2 523.466 9.624 < 0.001
sex × genotype × diet 1 1 194.880 1 194.880 4.557 0.038
Residual 44 11 537.470 262.215
Total 51 49 807.077 976.609
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex ♂ vs. ♀ 11.103 2.308 0.026
genotype wt vs. p48 +/Cre; Kras +/LSL-G12D 19.532 4.060 < 0.001
diet LFD vs. HFD 31.270 6.500 < 0.001
ree-way interaciton term analysis
Evaluated diet × sex across levels of genotype:
diet × sex interaction in wt: p = 0.001
diet × sex interaction in p48 +/Cre; Kras +/LSL-G12D: p = 0.902
Simple, simple main eﬀect in wt
e diﬀerence in the mean values among the diﬀerent levels of diet evaluated within ♂ wt is
greater than would be expected by chance (p < 0.001).
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
sex within HFD wt ♂ vs. ♀ 44.890 5.734 < 0.001
diet within ♂ wt LFD vs. HFD 68.890 8.799 < 0.001
diet within ♀ wt LFD vs. HFD 23.500 2.715 0.009
power of performed test with α = 0.05 for sex 0.522
power of performed test with α = 0.05 for genotype 0.982
power of performed test with α = 0.05 for diet 1.000
power of performed test with α = 0.05 for sex × genotype 0.521
power of performed test with α = 0.05 for sex × diet 0.645
power of performed test with α = 0.05 for genotype × diet 0.834
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Table E.14: Statistical analysis of random-fed glucose at 12 weeks
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 60.902 60.902 0.040 0.843
genotype 1 4 841.720 4 841.720 3.176 0.082
diet 1 6 043.120 6 043.120 3.964 0.053
sex × genotype 1 0.152 0.152 0.0000999 0.992
sex × diet 1 93.639 93.639 0.0614 0.805
genotype × diet 1 5 714.254 5 714.254 3.749 0.060
sex × genotype × diet 1 512.191 512.191 0.375 0.543
Residual 42 64 022.845 1 524.353
Total 49 89 493.120 1 826.390
power of performed test with α = 0.05 for sex 0.050
power of performed test with α = 0.05 for genotype 0.287
power of performed test with α = 0.05 for diet 0.376
power of performed test with α = 0.05 for sex × genotype 0.352
power of performed test with α = 0.05 for sex × diet 0.050
power of performed test with α = 0.05 for genotype × diet 0.050
Table E.15: Statistical analysis of fasting insulin at 4 weeks
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 0.232 0.232 1.721 0.197
genotype 1 0.062 0.062 0.457 0.503
diet 1 0.126 0.126 0.935 0.503
sex × genotype 1 0.003 0.003 0.022 0.883
sex × diet 1 0.123 0.123 0.910 0.346
genotype × diet 1 0.020 0.020 0.149 0.702
sex × genotype × diet 1 0.044 0.044 0.326 0.572
Residual 38 5.117 0.135
Total 45 6.015 0.134
power of performed test with α = 0.05 for sex 0.123
power of performed test with α = 0.05 for genotype 0.050
power of performed test with α = 0.05 for diet 0.050
power of performed test with α = 0.05 for sex × genotype 0.050
power of performed test with α = 0.05 for sex × diet 0.050
power of performed test with α = 0.05 for genotype × diet 0.050
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Table E.16: Statistical analysis of fasting insulin at 8 weeks
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 0.664 0.664 3.253 0.080
genotype 1 0.818 0.818 4.008 0.053
diet 1 0.005 0.005 0.026 0.872
sex × genotype 1 0.771 0.771 3.775 0.060
sex × diet 1 0.006 0.006 0.032 0.860
genotype × diet 1 0.024 0.024 0.117 0.734
sex × genotype × diet 1 0.058 0.058 0.283 0.598
Residual 36 7.352 0.204
Total 43 10.954 0.255
power of performed test with α = 0.05 for sex 0.294
power of performed test with α = 0.05 for genotype 0.378
power of performed test with α = 0.05 for diet 0.050
power of performed test with α = 0.05 for sex × genotype 0.353
power of performed test with α = 0.05 for sex × diet 0.050
power of performed test with α = 0.05 for genotype × diet 0.050
Table E.17: Statistical analysis of random-fed insulin at 12 weeks
ree-way ANOVA with Holm-Sidak post-test; DF: degrees of freedom; ΣS: sum of squares; MS: mean square; DM: diﬀerence of
means; F: critical value of F-statistic; t: critical value of t-statistic; p: signiﬁcance level, printed in green when signiﬁcant (≤ 0.05); wt:
wild type (all animals not carrying p48 +/Cre and Kras +/LSL-G12D alleles at the same time).
main eﬀects
source of variation DF ΣS MS F p
sex 1 1 731.990 1 731.990 1.292 0.262
genotype 1 1 611.692 1 611.692 1.202 0.279
diet 1 1 883.171 1 883.171 1.405 0.243
sex × genotype 1 1 688.362 1 688.362 1.260 0.268
sex × diet 1 1 452.859 1 452.859 1.084 0.304
genotype × diet 1 1 408.133 1 408.133 1.051 0.311
sex × genotype × diet 1 1 536.438 1 536.438 1.146 0.290
Residual 42 56 293.980 1 340.333
Total 49 75 866.930 1 548.305
power of performed test with α = 0.05 for sex 0.0778
power of performed test with α = 0.05 for genotype 0.0685
power of performed test with α = 0.05 for diet 0.0896
power of performed test with α = 0.05 for sex × genotype 0.0745
power of performed test with α = 0.05 for sex × diet 0.0562
power of performed test with α = 0.05 for genotype × diet 0.0528
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Table F.1: Overrepresentation analysis for TBL1X knockdown on GOPB pathways
Pathways belonging to various cell functions were obtained from public external databases (http://www.geneontology.org/GO)
and a Fisher’s exact test was performed to detect the signiﬁcantly regulated pathways. Enrichment score: measure of pathway
cluster enrichment over the other clusters; count: number of regulated genes within the pathway; raw p value: signiﬁcance of
pathway enrichment; list total: number of genes within the analyzed list of target genes having at least one GOBP annotation; pop
hits: number of genes available on the entire microarray, annotated by the considered GOBP category or annotation cluster; pop
total: number of genes available on the entire microarray having at least one GOBP annotation; Bonferroni: adjusted p value by
Bonferroni method; Benjamini: adjusted p value by Benjamini method; FDR: false discovery rate.
Annotation Cluster 1 Enrichment Score: 4.024
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GO:0007049 cell cycle 71 8.17 8.05 × 10-8 635 776 13528 1.949 2.18 × 10-4 2.18 × 10-4 1.43 × 10-4
GO:0000278 mitotic cell
cycle
39 4.49 4.61 × 10-6 635 370 13528 2.246 0.0124 0.0062 0.0082
GO:0022403 cell cycle
phase
42 4.83 4.82 × 10-6 635 414 13528 2.161 0.0129 0.0043 0.0086
GO:0022402 cell cycle
process
52 5.98 5.15 × 10-6 635 565 13528 1.961 0.0138 0.0035 0.0092
GO:0051329 interphase
of mitotic cell cycle
16 1.84 8.65 × 10-5 635 103 13528 3.309 0.2087 0.0257 0.1539
GO:0051325 interphase 16 1.84 1.21 × 10-4 635 106 13528 3.216 0.2786 0.0321 0.2146
GO:0048285 organelle
ﬁssion
24 2.76 4.77 × 10-4 635 229 13528 2.233 0.7250 0.0945 0.8459
GO:0007067 mitosis 23 2.65 6.66 × 10-4 635 220 13528 2.227 0.8349 0.1207 1.1782
GO:0000280 nuclear di-
vision
23 2.65 6.66 × 10-4 635 220 13528 2.227 0.8349 0.1207 1.1782
GO:0000087 M phase of
mitotic cell cycle
23 2.65 8.47 × 10-4 635 224 13528 2.187 0.8991 0.1418 1.4977
GO:0000082 G1/S transi-
tion of mitotic cell cycle
10 1.15 0.0011 635 56 13528 3.804 0.9467 0.1674 1.9101
GO:0051301 cell division 27 3.11 0.0015 635 295 13528 1.950 0.9833 0.2032 2.6550
GO:0000279 M phase 29 3.34 0.0017 635 329 13528 1.878 0.9902 0.2162 2.9992
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Table F.2: Overrepresentation analysis for TBL1X knockdown on KEGG pathways
Pathways belonging to various cell functions were obtained from public external databases (http://www.genome.jp/kegg/) and
a Fisher’s exact test was performed to detect the signiﬁcantly regulated pathways. count: number of regulated genes within the
pathway; raw p value: signiﬁcance of pathway enrichment; list total: number of genes within the analyzed list of target genes having
at least one KEGG annotation; pop hits: number of genes available on the entire microarray, annotated by the considered KEGG
category or annotation cluster; pop total: number of genes available on the entire microarray having at least one KEGG annotation;
Bonferroni: adjusted p value by Bonferroni method; Benjamini: adjusted p value by Benjamini method; FDR: false discovery rate.
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hsa04115 p53 signaling pathway 15 1.46 1.74 × 10-5 286 68 5085 3.922 0.0030 0.0030 0.0213
hsa04120 ubiquitin mediated
proteolysis
15 1.46 0.0205 286 137 5085 1.947 0.9732 0.7007 22.3944
hsa04110 cell cycle 14 1.37 0.0220 286 125 5085 1.991 0.9795 0.6218 23.8511
hsa04144 endocytosis 18 1.76 0.0279 286 184 5085 1.739 0.9929 0.6279 29.2695
hsa00564 glycerophospholipid
metabolism
9 0.88 0.0350 286 68 5085 2.353 0.9980 0.6463 35.393
hsa04010 MAPK signaling path-
way
23 2.25 0.0426 286 267 5085 1.532 0.9995 0.6629 41.3316
Table F.3: Overrepresentation analysis for TBL1XR1 knockdown on KEGG pathways
Pathways belonging to various cell functions were obtained from public external databases (http://www.genome.jp/kegg/) and
a Fisher’s exact test was performed to detect the signiﬁcantly regulated pathways. count: number of regulated genes within the
pathway; raw p value: signiﬁcance of pathway enrichment; list total: number of genes within the analyzed list of target genes having
at least one KEGG annotation; pop hits: number of genes available on the entire microarray, annotated by the considered KEGG
category or annotation cluster; pop total: number of genes available on the entire microarray having at least one KEGG annotation;
Bonferroni: adjusted p value by Bonferroni method; Benjamini: adjusted p value by Benjamini method; FDR: false discovery rate.
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hsa04115 p53 signaling pathway 10 1.18 0.0053 249 68 5085 3.003 0.5885 0.5885 6.2924
hsa04350 TGFβ signaling path-
way
11 1.3 0.0092 249 87 5085 2.582 0.786 0.5374 10.6721
hsa04114 oocyte meiosis 12 1.42 0.0176 249 110 5085 2.228 0.9474 0.6253 19.3929
hsa04070 phosphatidylinositol
signaling system
9 1.06 0.0266 249 74 5085 2.484 0.9887 0.6737 27.957
hsa04910 insulin signaling path-
way
13 1.53 0.0310 249 135 5085 1.967 0.9947 0.6487 31.8110
hsa04310 Wnt signaling path-
way
14 1.65 0.0319 249 151 5085 1.893 0.9954 0.5920 32.5494
hsa04110 cell cycle 12 1.42 0.0405 249 125 5085 1.960 0.9989 0.5756 39.4626
hsa05200 pathways in cancer 24 2.83 0.0475 249 328 5085 1.494 0.9997 0.5545 44.6651
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Table F.4: GSEA for TBL1X knockdown on KEGG pathways
Gene Set Enrichment Analysis (GSEA), was used to determine whether deﬁned lists (or sets) of genes exhibit a statistically signiﬁcant
bias in their distribution within a ranked gene list. Pathways belonging to various cell functions such as cell cycle or apoptosis were
obtained from public external databases (KEGG, http://www.genome.jp/kegg/). 140 of 204 gene sets were downregulated in
TBL1X knockdown compared to shNC-treated cells. Of these, 24 were signiﬁcantly enriched at an FDR ழ 25% and are shown in this
table. A guide to interpret GSEA results is available at http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.
html?_Interpreting_GSEA_Results
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hsa04914 progesterone-mediated oocyte maturation 81 -0.5778 -1.8797 0.0000 0.1155 0.098 1998
hsa04110 cell cycle 119 -0.5344 -1.8163 0.0000 0.1392 0.221 2217
hsa05212 pancreatic cancer 69 -0.5710 -1.7736 0.0065 0.1522 0.327 2330
hsa05142 chagas disease (american trypanosomiasis) 99 -0.5198 -1.7390 0.0016 0.1615 0.437 2897
hsa05222 small cell lung cancer 82 -0.5289 -1.7110 0.0000 0.1749 0.545 717
hsa05218 melanoma 71 -0.5296 -1.6756 0.0064 0.2016 0.660 1429
hsa04622 RIG-Ⅰ-like receptor signaling pathway 65 -0.5278 -1.6397 0.0100 0.2441 0.784 1743
hsa04662 B-cell receptor signaling pathway 74 -0.5151 -1.6367 0.0067 0.2205 0.798 1586
hsa05131 shigellosis 57 -0.5376 -1.6349 0.0083 0.1990 0.802 2388
hsa05215 prostate cancer 87 -0.4971 -1.6235 0.0061 0.1977 0.830 3040
hsa04360 axon guidance 127 -0.4658 -1.6156 0.0047 0.1911 0.841 2503
hsa04114 oocyte meiosis 105 -0.4812 -1.6114 0.0047 0.1811 0.855 1848
hsa04621 NOD-like receptor signaling pathway 56 -0.5253 -1.6087 0.0066 0.1706 0.862 3040
hsa05221 acute myeloid leukemia 56 -0.5232 -1.5963 0.0215 0.1734 0.880 1448
hsa04660 T-cell receptor signaling pathway 107 -0.4647 -1.5775 0.0079 0.1879 0.914 1486
hsa04810 regulation of actin cytoskeleton 207 -0.4262 -1.5730 0.0041 0.1821 0.920 2388
hsa00604 glycosphingolipid biosynthesis – ganglio
series
15 -0.6566 -1.5588 0.0509 0.1907 0.932 3505
hsa00564 glycerophospholipid metabolism 74 -0.4870 -1.5507 0.0177 0.1920 0.946 1592
hsa04620 Toll-like receptor signaling pathway 94 -0.4638 -1.5504 0.0143 0.1824 0.946 3037
hsa05145 toxoplasmosis 122 -0.4516 -1.5457 0.0148 0.1792 0.951 1871
hsa04210 apoptosis 85 -0.4758 -1.5275 0.0146 0.1951 0.975 717
hsa05100 bacterial invasion of epithelial cells 68 -0.4792 -1.5094 0.0302 0.2137 0.990 1453
hsa04141 protein processing in endoplasmic reticu-
lum
159 -0.4236 -1.5054 0.0105 0.2100 0.990 2379
hsa05200 pathways in cancer 318 -0.3842 -1.4864 0.0013 0.2301 0.995 1783
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Table F.5: GSEA for TBL1XR1 knockdown on KEGG pathways
Gene Set Enrichment Analysis (GSEA), was used to determine whether deﬁned lists (or sets) of genes exhibit a statistically signiﬁcant
bias in their distribution within a ranked gene list. Pathways belonging to various cell functions such as cell cycle or apoptosis
were obtained from public external databases (KEGG, http://www.genome.jp/kegg/). 147 of 204 gene sets were downregulated
in TBL1XR1 knockdown compared to shNC-treated cells. Of these, 43 were signiﬁcantly enriched at an FDR ழ 25% and the top
25 are shown in this table. A guide to interpret GSEA results is available at http://www.broadinstitute.org/gsea/doc/
GSEAUserGuideFrame.html?_Interpreting_GSEA_Results
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hsa04810 regulation of actin cytoskeleton 207 -0.5136 -2.0129 0.0000 0.0128 0.011 1773
hsa04971 gastric acid secretion 71 -0.5899 -1.9861 0.0000 0.0126 0.022 2388
hsa05212 pancreatic cancer 69 -0.5584 -1.8920 0.0015 0.0303 0.078 1445
hsa04350 TGFβ signaling pathway 82 -0.5303 -1.8628 0.0015 0.0322 0.110 1083
hsa00450 selenocompound metabolism 17 -0.6975 -1.7921 0.0091 0.0650 0.252 1804
hsa04510 focal adhesion 197 -0.4490 -1.7500 0.0000 0.0886 0.380 1773
hsa04270 vascular smooth muscle contraction 108 -0.4823 -1.7334 0.0000 0.0884 0.430 2005
hsa04972 pancreatic secretion 91 -0.4955 -1.7308 0.0000 0.0795 0.441 2395
hsa03060 protein export 23 -0.6204 -1.7224 0.0139 0.0756 0.460 1886
hsa00360 phenylalanine metabolism 17 -0.6664 -1.6799 0.0202 0.1026 0.596 1306
hsa05215 prostate cancer 87 -0.4758 -1.6669 0.0015 0.1081 0.652 1445
hsa05211 renal cell carcinoma 67 -0.4876 -1.6512 0.0148 0.1145 0.707 1971
hsa04664 Fc epsilon RⅠ signaling pathway 75 -0.4724 -1.6112 0.0076 0.1500 0.823 2005
hsa04730 long-term depression 65 -0.4819 -1.6067 0.0110 0.1444 0.833 2388
hsa05220 chronic myeloid leukemia 72 -0.4631 -1.5906 0.0176 0.1539 0.878 1540
hsa04964 proximal tubule bicarbonate reclamation 23 -0.5879 -1.5886 0.0260 0.1474 0.883 64
hsa05210 colorectal cancer 62 -0.4762 -1.5786 0.0110 0.1513 0.905 1445
hsa04520 adherens junction 72 -0.4665 -1.5775 0.0154 0.1447 0.910 2553
hsa04914 progesterone-mediated oocyte maturation 81 -0.4554 -1.5771 0.0106 0.1376 0.911 2670
hsa00670 one carbon pool by folate 17 -0.6220 -1.5738 0.0374 0.1344 0.921 660
hsa05130 pathogenic escherichia coli infection 48 -0.4872 -1.5514 0.0155 0.1531 0.952 1740
hsa00910 nitrogen metabolism 23 -0.5724 -1.5435 0.0379 0.1562 0.963 1722
hsa00600 sphingolipid metabolism 36 -0.5118 -1.5236 0.0417 0.1725 0.976 1426
hsa05218 melanoma 71 -0.4454 -1.5167 0.0249 0.1747 0.980 1445
hsa04310 Wnt signaling pathway 146 -0.4000 -1.5131 0.0100 0.1718 0.981 1601
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A B
C
Figure F.1: Enrichment plots of GSEA analysis
Enrichment plots from GSEA for “hsa04110 cell cycle‘‘ (A) and “hsa05215 pancreatic cancer‘‘ (B) in TBL1X knockdown and for
“hsa05215 pancreatic cancer” in TBL1XR1 knockdown (C). A guide to interpret GSEA results and enrichment plots is available at
http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html?_Interpreting_GSEA_Results
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Figure F.2: Heat map from GSEA for gene set “hsa04110 cell cycle” in TBL1X knockdown
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Figure F.3: Heat map from GSEA for gene set “hsa05212 pancreatic cancer” in TBL1X knockdown
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Figure F.4: Heat map from GSEA for gene set “hsa05212 pancreatic cancer” in TBL1XR1 knockdown
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Figure F.5: Validation of microarray
RNA used for microarray was reverse transcribed to cDNA and gene expression was analyed with TaqMan® quantitative PCR.
Besides TBL1X and TBL1XR1 four other genes with strong regulation in the microarray were chosen. CDK2: cyclin dependent
kinase 2; KIF3B: Kinesin-like protein KIF3B; MEST: Mesoderm-speciﬁc transcript homolog protein; PFKFB3: 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatase 3. Data ploed as mean ± SEM.
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G Seahorse extracellular flux measurement
Cells take up oxygen and nutrients and convert them to energy that is stored as ATP. Byproducts of cellular energy
metabolism are heat, lactate and CO2 that are dissipated to the extracellular environment.
Measuring the oxygen consumption rate (OCR) in cells can give valuable insight into their physiological state. Cells,
especially cancer cells, also use glycolysis to generate ATP independent of oxygen availability by converting glucose to
lactate. Production of the laer results in an eﬄux of protons to the extracellular medium, causing acidiﬁcation of the
medium which can be measured by changes in pH, providing the extracellular acidiﬁcation rate (ECAR).
G.1 Mito Stress Test Kit
In this assay the cells are metabolically challenged by subsequently adding three diﬀerent chemicals that shi the bioen-
ergetic proﬁle of the cell (ﬁgure G.1).
First, oxygen consumption is measured under basal conditions. en oligomycin is injected into the culture medium
which inhibits ATP synthesis by blocking the proton channel of the F0 portion ATP synthase (Complex Ⅴ). is way,
it can be distinguished between the percentage of oxygen consumption used for ATP synthesis and the percentage of
oxygen consumption required to overcome the natural proton leak across the inner mitochondrial membrane.
e second injection is FCCP (carbonyl cyanide-p-triﬂuoromethoxyphenylhydrazone), an ionophore that serves as an
uncoupling agent. It disrupts ATP synthesis by transporting hydrogen ions across the mitochondrial membrane instead
of the proton channel of ATP synthase (Complex Ⅴ). e resulting collapse of the mitochondrial membrane potential
leads to a rapid consumption of energy and oxygen, without the generation of ATP as the cell tries to maintain its
membrane potential.
e third injection is a combination of the Complex Ⅰ inhibitor rotenone and the Complex Ⅲ inhibitor antimycin A.
is combination blocks mitochondrial respiration resulting in a decrease in OCR. is way the non-mitochondrial
oxygen consumption can be determined.
Figure G.1: Mito Stress Test Kit
Besides the basal respiration and cellular response to the indicated chemicals, several other parameters can be determined. Non-
mitochondrial respiration is the diﬀerence in OCR aer application of oligomycin and aer injection of antimycin A and rotenone
and accounts for the fraction of oxygen that is consumed by non-mitochondrial processes. e coupling eﬃciency is the percentage
of oxygen that is used to produce ATP via Complex Ⅴ. e spare respiratory capacity is the diﬀerence in OCR under basal conditions
and aer application of FCCP. is is the actual ‘stress test’ measure of the assay, as it provides an idea of a cell’s maximum ATP
production and thus its ability to respond to stress in form of an increase in energy demand. Figure is adapted from the Mito Stress
Test Kit manual from Seahorse Bioscience.
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G.2 Glycolysis Stress Test Kit
is assay measures the three key parameters of glycolytic function: Glycolysis, Glycolytic Capacity, and Glycolytic
Reserve (ﬁgure G.2).
First, the cells are incubated under basal conditions without glucose and ECAR is measured. Next, glucose is injected
into the culture medium to a ﬁnal concentration of 10mm. It is taken up by the cells and catabolized through the
glycolytic pathway to lactate, producing ATP and protons. e extrusion of protons into the surrounding medium
produces a rapid increase in ECAR. is glucose-induced response is reported as the rate of glycolysis
Next, oligomycin is injected which inhibits ATP synthesis by blocking the proton channel of the F0 portion of the
mitochondrial ATP synthase (Complex Ⅴ). is inhibition of mitochondrial ATP production forces the cell to shi its
energy production to glycolysis to meet its ATP demands, resulting in an increase in ECAR revealing the maximum
glycolytic capacity of the cell.
e ﬁnal injection is 2-deoxyglucose, a glucose analog which inhibits glycolysis through competitive binding to glu-
cose hexokinase, the ﬁrst enzyme in the glycolytic pathway. e resulting decrease in ECAR gives the non-glycolytic
acidiﬁcation and further conﬁrms that the ECAR observed in the experiment is due to glycolysis.
Figure G.2: Glycolysis Stress Test Kit
Besides the basal acidiﬁcation rate and cellular response to the indicated chemicals, several other parameters can be determined.
Non-glycolytic acidiﬁcation is due to basal proton extrusion as well as CO2 release to the media followed by its hydration to carbonic
acid and bicarbonate. Glycolysis rate is the diﬀerence in ECAR aer glucose injection and aer application of 2-deoxyglucose.
Glycolytic capacity is the diﬀerence in ECAR aer 2-deoxyglucose injection and aer application of oligomycin. e diﬀerence
between glycolytic capacity and glycolysis rate is the glycolytic reserve, the cells ability to increase its glycolytic ﬂux to meet an
increase in energy demand. Figure is adapted from the Glycolysis Stress Test Kit manual from Seahorse Bioscience.
118
H Statistical analysis of subcutaneous shTBL1X-Panc02 allogras
Table H.1: Statistical analysis of subcutaneous shTBL1X-Panc02 allogras growth
Two-way ANOVAwith Holm-Sidak post-test was performed using SigmaPlot. Analysis was either done on all experimental groups or
only on NaCl control vs. 20 mg/kg gemcitabine (GEM-20) since this was the dosage where the synergistic eﬀect of TBL1X-knockdown
and chemotherapeutic treatment was most prominent. Signiﬁcant values (p ஸ 0.05) are printed in green.
absolute tumor volume relative tumor volume
source of variation all groups NaCl/GEM-20 all groups NaCl/GEM-20
shRNA < 0.001 0.002 0.086 0.192
gemcitabine 0.023 0.254 < 0.001 0.006
interaction 0.189 0.486 0.769 0.464
absolute tumor volume relative tumor volume
Holm-Sidak post-tests all groups NaCl/GEM-20 all groups NaCl/GEM-20
shNC vs. shTBL1X < 0.001 0.002 0.086 0.192
NaCl vs. GEM-20 0.449 0.254 0.006 0.006
NaCl vs. GEM-60 0.037 0.028
NaCl vs. GEM-120 0.050 < 0.001
GEM-20 vs. GEM-60 0.477 0.441
GEM-20 vs. GEM-120 0.461 0.363
GEM-60 vs. GEM-120 0.843 0.114
within shNC NaCl vs. GEM-20 0.356 0.211 0.251 0.115
within shNC NaCl vs. GEM-60 0.009 0.240
within shNC NaCl vs. GEM-120 0.014 0.006
within shNC GEM-20 vs. GEM-60 0.315 0.833
within shNC GEM-20 vs. GEM-120 0.322 0.239
within shNC GEM-60 vs. GEM-120 0.814 0.300
within shTBL1X NaCl vs. GEM-20 0.987 0.735 0.015 0.012
within shTBL1X NaCl vs. GEM-60 0.986 0.106
within shTBL1X NaCl vs. GEM-120 0.978 0.009
within shTBL1X GEM-20 vs. GEM-60 0.994 0.601
within shTBL1X GEM-20 vs. GEM-120 0.979 0.811
within shTBL1X GEM-60 vs. GEM-120 0.964 0.591
within NaCl shNC vs. shTBL1X < 0.001 0.050 0.619 0.661
within GEM-20 shNC vs. shTBL1X 0.010 0.050 0.112 0.166
within GEM-60 shNC vs. shTBL1X 0.165 0.303
within GEM-120 shNC vs. shTBL1X 0117 0.755
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Table H.2: Statistical analysis of subcutaneous shTBL1X-Panc02 allogras proliferation
Two-way ANOVA with Holm-Sidak post-test was performed using SigmaPlot. Signiﬁcant values (p ஸ 0.05) are printed in green.
main eﬀects
source of variation DF ΣS MS F p
shRNA 1 408.868 408.868 14.609 0.092
gemcitabine 1 17.665 17.665 0.631 0.441
shRNA × gemcitabine 1 82.100 82.100 2.933 0.110
Residual 13 363.847 27.988
Total 16 849.752 53.110
pairwise multiple comparison procedures (Holm-Sidak method)
factor comparison DM t p
shRNA shNC vs. shTBL1X 9.854 3.822 0.002
gemcitabine NaCl vs. GEM-20 2.048 0.794 0.441
shRNA within NaCl shNC vs. shTBL1X 14.270 3.815 0.002
shRNA within GEM-20 shNC vs. shTBL1X 5.438 1.532 0.149
gemcitabine within shNC NaCl vs. GEM-20 6.464 1.821 0.092
gemcitabine within shTBL1X NaCl vs. GEM-20 2.367 0.633 0.538
power of performed test with α = 0.05 for shRNA 0.939
power of performed test with α = 0.05 for gemcitabine 0.050
power of performed test with α = 0.05 for shRNA × gemcitabine 0.240
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Table J.1: Relevant publications on TBL1X and TBL1XR1
reference key ﬁndings
Bassi et al. (1999) [85] identiﬁcation of the TBL1X gene and associationwith X-linked late-onset sen-
sorineural deafness
Guenther et al. (2000) [87] TBL1X is part of the SMRT/HDAC3 co-repressor complex
Zhang et al. (2002) [88] GPS2 and TBL1X interact cooperatively with repression domain 1 of NCoR to
form a heterotrimeric structure
Yoon et al. (2003) [89] function of TBL1X and TBL1XR1 in the NCoR complex
Tomita et al. (2003) [195] TBL1XR1 forms a complex with NCoR and is recruited to target gene promot-
ers of the oncoproteins PML and PLZF
Perissi et al. (2004) [90] function of TBL1X and TBL1XR1 as exchange factors for nuclear receptor
corepressors
Tomita et al. (2004) [196] unliganded thyroid hormone receptor interacts with TBL1XR1 and recruits
TBL1XR1 to its chromatinized target promoter
Yoon et al. (2005) [197] TBL1X and TBL1XR1 bind preferentially to hypoacetylated histones H2B and
H4
Ishizuka and Lazar (2005) [198] characterization of binding regions of NCoR for TBL1X and TBL1XR1
Gerlitz et al. (2005) [199] e LisH domain of TBL1X is important for nuclear import of TBL1X
Zhang et al. (2006) [200] TBL1XR1 regulates the expression of nuclear hormone receptor co-repressors
Liu et al. (2007) [100] TBL1XR1 is upregulated in lung squamous cell carcinoma
Li and Wang (2008) [92] TBL1X and TBL1XR1 interact with β-catenin upon Wnt activation
Perissi et al. (2008) [91] TBL1X and TBL1XR1 are diﬀerently phosphorylated thus exerting their dis-
tinct functions
Choi et al. (2008) [201] the LisH motif of TBL1X and TBL1XR1 is required for histone binding,
oligomerization, and transcriptional repression
Parker et al. (2008) [101] deletion of TBL1XR1 is a recurrent abnormality in ETV6-RUNX1 positive
acute lymphoblastic leukemia
Huang et al. (2009) [202] TLR2 signaling leads to rapid activation of CaMKⅡ and phosphorylation of
TBL1XR1
Kadota et al. (2009) [102] TBL1XR1 is ampliﬁed in breast cancer and knockdown leads to reduced cell
migration, invasion, and tumorigenesis in a mouse xenogra model
Dimitrova et al. (2010) [203] TBL1X protects β-catenin from Siah-1-mediated ubiquitination
Toropainen et al. (2010) [204] Myc expression is depended on TBL1X
Foulds et al. (2010) [205] TBL1X is a target gene of human steroid receptor RNA activator
Keutgens et al. (2010) [206] TBL1XR1 is involved in the degradation of the oncogene Bcl-3
Chung et al. (2011) [207] a SNP in the TBL1X gene is associated with autism spectrum disorder
Ramadoss et al. (2011) [208] TBL1X binds to NF-κB and facilitates its recruitment to target gene promoters
Kulozik et al. (2011) [105] TBL1X and TBL1XR1 regulate hepatic lipid metabolism via PPARα
Choi et al. (2011) [93] TBL1X and TBL1XR1 are SUMOylated in a Wnt signaling-dependent manner
and recruited to Wnt target gene promoters
Table continued on next page
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Table J.1 continued: relevant publications on TBL1X and TBL1XR1
reference key ﬁndings
Sco et al. (2012) [103] fusion of TBL1XR1 and TP63 is a recurrent event in B-cell non-Hodgkin lym-
phoma
Gonzalez-Aguilar et al. (2012) [104] TBL1XR1 is frequently mutated in primary central nervous system lym-
phomas
O’Roak et al. (2012) [209] recurrent disruptive mutations of TBL1XR1may contribute to 1% of sporadic
autism spectrum disorders
Han et al. (2013) [210] miRNA 483-5p modulates the levels of proteins of the MeCP2-interacting
corepressor complexes, including HDAC4 and TBL1X
Rohm et al. (2013) [106] TBL1XR1 controls lipid mobilization in white adipose tissue
Garca-Ibarbia et al. (2013) [211] TBL1X gene and other Wnt target genes are diﬀerently methylated in osteo-
porotic hip fractures compared to osteoarthritis
Huang et al. (2014) [151] TBL1XR1 is a predicted target gene of miRNA 205 and is downregulated in
lung squamous cell carcinoma
Daniels et al. (2014) [152] TBL1XR1 is a coactivator of androgen receptor in prostate cancer cells
Olsson et al. (2014) [153] deletions or uniparental isodisomies of TBL1XR1 were signiﬁcantly more
common in B-cell precursor acute lymphoblastic leukemia patients who re-
lapsed compared with those remaining in complete remission
Liu et al. (2014) [156] TBL1XR1 is highly expressed in esophageal squamous cell carcinoma, posi-
tively correlatedwith disease stage and negatively correlatedwith patient sur-
vival; it regulates lymphangiogenesis and lymphatic metastasis and induces
VEGF-C expression
Chen et al. (2014) [155] TBL1XR1 fuses to retinoid acid receptor alpha in a variant t(3;17)(q26;q21)
translocation of acute promyelocytic leukemia
de Oliveira et al. (2014) [212] TBL1X and PIK3CA genes are diﬀerentially regulated in the SOD1(G93A)
amyotrophic lateral sclerosis animal model
Wang et al. (2014) [157] TBL1XR1 is upregulated in cervical cancer, correlates with the clinical stage,
survival time and recurrence, and promotes epithelial-mesenchymal transi-
tion
Jones et al. (2014) [154] TBL1XR1 knockdown in acute lymphoblastic leukemia precursor cell lines
results in reduced glucocorticoid receptor recruitment to glucocorticoid re-
sponsive genes leading to decreased glucocorticoid signaling
Bi et al. (2014) [213] SUMOylation stabilizes GPS2 protein through promoting its interaction with
TBL1X and reducing its ubiquitination
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